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ABSTRACT 
 
Autism spectrum disorder (ASD) and Intellectual Disability (ID) are complex neuropsychiatric 
disorders characterized by extensive clinical and genetic heterogeneity and with overlapping risk 
factors.  
The aim of my project was to further investigate the role of Copy Numbers Variants (CNVs), 
identified through genome-wide studies performed by the Autism Geome Project (AGP) and the 
CHERISH consortium in large cohorts of ASD and ID cases, respectively. 
Specifically, I focused on four rare genic CNVs, selected on the basis of their impact on interesting 
ASD/ID candidate genes: a) a compound heterozygous deletion involving CTNNA3, predicted to 
cause the lack of functional protein; b) a 15q13.3 duplication containing CHRNA7; c) a 2q31.1 
microdeletion encompassing KLHL23, SSB and METTL5; d) Lastly, I investigated the putative 
imprinting regulation of the CADPS2 gene, disrupted by a maternal deletion in two siblings with 
ASD and ID.  
This study provides further evidence for the role of CTNNA3, CHRNA7, KLHL23 and CADPS2 as 
ASD and/or ID susceptibility genes, and highlights that rare genetic variation contributes to disease 
risk in different ways: some rare mutations, such as those impacting CTNNA3, act in a recessive 
mode of inheritance, while other CNVs, such as those occurring in the 15q13.3 region, are 
implicated in multiple developmental and/or neurological disorders possibly interacting with other 
susceptibility variants elsewhere in the genome. On the other hand, the discovery of a tissue-
specific monoallelic expression for the CADPS2 gene, implicates the involvement of epigenetic 
regulatory mechanisms as risk factors conferring susceptibility to ASD/ID. 
COPY NUMBER VARIANTS 
 
 
 
2 
 
CHAPTER 1: 
COPY NUMBER VARIANTS 
 
1.1 Copy Number Variants 
Before the availability of sequencing technology, the first differences observed in the human 
genetic composition were mainly rare changes in the quantity and structure of chromosomes, 
defined as microscopic structural variants (~ 3Mb or more in size). Subsequently, with the advent of 
DNA sequencing, smaller and more abundant alterations were observed: individual base changes 
called Single-Nucleotide Polymorphisms (SNPs) are the most numerous variants in the genome, 
with estimates of at least 10 million SNPs within the human population (Kruglyak & Nickerson, 
2001); various repetitive elements that involve relatively short DNA sequences (for example, 
micro- and mini-satellites), and small (usually <1 kb) insertions, deletions, inversions and 
duplications. More recently, new strategies and tools for analysis of the human genome have 
revealed DNA variation (ranging from ~1 kb to 3 Mb in size), involving segments that are smaller 
than those identified using a microscope, but larger than those detectable by conventional sequence 
analysis. These submicroscopic structural variants, defined as Copy number variants (CNVs), are 
DNA segments longer than 1kb, with a variable copy number compared to a reference genome 
(Feuk, Carson, & Scherer, 2006). CNVs have gained considerable interest as a source of genetic 
diversity likely to play a role in functional variation, as they are widespread in normal human 
genomes (Iafrate et al., 2004; Sebat et al., 2004). Recently two studies (Conrad et al., 2010; Mills et 
al., 2011) have shown that there are > 1000 CNVs in the genome, accounting for million base pairs 
of genomic difference. Therefore, although the number of SNPs in the genome exceed the number 
of CNVs, their relative contribution to genetic heterogeneity is similar if we consider the variation 
in terms of nucleotides implicated. 
A CNV can be a deletion, insertion, duplication or an inversion and  it can be inherited or may arise 
de novo on a paternally or maternally inherited chromosome. Moreover, these types of variants can 
encompass millions of bases of DNA, containing entire genes and their regulatory regions (Sebat et 
al., 2004; Sharp et al., 2005; Tuzun et al., 2005).  
Although some structural variants represent benign CNVs, others can predispose to or directly 
cause a disease or, in combination with other genetic and environmental factors, they might 
function as susceptibility alleles in complex genetic disorders.  
COPY NUMBER VARIANTS 
 
 
 
3 
 
Genes might be influenced in several ways, depending on their proximity to CNVs (figure 1.1) and 
their phenotypic effects usually depend on whether dosage-sensitive genes or regulatory regions are 
affected. In the simplest cases deletions, inversions or translocations can affect gene dosage directly 
or, in some cases, deletions can “unmask” a recessive pathogenic allele in the heterozygous state 
(figure 1.1a); CNVs can also lead to the reduced expression (figure 1.1b), indirectly alter gene 
expression through position effects (figure 1.1c). or result in fusion or abnormal gene products with 
a new function (Holt et al., 2012). Moreover two CNVs in combination could predispose to a 
complex disorder (figure 1.1d). 
 
 
Figure 1.1 (Feuk et al., 2006). Influence of structural variants on phenotype. a) Dosage-sensitive genes that are 
encompassed by a structural variant can cause disease through a deletion event (upper panel); dosage-insensitive genes 
can also cause disease if a deletion of the gene unmasks a recessive mutation on the homologous chromosome (lower 
panel). b) Genes that overlap structural variants can be disrupted directly by inversion (upper panel), translocation or 
deletion (lower panel). c) Structural variants that are located at a distance from dosage-sensitive genes can affect 
expression through position effects (upper panel). Alternatively, deletion of a functional element could unmask a 
functional polymorphism within an effector which could have consequences for gene function (lower panel). d) 
Structural variants can function as susceptibility alleles, where a combination of several genetic factors are required to 
produce the phenotype.  
 
1.2 Mutational mechanisms 
Different mechanisms can lead to the formation of CNVs.  
Structural variants can arise as a result of one or more DNA breaks, which are followed by a wrong 
restoration of the continuity of filaments involved. These alterations may result either from an error 
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in the repair process or from a defect of the recombination system. The four major mechanisms of 
structural mutations are: non-allelic homologous recombination (NAHR); non-homologous end 
joining (NHEJ), fork stalling and template switching (FoSTeS) and retrotransposition. Recent 
findings from the 1000 Genomes Project (Mills et al., 2011) have shown that about 70.8% of the 
deletions are caused by NHEJ; 89.6% of small insertions are attributed to retrotransposition activity, 
while most tandem duplications are likely formed by FoSTeS. 
 
1.2.1 Non-Allelic Homologous Recombination (NAHR). 
Low copy repeats (LCRs) or segmental duplications are DNA segments >1 kb in size that occur in 
two or more copies per haploid genome, with the different copies sharing >90% sequence identity. 
The size, orientation and relative arrangement of LCRs affect the genome architecture such that 
they result in genomic regions that are unstable and prone to subsequent Non-Allelic Homologous 
Recombination (NAHR). NAHR occurs by a chromosome/chromatid misalignment that enables 
non-allelic LCRs to pair as substrates for homologous recombination (Stankiewicz & Lupski, 
2002). NAHR can involve genomic rearrangements between paralogues on homologous 
chromosomes (inter-chromosomal), on sister chromatids (intra-chromosomal) and on the same 
chromatid (intra-chromatid) (Gu, Zhang, & Lupski, 2008). 
The result of unequal crossing over between flanking LCRs is the formation of homologous 
chromosomes, carrying a reciprocal deletion and a duplication of intervening sequence, which 
segregate from each other at the next cell division, leading to a change in copy number in both 
daughter cells. These two reciprocal products (tandem duplication and deletion) are produced when 
LCRs are directly oriented on homologous chromosomes (Figure 1.2a) or on sister chromatids 
(Figure 1.2d). Alternatively, unequal crossing-over between direct LCRs on the same chromatid 
leads to the loop excision and deletion (Figure 1.2g). Instead, mispairing between inverted repeats 
results in an inversion when crossover involves both repeats (Figure 1.2b and 1.2h). Some LCRs 
have complex structures with sequences among the LCRs oriented in a direct manner whereas 
others are inverted and they can lead to both inversion or deletion and duplication (Figure 1.2c, 
1.2f, 1.2i). 
NAHR can occur both in meiosis (Turner et al., 2008) and, at lower frequency, in mitotically 
dividing cells. The majority of NAHR events occurs between LCRs which have a sequence identity 
greater than ~97%, a size that ranges from about 10 to ~400 kb and are located at a distance less 
than ~10 Mb from each other (Lupski, 1998; Sharp et al., 2005).  
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Figure 1.2 (Stankiewicz & Lupski, 2002). Schematic representation of LCRs-NAHR based mechanisms for 
genomic rearrangements. LCRs are depicted as yellow arrows and their orientation is indicated. Interchromosomal 
misalignment leads to deletion/duplication (a) and inversion (b). Intrachromosomal mispairing of direct repeats results 
also in deletion/duplication (d). Intrachromatid misalignment of directed repeats (g) can result in deletion and an 
acentric fragment. Intrachromatid loop of inverted repeats results in inversion (h). Unequal exchange between complex 
LCRs can be responsible for deletion/duplication or inversion (c; f; i).  
 
NAHR has been shown to require segments of a minimal length (300-500 bp) sharing extremely 
high similarity or identity between the LCRs, called minimal efficient processing segments (MEPS) 
(>90%). Two studies (Rubnitz & Subramani, 1984; Waldman & Liskay, 1988) showed that 
introduction of only two single-nucleotide mismatches leads to a 20-fold reduction of the 
recombination frequency. Other studies have found that NAHR can also be mediated by highly 
repetitive sequences, such as Alu sequences (which are the main class of Short Interspersed 
Elements, SINEs) (Redon et al., 2006) or by L1 elements (which are the main class of Long 
Interspersed Elements, LINEs), but also by retrotransposons or satellite DNAs. Moreover, different 
studies have provided evidence that the majority of strand exchanges or crossovers are restricted to 
a specific region (positional recombination hotspots) located within the repeat and are responsible 
for some genomic disorders (Lupski, 2004; Reiter et al., 1996). 
Most of the rearrangements resulting from NAHR are “recurrent” rearrangements (figure 1.3a) , as 
they recur in multiple individuals, share a common size and have fixed breakpoints, which are 
clustered inside the LCRs. Instead, the “non-recurrent” rearrangements (figure 1.3b) present 
different sizes and distinct breakpoints for each event. However all of the non-recurrent 
rearrangements share a common genomic region of overlap, indicated as the smallest region of 
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overlap (SRO). Some of  non-recurrent rearrangements have grouping of breakpoints, as one of 
their breakpoints localized in one small genomic region (figure 1.3c) (Gu et al., 2008). 
 
 
Figure 1.3 (Gu et al., 2008) Recurrent and non-recurrent rearrangements. The black line indicates the genomic 
region hit by CNVs, blue and red bars indicate the rearrangements with their breakpoints. a. Recurrent rearrangements 
have a common size and clustered breakpoints; both breakpoints map within the same LCRs (hatching rectangles). b. 
The non-recurrent rearrangements have different length and different breakpoints, but might share a common region of 
overlap (SRO). In this example, the SRO encompasses one gene, indicated by the black rectangle. c. Some non-
recurrent rearrangements show one of their breakpoints localized in one small genomic region: the grouping of one 
breakpoint may occur in proximity of an architectural element important to the rearrangements mechanism. 
 
1.2.2 Non-Homologous End Joining (NHEJ)  
Another mechanism that can lead to CNVs formation is Non-Homologous End Joining (NHEJ), one 
of the main pathways for repairing double-stranded DNA breaks (DSBs). 
NHEJ proceeds in four steps (figure 1.4): detection of DSB; molecular bridging of both broken 
DNA ends; modification of the ends to make them compatible and ligatable; and the final ligation 
step (Weterings & van Gent, 2004)  
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Figure 1.4 (Gu et al., 2008). The NHEJ mechanism consists of four steps. The two thick lines represents the double 
stranded DNA with double strand breaks (DSB). When DSBs occur, they are detected (1) and the molecular machinery 
of NHEJ mediates the molecular bridging of the broken DNA ends (2). The DNA ends are modified to be compatible 
(3) and, finally, they are ligated (4) to restore the structural integrity.  
The ends of DNA double-strand breaks are repaired through many rounds of enzymatic activity 
and, since linkage of the two ends requires some addition or deletion of bases in order to make them 
complementary, NHEJ leaves “information scar” at the rejoining site. This mechanism is guided 
entirely by the information contained within or near the DNA lesion for repair, which makes it 
“error prone”, since it introduces mutations compared to reference sequence (Lieber, 2008). In 
contrast to NAHR, NHEJ does not require LCRs, MEPS or sequence homology to mediate the 
recombination. However, it can frequently occur within repetitive elements, such as long terminal 
repeats (LTRs), SINEs, LINEs, and mammalian interspersed repeats (MIRs). 
 
1.2.3 Fork Stalling and Template Switching  
Fork Stalling and Template Switching (FoSteS) is a replication-based genomic rearrangement 
mechanism induced by errors during DNA replication process: during DNA replication, the DNA 
replication fork stalls when it encounters a nick in a template strand, the lagging strand releases the 
original template and anneals, by virtue of micro-homology at the 3‟ end, to another replication fork 
nearby; then restarts the DNA synthesis (Lee, Carvalho, & Lupski, 2007) (figure 1.5).  
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Figure 1.5 (Gu et al., 2008). A schematic representation of the Fork Stalling and Template Switching (FoSteS) 
mechanism. Solid lines indicate the template DNA, dotted lines instead the newly synthesised strands. The original 
replication fork is represented by the red and blue lines. After the stalling, the lagging strand (red, dotted line) invades a 
second fork (indicated in purple and green) via microhomology (1). The 3‟end of the lagging strand allows the DNA 
extension in the second fork (green dotted line) (2). Serial replication fork disengaging and invasion could occur several 
times (3) before resumption of replication on the original template (4). 
 
A further generalization of the FoSteS mechanism is known as the Microhomology-Mediated 
Break-Induced Replication model (MMBIR) (Hastings, Ira, & Lupski, 2009). It is used to repair 
single double-strand ends when the 3‟end of a collapse fork is able to anneal to any single-stranded 
DNA stretch, available in physical proximity, with which it shares micro-homology. Whether the 
template switch occurs in front of the position of the original collapse, a deletion will be created, 
whereas switching to a fork located upstream will result in a duplication. Moreover, whether the 
switch occurs in direct or opposite orientation determines if the erroneously incorporated fragment 
will be in direct or inverted orientation with respect to its original position.  
Genomic rearrangements generated by this mutational mechanism vary greatly in size and 
complexity (Hastings, Lupski, Rosenberg, & Ira, 2009). When FoSteS/MMBIR is mediated by 
large inverted repeats (>300 kb apart) and coupled with NHEJ, it can cause also the formation of 
complex rearrangements with duplication-triplication/inversion-duplication structures (Carvalho et 
al., 2011). 
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1.2.4 Retrotransposition 
Retrotransposons, mainly LINEs (Long Interspersed Nuclear Elements), SINEs (Short Interspersed 
Nuclear Elements), and endogenous retroviruses, make up about 40% of the mammalian genome.  
LINE1 or L1 are the only currently active class of retrotransposons in humans, moving their own 
and SINE sequences into new genomic locations. 
Although ~500,000 copies are present in the genome, only about 80-100 are active full-length 
elements (6 Kb) and are able to transpose their own sequences or non-autonomous elements to new 
genomic locations by a “Target Primed Reverse Transcription” (TPRT) mechanism (Goodier & 
Kazazian, 2008). TPRT results in the insertion of a new, often 5‟-truncated, L1 copy at a new 
genomic location that generally is flanked by “target site duplications” (TSDs) (figure 1.6.1). 
Retrotransposition occasionally can generate target site deletions (figure 1.6.2). Moreover 
recombination between retrotransposons may causes deletions, duplications, or rearrangements of 
gene sequence (fig 1.6.5). However, the greatest impact of retrotransposon insertions is on the 
expression of nearby genes: such as pausing in transcriptional elongation and premature transcript 
termination (figure 1.6.6), producing new transcription start sites (fig 1.6.7), leading to new exons 
within genes (figure 1.6.8) or altering the chromatin state (figure 1.6.9), producing chimeric 
insertions in the genome (figure 1.6.11) and suppressing gene expression (fig 1.6.12).  
Both germline and somatic L1 activity contribute significantly to structural variation in human 
genomes (Lupski, 2010).  
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Figure 1.6 (Goodier & Kazazian, 2008). Examples of genomic changes caused by retrotransposons. (1) Insertion of 
the L1 element to a new location. In the example a, the insertion causes the formation of TSDs. (2) The insertion of the 
L1 determines a deletion at the insertion site. (3 and 4) Regions flanking the retrotransposon in the original location (at 
5‟ or 3‟) may be carried along with the L1 element during the retrotransposition. (5) Mispairing and crossing over 
between LINE or SINE elements via NAHR, leading to deletions and duplications. (6) The retrotransposon sequence 
can cause a pausing in the transcriptional elongation, and poly(A) signals within an L1 can lead to premature 
termination of transcription. (7) The antisense promoter in the L1 5‟ UTR can produce new transcription start sites for 
genes upstream of the L1 on the opposite strand. (8) Splice sites within L1s residing in introns can lead to new exons 
within genes, in a process called “exonization”. (9) L1s can alter the chromatin state, thereby altering gene expression. 
(10) L1 reverse transcriptase can mobilize Alu, leading to further genome expansion. (11) Template switching of L1 
reverse transcriptase from L1 RNA to other sequences, such as U6 RNA, can produce chimeric insertions in the 
genome. (12) Editing of inverted Alu can suppress gene expression by nuclear retention of the mRNA. (13) Alu 
elements can promote formation and expansion of microsatellites. 
 
1.3 CNV detection methods  
Chromosome banding techniques, developed in the early 1970s, enabled the identification of each 
of the 23 pairs of human chromosomes and the specific bands involved in rearrangements. 
However, since the resolution obtained using banding methods is 2-5 Mb, molecular cytogenetic 
methods, such as fluorescence in situ hybridization (FISH) (figure 1.7) (Speicher & Carter, 2005), 
have been required to visualize the submicroscopic rearrangements, which are too subtle to be 
detected by routine analysis. FISH analysis uses fluorescent DNA probes, that hybridize to either 
metaphase or interphase chromosomes in order to detect and localize specific DNA sequences.  
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This technology allows the identification of small genomic alterations, from 50 Kb to 100 Kb, and 
the diagnosis of both micro-deletion/micro-duplications syndromes and cancer. However, the main 
limitation of FISH is represented by the detection of specific chromosomal loci clearly associated 
with known syndromes, not providing thus an analysis of the entire genome. 
 
 
Figure 1.7 (Speicher & Carter 2005). Fluorescence in situ hybridization (FISH). a) FISH uses a DNA probe and a 
target sequence. b) the DNA probe is labelled before hybridization; there are two main labelling strategies: for indirect 
labelling (left panel) probes are labelled with modified nucleotides that contain a HAPTEN, whereas direct labelling 
(right panel) uses nucleotides that have been directly modified to contain a fluorophore. c) The labelled probe and the 
target DNA are denatured d) Then they anneal to complementary DNA sequences. e) If the probe has been labelled 
indirectly, an extra step is required for visualization of the non-fluorescent hapten that uses an enzymatic or 
immunological detection system.  
 
The advent of new experimental methods, which are able to assay the genome in either a genome-
wide (such as array-CGH and SNPs arrays) or a targeted manner (such as Real-time qPCR) with 
varying degrees of resolution (ranging from kb to base pair resolution), has led to dramatically 
increase the number of identified CNVs. Moreover, the development of Next Generation 
Sequencing (NGS) technologies has allowed sequence-based approaches for mapping CNVs at fine 
scale. 
 
1.3.1 CGH-array and ROMA 
Array Comparative Genomic Hybridization (CGH-array) is the most robust array-based method for 
carrying out genome-wide scans to find novel CNVs (Pinkel et al., 1998). In array-CGH two DNA 
sample, a reference DNA and a DNA of interest (test DNA), labelled with different fluorescent dyes 
(e.g. Cy5 and Cy3), compete to hybridize to arrays that are spotted with DNA fragments to cover 
the whole genome. After hybridization, the fluorescence ratio between the two dyes is determined, 
revealing copy-number differences between the two genomes (figure 1.8a). Typically, array-CGH 
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is carried out using a „dye-swap‟ method, in which the initial labelling of the reference and test 
DNA samples is reversed for a second hybridization (indicated by the left and right sides of the 
figure 1.8a). This allows the detection of spurious signals, which are not common to both 
hybridizations. The array can be spotted with one of several DNA sources, including genomic 
clones (for example, BACs), PCR fragments or oligonucleotides. The use of BACs gives the 
advantage of extensive coverage of the genome, reliable mapping data and ready access to clones. 
Instead the use of CGH with long oligonucleotides (60-100 bp) can improve the detection resolution 
(from 50 kb to, theoretically, a few kb) compared to BACs.  
A variant of array-CGH is Representational Oligonucleotide Microarray Analysis (ROMA) (figure 
1.8b) (LaFramboise, 2009; Lucito et al., 2003) in which, in order to reduce the complexity of the 
DNA that will be hybridized to the array,  the reference and test DNA samples are digested with a 
restriction enzyme and then ligated to adapters, which results in the PCR-based amplification of 
fragments in a specific size-range. It is estimated that around 200,000 fragments of DNA are 
amplified (approximately 2.5% of the human genome), leading thus to a reduction in background 
noise. 
 
Figure 1.8 (Feuk et al., 2006). a) Array-based comparative genome hybridization (array-CGH) and b) 
Representational Oligonucleotide Microarray Analysis (ROMA). a) Reference and test DNA samples are 
differentially labeled with fluorescent tags (Cy5 and Cy3, respectively), and are then hybridized to genomic arrays after 
repetitive-element binding is blocked using COT-1 DNA (which is mainly composed of repetitive sequences). After 
hybridization, the fluorescence ratio (Cy3:Cy5) is determined, which reveals copy-number differences between the two 
DNA samples. An example output for a dye-swap experiment is shown at the bottom: the red line represents the 
original hybridization, whereas the blue line represents the reciprocal, or dye-swapped, hybridization. b) Before 
hybridization the reference and test DNA samples are digested with a restriction enzyme that has uniformly distributed 
cleavage sites (BglII in this example). Adaptors (with PCR primer sites) are then ligated to each fragment, which are 
amplified by PCR. Only DNA of less than 1.2 kb (yellow) is amplified, while fragments that are greater than this size 
(red) are lost, therefore reducing the complexity of the DNA that will be hybridized to the array. An oligonucleotide 
array is used, which is spotted with computationally designed 70-nt probes.  
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1.3.2 SNPs arrays 
Others array-based approaches are SNPs arrays which, compared to CGH-arrays, have the added 
advantage of providing information about both copy number and genotype, leading to considerable 
progress in genome-wide detection of various types of DNA sequence-level human variation.  
Two commercial SNPs arrays, which work using different chemistries but sharing several aspects, 
are the Affymetrix and Illumina SNPs arrays (figure 1.9) (LaFramboise, 2009). Both protocols are 
based on the hybridization of fragmented single-stranded DNA to arrays containing hundreds of 
thousands of oligonucleotidic sequences. Each probe is designed to bind to a target DNA 
subsequence and it is represented multiple times within an array. The number of SNPs represented 
on the array through these probes is proportional to the resolution of the array. After the 
hybridization, a detection system measures the fluorescent signal associated with each probe. The 
signal intensity depends upon the amount of target DNA in the sample, as well as the affinity 
between target and probe. 
 
Figure 1.9 (LaFramboise, 2009). Overview of SNP array technologies. A genomic region containing the SNP A/C is 
shown at the top. (a) Affymetrix assay: each probe (25-nt long) targets either allele A or allele B of each SNP 
interrogated. The location of the SNP locus varies from probe to probe. The DNA of interest binds to the 
complementary probes on the array, regardless of the allele it carries. However, it does so more efficiently when it is 
complementary to all 25 bases rather than mismatching the SNP site (indicated by a less bright yellow signal). (b)  
Illumina BeadArray: there are 50-mer probes consisting of a sequence complementary to sequence adjacent to the SNP 
site. A single-base extension (T or G) with labelled nucleotides results in a appropriated-colour signal (red or green, 
respectively). 
 
 
In contrast with array-CGH, in SNP arrays the signal intensities are not compared with those of a 
reference sample, but they are directly proportional to DNA quantity: an aberrant, increased or 
decreased, signal intensity means a copy number variation.  
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The intensity measures are converted into genotype inferences (AA, AB or BB) by a computational 
analysis of the raw signal data (figure 1.10). The inferences regard the presence or absence of each 
of the two alleles of the SNP, which are labeled as A and B. Each individual usually inherits one 
copy of each SNP position from each parent, therefore the genotype at a SNP site is typically either 
AA (homozygous for allele A), AB (heterozygote) or BB (homozygous for allele B). 
The computational algorithms that have been developed to convert the signal intensities into 
genotypes use two measures, the Log R Ratio (LRR) and the B Allele Frequency (BAF). LRR is a 
normalized measure of the total signal intensity at each SNP. In autosomic regions without CNVs 
(copy number = 2), LRR is ~0. LRR lower than zero may indicate a deletion, LRR>0 a duplication. 
BAF represents the relative ratio of the fluorescent signals between two probes/alleles (B/A) at each 
SNP. BAF values range from 0 to 1: BAF close to 1 indicate that the marker is homozygous for 
allele B, while BAF close to 0 indicate that the marker is homozygous for allele A. Values close to 
0.5 indicate a heterozygous genotype AB. Duplicated regions are characterized by intermediate 
BAF values (between 0.5 and 1 and between 0.5 and 0), correspondent to the genotypes ABB and 
AAB.  
 
Figure 1.10. The figure shows examples of LRR and BAF plots for a deleted region (1 copy, genotype B0 or A0), for a 
region with 2 normal copies (three possible genotypes for each SNP: AA, AB, BB) and a duplicated region (3 copies, 
four possible genotypes for each SNP: AAA, AAB, ABB, BBB). 
 
 
1.3.3 PCR-based approaches  
The PCR-based assays are useful for screening targeted regions of the genome. 
The best established of these approaches is real-time quantitative PCR (qPCR), that allows to 
confirm the presence of a predicted deletion or duplication. In a qPCR assay a DNA-binding dye 
(such as SYBR Green) binds to DNA, causing fluorescence of the dye. An increase in DNA product 
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during PCR leads to an increase in fluorescence intensity and is measured at each cycle, thus 
allowing DNA concentrations to be quantified. The comparison between a target region and a 
region with known copy number determines whether there is a gain or loss. Alternative methods to 
qPCR for the simultaneous interrogation of multiple regions include Multiplex Ligation-Dependent 
Probe Amplification (MLPA) (Schouten et al., 2002) and Quantitative Multiplex PCR of Short 
Fluorescent Fragments (QMPSF) (Charbonnier et al., 2000). 
Long range PCR can instead be used in order to accurately characterize the breakpoints of a CNV. 
For the deletions, primers spanning the CNV breakpoints generate a PCR product shorter than the 
expected for the reference genomic sequence and, if resolution is sufficient, this allows the fine 
mapping of the boundaries. For copy number gains instead, this approach is complicated by the two 
possible orientations of the duplicated region.  
 
1.3.4 Next Generation Sequencing-based approaches 
Despite progress in detection of human variation, the nucleotide resolution architecture of most 
structural variants remains unknown. The detailed characterization of structural variation requires 
the knowledge of precise sequences. The recent introduction of Next Generation Sequencing 
technologies (NGS) has enabled the mapping of CNVs at fine scale.  
Massively parallel sequencing platforms, such as the Roche 454 System and the Illumina HiSeq 
System, are able to perform sequencing of millions of small DNA fragments in parallel, providing 
an unprecedented increase in DNA sequencing throughput. Indeed these technologies produce high-
quality short “reads” (from 25 to 500 bp in length), which are substantially shorter than the ones 
that can be obtained by the capillary-based sequencing technology (500 pb-700 bp in length). 
Moreover the total number of base pairs sequenced in a given run is orders of magnitude higher.  
These newer approaches use various strategies that rely on a combination of template preparation, 
sequencing and imaging, genome alignment and assembly methods. The unique combination of 
specific protocols distinguishes one technology from another and determines the type of data 
produced from each platform (Metzker, 2010).  
Moreover, the ability to sequence the whole genome of many related organisms has allowed to 
perform large-scale comparative and evolutionary studies and to understand how genetic 
differences affect health and disease. Several projects, aimed at sequencing more individuals, have 
arisen. In particular the 1000 Genomes Project is the first project to sequence the genomes of a large 
number of people, combining the data from 2500 samples in order to provide a comprehensive 
resource on human genetic variation. Based on whole genome DNA sequencing data from 185 
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human genomes, the Structural Variation Analysis Group of the 1000GP has recently generated a 
comprehensive map of human genetic variation, integrating evidence from complementary 
sequence-based approaches with extensive experimental validations (Mills et al., 2011).  
One of the main advantages of the sequence-based approaches is the base-pair resolution of the 
CNVs detected, which also enables the identification of the breakpoint position. Analysis of DNA 
region motifs surrounding the breakpoints allows to hypothesize the formation mechanism. 
These sequence-based approaches include (figure 1.11):  
 Paired-end mapping (or read pair „RP‟ analysis): it is based on sequencing and analysis of 
abnormally mapping pairs of clone ends (Kidd et al., 2008; Korbel et al., 2007; Tuzun et al., 
2005) or high-throughput sequencing fragments. When the region spanned by the paired-ends in 
the sample genome is shorter than the correspondent region in the reference genome, this can 
indicate a deletion; when it is longer instead, this might indicate a simple insertion. 
 Read-depth („RD‟) analysis: evaluates the read depth-of-coverage, which is measure by counting 
the number of reads mapping to a certain genomic window. An increase or a decrease of the 
normalized read count in a certain region may indicate a gain or a loss, respectively (Yoon, 
Xuan, Makarov, Ye, & Sebat, 2009).  
 Split-read („SR‟) analysis: maps the boundaries (breakpoints) of structural variants by sequence 
alignment (K. Ye, Schulz, Long, Apweiler, & Ning, 2009). When a read spans across the 
breakpoint of a deletion, this sequence does not map to a single position on the reference 
genome, but it will be split into two fragments that map separately, indicating the position of the 
breakpoints.  
 Sequence assembly („AS‟), which enables the fine-scale discovery of CNVs, including novel 
sequence insertions (Hajirasouliha et al., 2010; Simpson et al., 2009), by using algorithms to 
assemble together the reads that do not map to any region of the genome. 
 
 
Figure 1.11 (Mills et al., 2011). Schematic representation of the different sequence-based approaches to detect 
CNVs. The arrows indicate the reads. Different sequence-based CNV-detection approaches are represented by 
different coloured reads. 
COPY NUMBER VARIANTS 
 
 
 
17 
 
In addition to whole-genome sequencing, the NGS platforms can be used to target specific regions 
of interest, such as all the protein-coding regions of the human genome. Since the exons constitute 
only approximately 1% of the human genome, but harbor 85% of the mutations with large effects 
on disease-related traits, sequencing complete coding regions (i.e., „„whole exome sequencing‟‟) 
has the potential to play a major role in disease gene discovery and also in clinical use for 
establishing a genetic diagnosis (Choi et al., 2009; Risch & Merikangas, 1996). 
 
1.4 CNVs and neurodevelopmental disorders 
Neurodevelopmental disorders are characterized by impairment of growth and development of the 
brain often associated with cognitive, neurological, or psychiatric dysfunction, such as intellectual 
disability (ID), developmental delay (DD), autism spectrum disorders (ASDs), schizophrenia 
(SCZ), and bipolar disorder (BD) (Coe, Girirajan, & Eichler, 2012). These different neurological 
conditions show a high heritability, but they have been proven to have a complex genetic 
architecture, in which multiple loci contribute to the overall risk. 
In the past two decades, the mapping of genes underlying these diseases has been focused on two 
alternative hypotheses: the “common disease-common variants” model (Risch & Merikangas, 1996) 
and the “common disease-rare variants” model.  
Studies attempting to test the first hypothesis have found that common variants confer only a small 
or moderate level of risk, suggesting that the aetiology of these common diseases might be 
explained instead by the “common disease-rare variants” model, in which a number of different 
causes (SNPs or CNVs), each of them with low frequency in the population and typically highly 
penetrant, could collectively account for a large proportion of attributable risk (McClellan & King, 
2010). These two hypotheses have been subsequently integrated in a new multifactorial model, in 
which common disorders could be result of a heterogeneous set of numerous rare and common 
variants, with different impact on the phenotype and collectively implicating a large number of 
different genes. 
Detection of CNVs has become an important field of genetic studies of complex disorders, as CNVs 
can make a substantial contribution to the genetic mechanisms underlying disease susceptibility 
and, in particular, rarer CNVs have been indicated as a potential source of missing heritability 
(Manolio et al., 2009).  
Within CNVs research, three study designs have been widely used (figure 1.12).  
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1) Family-based approach: this approach, which examines CNVs at individuals level, enables the 
identification of de novo CNVs, the determination of their frequency and the association of these 
mutations with the disorder;  
2) Case-control analysis of CNV burden: this approach analyses CNVs at population levels and 
examines whether the cases show a greater CNV genome-wide burden (i.e. the number of CNVs 
carried by an individual) compared to controls. The comparison of the collective frequency of rare 
variants (with frequency less than 1% in the general population) between cases and controls allows 
to investigate the contribution of rare CNVs to the disease.  
3) Association of Target regions or Genes: this approach analyses the association of specific CNV 
loci with the disease phenotype in large case control cohorts.  
 
 
Figure 1.12 (Molhotra 2012). Genetic approaches for CNV discovery. (A) Family-based studies of de novo mutation 
and (B) case control studies of genome-wide CNV burden, with CNV positions denoted by a red star (C) followed by 
single marker tests for association in large cohorts. 
 
Several interesting themes have begun to emerge from CNV studies in psychiatric and 
neurodevelopmental diseases.  
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Studies of large cohorts have revealed several highly penetrant loci associated with these disorders 
and a significant increase in large rare/de novo CNV burden in affected individuals compared to 
unaffected siblings and controls. In particular, in autism and schizophrenia, burden analyses have 
shown a general enrichment of potentially pathogenic duplications in a larger size range (>500 kb), 
and of deletions in smaller size range (30-500 kb) (Pinto et al., 2010). 
CNVs larger than 500 kb usually contain multiple genes and can be found in a small proportion of 
the general population (~8%), suggesting that these large rearrangements are under purifying 
selection and they are likely to be potentially pathogenic. Small CNVs instead are more frequent in 
the general population and this complicates the identification of pathogenic CNVs; however small 
CNVs can also represent important risk factors and the investigation of their role needs future 
studies with sufficient power in sample size and resolution. Moreover, it has been hypothesized that 
de novo CNVs might contribute to risk of sporadic forms of these disorders, since de novo 
mutations seem to have a stronger and more robust effect size compared to inherited CNVs. In 
particular, family-based studies have showed that de novo CNVs represent a contributing factor in 
5-10% of ASD patients (D. Levy et al., 2011; Pinto et al., 2010; Sanders et al., 2011), 5-10% of 
schizophrenia cases (Kirov et al., 2012; Malhotra et al., 2011) and 4.3% of individuals affected by 
bipolar disorder (Malhotra et al., 2011). 
The common theme amongst the CNV studies is the fact that the size and the rate of rare/de novo 
CNVs seem to correlate with the severity of the phenotype. The highest burden of large rare/de 
novo CNVs has been observed in cases with intellectual disability (ID) and dysmorphic features 
(Girirajan et al., 2012), the lowest burden in bipolar cases, in between the extremities are 
schizophrenia and autism. This trend seems to support a model where neurodevelopmental 
disorders, based on their severity and co-morbidities of ID, are considered part of a continuum 
(Figure 1.13). 
 
Figure 1.13 (Coe et al., 2012). An oligogenic model for neurodevelopmental disorders. In this model, a higher 
number of large, rare, de novo CNVs and, more in general, disruptive genetic mutations correlates with an increase in 
the severity of the clinical phenotype. 
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Another interesting observation is that a CNV locus can be recurrently identified in association with 
a variety of multiple neurological phenotypes (pleiotropic effect). In some cases, a CNV is 
necessary and sufficient to result in a specific phenotype: these CNVs are associated with known 
syndromes (“syndromic CNVs”) and most often they occur in patients with moderate-to-severe ID. 
Examples are the 17q21.31 microdeletion syndrome and the Williams syndrome deletion on 
chromosome 7q11.23. By contrast, there are CNVs which are much more variable in their outcome. 
These loci exhibit a variable expressivity, which means that individuals carrying the same CNV 
show either a qualitative or quantitative phenotypic variation, and a reduced penetrance, as these 
CNVs can be identified also in asymptomatic carriers.  
Therefore, these recurrent CNVs often show an incomplete segregation within multiplex families 
and are likely to be inherited from a parent, who may present any of the phenotypic manifestations 
associated with the CNV or have normal phenotype. Some of these CNV hotpots are 16p11.2, 
15q13.3, 1q21.2, 3q29, 17q21.31 and 7q11.23 loci (Coe et al., 2012).  
Moreover, losses and gains occurring at the same locus can lead to drastically different phenotypes 
or, instead, to surprisingly overlapping phenotypes. An example of different outcomes associated 
with CNVs at the same locus is given by the 16p11.2 region. Both the deletions and duplications in 
this locus have been observed in multiple conditions with significant enrichment compared to 
healthy controls. However, while deletions are associated with more severe phenotypes, including 
cases with autism, ID, macrocephaly, dysmorphic features, and obesity (Walters et al., 2010), the 
reciprocal duplications are seen in a wider range of conditions, including clinically underweight 
cases, schizophrenia and microcephaly. Similarly, duplications of 1q21.1 locus were identified in 
patients with ASD, whereas both deletions and duplications were associated with mental 
retardation. The 15q13.3 microdeletion is also detected across multiple phenotypes. In particular 
deletions in this locus have been indentified in individuals with idiopathic generalized epilepsy 
(Helbig et al., 2009), ID (Sharp et al., 2008), autism and schizophrenia. Instead the reciprocal 
duplication shows a more variably expression across neurological phenotypes, such as ID, bipolar 
disorder and autism, and its role in pathogenicity remains unclear (Szafranski et al., 2010).  
These examples suggest that differences between clinical phenotypes caused by reciprocal CNVs 
(duplication/deletion) can be attributed in part to the variable dosage sensitivity of the genes 
encompassed by the CNV: for some genes, an increased or a reduced dosage can determine 
opposite consequences (“mirror” phenotype); for other genes, the dosage imbalance alters certain 
cellular functions, irrespectively of the type of copy-number change. Moreover, the variable 
expressivity observed among the cases carrying the same CNV might be determined by secondary 
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“hits”, including additional pathogenic CNVs or damaging sequence mutations and by differences 
in the genetic background and epigenetic regulation. However, it is worth noting that this complex 
variability in phenotypic expression is not limited to the hotspots loci but might be true also for 
other genomic regions. 
Another interesting theme that emerged from CNVs analyses is that CNVs implicated in 
neurodevelopmental disorders affect genes that converge on common pathways, suggesting that 
there are some key genes important for several aspects of brain development and that, if mutated, 
can contribute to a range of neurological conditions, depending on the genetic background. 
Therefore, genic CNVs can be an important source for the discovery of the genes contributing to 
complex disorders and of pathways implicated in complex disorders. 
Interestingly, whole-genome or exome studies are very fruitful to identify particular candidate 
genes. Moreover, network analyses have allowed to estimate the amount of genes involved in 
neurodevelopmental disorders, confirming heterogeneity underlying these complex diseases. In the 
next years, the gene discovery effort is expected to be facilitated by the increasing availability of 
high-throughput CNV and sequencing data. The integration of structural and sequence information 
will allow the capture of a larger fraction of the rare disease-causing variants and to explain a larger 
proportion of the risk. 
 
1.5 Recurrent CNVs on chromosome 15q11-13. 
The proximal region of the long arm of chromosome 15 (15q11-q13) is a well-known hotspot for 
CNVs, due to the presence of complex patterns of highly homologous LCRs, that make this locus 
one of the most unstable regions in the human (Makoff & Flomen, 2007; Toth-Fejel et al., 1995). 
CNVs in this region include deletions, duplications, translocations, inversions and, also, 
supernumerary inv-dup(15) chromosomes (Jauch, Robson, & Smith, 1995; Schinzel et al., 1994). 
Deletions and duplications are likely to be caused by NAHR between the LCRs. The breakpoints of 
these CNVs are localized within clusters of LCRs, that have been designated BP1-BP5 (figure 
1.14). 
The structural and sequence features of the 15q11-13 region can lead to a number of different 
rearrangements: 
1. BP1-BP3 deletions or BP2-BP3 deletions can result in Prader-Willi Syndrome (PWS), if the 
deletion is inherited from the father, or Angelman Syndrome (AS), if the deletion is 
inherited from the mother (Amos-Landgraf et al., 1999). 
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2. Duplications instead can be associated with learning disabilities, seizures and autism. The 
15q11-q13 maternal duplication is the most frequent cytogenetic cause of autism, which 
occurs in 1-3% of individuals with ASD (Veenstra-VanderWeele & Cook, 2004). This 
duplication includes imprinted genes, therefore the effects of mutations in this region 
depend on the origin (maternal or paternal) of the chromosome in which they occur. 
3. BP1-BP2 microdeletions and microduplications have been proposed as risk factors for a 
range of neurological problems, in particular, language delay and developmental delay 
(Doornbos et al., 2009), ID, ASD (Sanders et al., 2011; van der Zwaag et al., 2010), 
schizophrenia (Kirov et al., 2012; Stefansson et al., 2008) and epilepsy (de Kovel et al., 
2010), but they have been observed also in controls .  
4. recurrent large BP4-BP5 deletions and duplications have been found across multiple 
conditions and also in asymptomatic carriers. However, BP4 and BP5 have a complex 
organization and can lead also to smaller microdeletions and microduplications (350-680 
kb), which have also been identified in a similar range of neuropsychiatric phenotypes 
(Szafranski et al., 2010). 
 
Figure 1.14 (Sanders et al., 2011) The genomic architecture of the BP1-BP5 region on chromosome 15q. The position 
of each BP is indicated. Class 1 indicates BP1-BP3 deletions, class 2 instead indicates the BP2-BP3 deletions. 
 
The typical rearrangements occurring between BP4 and BP5 are CNVs with a size of ~1.6 Mb and 
encompass six RefSeq genes (MTMR15, MTMR10, TRPM1, KLF13, OTUD7A and CHRNA7) and 
the microRNA gene hsa-mir211. In particular, the BP4-BP5 deletion has been reported in cases of 
mental retardation with seizures (Sharp et al., 2008), autism (Miller et al., 2009; Pagnamenta et al., 
2009), schizophrenia (Stefansson et al., 2008), bipolar disorder, epilepsy (de Kovel et al., 2010)and 
language delay (Ben-Shachar et al., 2009). 
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A recent study (Moreno-De-Luca et al., 2013) performed on a group of 31,516 cases (including 
patients with developmental delay, ID, ASD or multiple congenital abnormalities) has found  
statistical support for a pathological role for several CNV loci, including the BP4-BP5 region 
(Table 1.1 and Table 1.2). The BP4-BP5 deletion was detected in 88 cases, whereas the BP4-BP5 
duplication was identified in 34 cases and 5 controls. Both CNV types were reported to have a 
statistical significant increase in cases compared to controls. However, while the deletion appears to 
have a complete penetrance, the reciprocal microduplication has a less certain clinical significance 
in comparison with the deletions. The clinical uncertainty of the 15q13.3 duplications could be due 
to the fact that a larger sample size is necessary to detect a low penetrant effect. 
 
Table 1.1 (Moreno-De-Luca et al., 2013). Deleterious recurrent deletions in clinical cohorts. 
 
 
Table 1.2 (Moreno-De-Luca et al., 2013). Deleterious recurrent duplications in clinical cohorts 
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In conclusion, BP1-BP2 and BP4-BP5 CNVs can be observed in a wide spectrum of clinical 
phenotypes of variable severity and some of them, such as BP1-BP2 microdeletions and BP4-BP5 
microduplications, are present also in healthy individuals, suggesting that they have variable 
expressivity and incomplete penetrance and are probably not sufficient to cause pathological 
phenotypes (Leblond et al., 2012; van Bon et al., 2009). However, since they involve interesting 
candidate genes and have a higher frequency in clinical cohorts, they might contribute to the 
susceptibility to certain neuropsychiatric disorders in specific genetic backgrounds, where 
secondary alterations could have an additive or epistatic effect. 
AUTISM SPECTRUM DISORDER 
 
 
 
25 
 
CHAPTER 2: 
AUTISM SPECTRUM DISORDER 
 
2.1 Autism Spectrum Disorder  
The word “autism” was first used in 1943 by psychiatrist Leo Kanner (Kanner, 1968) who 
described 11 children, mostly boys, with a combination of severe social and variable language 
dysfunction and the presence of repetitive restrictive behaviors. Kanner‟s reuse of autism led to 
decades of confused terminology like infantile schizophrenia, and it was suggested that autism may 
be related to a “genuine lack of maternal warmth”. The “refrigerator mother” theory was then 
rejected and, starting in the late 1960s, autism was established as a distinct syndrome, 
distinguishing it from intellectual disability and schizophrenia and from other developmental 
disorders, and demonstrating the benefits of involving parents in active programs of therapy 
(Fombonne, 2003).  
A major change in perspective came with the pioneering twin studies of Rutter and Folstein that 
demonstrated a genetic susceptibility to the disorder (Folstein & Rutter, 1977a, 1977b). Over the 
past two decades, the concept of autism has extended from the strict diagnosis of autistic disorder to 
include a group of related lifelong neurodevelopmental conditions, called Autism Spectrum 
Disorders (ASDs) (figure 1.1). According to the fourth edition of the Diagnostic and Statistical 
Manual of Mental disorders (DSM-IV) ([APA], 1994), the ASDs are characterized by delays or 
abnormal functioning in one or more of the following three domains: social interaction; social 
communication and restricted and repetitive behaviours and interests, and they include four 
disorders: 
1) Autism, which presents deficits in communication, social interactions and repetitive 
behaviours;  
2) Asperger‟s disorder, which is characterized by the absence of clinically significant delay in 
language and cognitive development;  
3) Childhood Disintegrative Disorder (CDD), which typically occurs later than autism and 
involves a more dramatic loss of skills (regression);  
4) Pervasive Development Disorder-not otherwise specified (PDD-NOS), which presents sub-
threshold symptoms and/or later onset.  
These neurological conditions differ in the severity and in the pattern of the core symptoms, 
developmental course, and cognitive and language abilities. Therefore, given the absence of a clear 
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discrimination, both etiological and clinical, between these categories, in the last version of manual, 
the DSM-V ([APA], 2013), the category of Asperger syndrome was removed and the diagnostic 
criteria for autism were modified under the new heading of Autism Spectrum Disorder (ASD). The 
word “spectrum” refers to the decomposition of light through a prism, in which multiple dimensions 
are present, indicating the heterogeneity underlying these disorders.  
Therefore, individuals with ASD are best represented as a single diagnostic category because they 
show similar types of symptoms and are better differentiated by clinical presentations (i.e., severity, 
verbal ability) and by associated features (i.e., known genetic disorders, epilepsy and intellectual 
disability). An individual with an ASD diagnosis will be described in terms of severity of social 
communication symptoms, severity of fixated or restricted behaviors or interests and associated 
features.  
ASD has an estimated prevalence of ~60/10,000 individuals (Elsabbagh et al., 2012) and a male to 
female gender bias, with a ratio of ~4:1 (E. Williams, Thomas, Sidebotham, & Emond, 2008). 
 
 
Figure 2.1 (Devlin & Scherer, 2012). Autism phenotypic classification. Autism is the prototypic form of a group of 
conditions, collectively called autism spectrum disorders (ASD), which share defects in three core domains: social 
communication; language development and restricted and repetitive behaviours and interests).  
 
 
2.2 Clinical phenotype and diagnostic instruments 
Autism is a developmental neuropsychiatric syndrome characterized by onset prior to 3 years of age 
and by a triad of behavioral signs and symptoms including the following domains:   
1) social interaction: people with autism have social impairments which become apparent early 
in childhood. They show lack of interest, tendency to isolation, less attention to social 
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stimuli and smile. They also have difficulties to establish a direct visual contact, to start a 
conversation and to answer questions or to their own name. 
2) communication: about 50% of autistic children not develop any verbal language or show a 
marked delay in the development of spoken language (Hus, Pickles, Cook, Risi, & Lord, 
2007). Impairments in communication include babbling, unusual gestures which are not 
integrated with words, vocal patterns that are not synchronized with the caregiver, deficits in 
joint attention and imaginative play. They often repeat others words, expressions or sounds 
(echolalia) and they may refer to themselves with the own name. 
3) restricted interests and repetitive behavior: autistic individuals display repetitive movements, 
such as hand flapping, head rolling, or body rocking (stereotypy); compulsive behaviors, 
like arranging objects in stacks or lines; ritualistic behaviors which involve a invariable 
pattern of daily activities, such as an unchanging menu or a dressing ritual; restricted 
behaviors or movements which cause self-injury, such as eye-poking, skin-picking, hand-
biting and head-banging.  
However, it should be noted that autism shows a high heterogeneity of symptomatology. Rare 
autistic cases with an extraordinary capacity for mathematical calculation, musical sensitivity, 
exceptional audio-visual memory or other unusual abilities, are reported. Autism presents also a 
high variation in cognitive skills, ranging from profound mental retardation to cognitive levels high 
or higher than normal. Moreover one ASD child out of four develops seizures, which usually occur 
in early childhood or adolescence (Zappella, 2010), while others may show motor retardation, 
dysmorphisms, gastrointestinal problems and other co-morbidities.  
Two diagnostic instruments commonly used in autism diagnosis are the Autism Diagnostic 
Interview-Revised (ADI-R) (Lord, Rutter, & Le Couteur, 1994) and the Autism Diagnostic 
Observation Schedule–Generic (ADOS-G) (Lord et al., 2000). The ADI-R is a standardized 
interview conducted with caregivers of autistic individuals. The questionnaire explores the areas of 
communication, social interactions, restricted and repetitive behaviours and developmental history. 
An algorithm was generated to make a standard diagnosis on the basis of the ADI-R scores obtained 
in each area and it includes only the items that more closely depicted the phenotypic abnormalities 
described in the Diagnostic and Statistical Manual of mental disorders-4th edition (DSM-IV) 
([APA], 1994). The algorithm specifies a cutoff score for each of three core domains of autism, 
therefore, only the individuals who meet all the cutoffs, meet diagnostic criteria for autism, the most 
severe form of ASD. The ADOS-G is an interactive test that aims to assess social interactions, 
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communication, play and spontaneous behaviours in a standardized context. ADOS-G is an 
implementation of ADOS (Lord et al., 1989), which was proposed as a complementary instrument 
to ADI. As for ADI-R, subsets of items in each module of ADOS-G were selected to generate 
diagnostic algorithms. Classification is made on the basis of exceeding cutoffs in social behaviour, 
communication and social-communication totals. 
 
2.3 The genetic basis of ASD 
Twin and family studies have indicated a strong genetic basis for ASD susceptibility.  
The first twin studies observed concordance rates of 82-92% in monozygotic twins (MZ) compared 
with 1-10% in dizygotic twins (DZ) (Bailey et al., 1995; Folstein & Rutter, 1977b). A higher 
disease co-occurrence in MZ twins than DZ twins supports a genetic etiology, because MZ share 
100% of their genetic material and dizygotic twins (DZ) share 50% (similar to non-twin siblings) 
and both share the in utero environment with their twin. However, more recent studies have 
indicated that the concordance in dizygotic twins might be higher (>20%), suggesting that shared 
environment could play a larger role than had been previously estimated (Hallmayer et al., 2011). 
Concordance rates between MZ twins do not take into account the genetic factors that may differ in 
co-twins, such as epigenetic factors, X-inactivation and mutations de novo arisen after the 
separation of the embryos. Therefore, these genetic and epigenetic differences can produce 
phenotypic differences between MZ which are not due to environmental factors, but that can result 
in a decrease of estimated hereditability. 
A further support for a strong genetic background in ASD comes from family-based studies, which 
have found that first-degree relatives of autistic probands have a markedly increased risk for autism 
compared with the population, as they show behavioral or cognitive features which are similar to 
ASD proband (such as social or language dysfunction), but in lesser forms. These mild forms of 
impairments, usually affecting only one of the core domains, are classified as “broader phenotypes” 
(Losh et al., 2009). The recurrence risk in families with one child with ASD was initially estimated 
at 5%, compared with 1% in the general population, but recent studies investigating early signs of 
ASD in siblings of individuals with ASD revealed an even higher recurrence rate (up to 20%) 
(Hallmayer et al., 2011; Ozonoff et al., 2011). These sub-threshold autistic traits are highly heritable 
and show a continuous distribution in the population, suggesting that different features of autism 
represent a quantitative continuum of function that could be inherited in distinct patterns.  
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However, despite high heritability of ASD, its genetic architecture is complex, as several different 
genes are involved in the disorder (Betancur, 2011) and the exact underlying causes are identifiable 
only in a minority of patients.  
The first genetic causes of ASD (Figure 2.2) were identified in known single-gene disorders, 
accounting for approximately 10% of individuals with ASD, with fragile X syndrome being the 
most common (1%-3% of cases), followed by PTEN macrocephaly syndrome, tuberous sclerosis 
and Rett syndrome (each accounting for approximately 1% of children diagnosed with autism) 
(Miles, 2011). In addition to this syndromic forms of autism, rare cytogenetically visible 
chromosome rearrangements may account in about 5% of individuals with ASD. Among these 
cytogenetic abnormalities, the maternal 15q11-q13 duplication is the most common, detected in 1-
3% of cases (Baker, Piven, Schwartz, & Patil, 1994). 
On the other hand, recent findings have shown that some rare, highly penetrant mutations in several 
ASD candidate genes, including NLGN3, NLGN4 (Jamain et al., 2003; Laumonnier et al., 2004), 
SHANK1 (Sato et al., 2012), SHANK2 (Berkel et al., 2010), SHANK3 (Durand et al., 2007), NRXN1 
(Ching et al., 2010), NRXN3 (Vaags et al., 2012), DPYD (Carter et al., 2011), DPP6 (Marshall et 
al., 2008) and CNTNAP2 (Bakkaloglu et al., 2008) could collectively account for a large proportion 
of risk (5% of ASD cases). Moreover, recent high-throughput screenings have begun to uncover a 
large number of individually rare submicroscopic structural variants (Copy Number Variants, 
CNVs), both de novo and inherited, potentially contributing to the ASD susceptibility in about 5% 
of individuals with ASD (Devlin & Scherer, 2012). (For a detailed discussion of Copy Number 
Variants see Chapter 1). 
 
 
Figure 2.2 (Devlin and Scherer, 2012). Genetic architecture in ASD. Rare genetic risk factors and their estimated 
contribution to ASD are represented in four groupings. Additional rare and common genetic variants may modify 
clinical presentation or operate under a threshold model. Genetic contributions to ASD can also arise from direct or 
indirect effects on genes and proteins by environmental influences. 
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2.4 Molecular genetic studies of ASD susceptibility  
In order to identify the genetic risk factors conferring susceptibility to ASD, linkage and association 
studies have been performed. Both approaches are based on the genotyping and analysis of genetic 
markers, which are polymorphic variants with a known position in the genome (e.g. SNPs or 
microsatellites). 
 
2.4.1 Linkage studies in ASD 
Linkage studies are based on the principle that polymorphic genetic markers located in proximity of 
disease-causing variants co-segregate with the affection status, across generations: the linkage 
between these markers and the disease-causing variants is detected when they are transmitted 
together to the offspring more often than expected under independent inheritance. Their probability 
of being separated by a crossing over during meiosis is proportional to their distance on the 
chromosome. These studies involve related individuals and can include large pedigrees (with 
extended families and/or multiple generations) or a large number of small nuclear families 
(consisting of a father, a mother, and their children).  
Linkage studies usually identify large regions of susceptibility (in the order of Mb), encompassing a 
large number of genes, and their success is affected by genetic and phenotypic heterogeneity of the 
disorder. 
Several whole-genome linkage studies have been performed for ASD and, although many loci have 
been implicated, replicated regions between samples are rare, reflecting the extensive heterogeneity 
underlying the disorder and the likely small effect size attributable to single genes. The first regions 
linked to autism were identified by the International Molecular Genetic Study of Autism 
Consortium ((IMGSAC), 2001; Maestrini et al., 2010) on chromosomes 7q (designated AUTS1, 
7q21-q32, OMIM 209850) and 2q (designated AUTS5, 2q24-q33, OMIM 606053) and these have 
been also the most consistently replicated loci (Badner & Gershon, 2002; Buxbaum et al., 2001; 
Schellenberg et al., 2006; Shao et al., 2002; Trikalinos et al., 2006).  
A possible strategy to increase the chances of identifying contributory risk genes in a context of 
high heterogeneity is to analyse a large sample of multiplex families. However, although linkage 
studies with higher resolution and larger cohorts of ASD families (Szatmari et al., 2007; Weiss, 
Arking, Daly, Chakravarti, & Consortium, 2009) have been performed, they showed that the 
linkage regions described above failed to reach genome-wide significance. In the study realized by 
the Autism Genome Project (Szatmari et al., 2007) using Affymetrix 10K SNP arrays and 1,168 
families with at least two affected individuals, suggestive linkage was obtained only for a region on 
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chromosome 11p12-p13. The samples were also stratified in categories, but, even in these subsets, 
the loci on 7q and 2q reached only suggestive evidence of linkage in the individuals of European 
ancestry, confirming the genetic heterogeneity underlying the ASD and hindering the identification 
of genetic cause. 
 
2.3.2 Association studies in ASD 
Association studies aim to find an allelic association between specific genetic variants and the 
disease phenotype in a population, assuming that the marker itself or a variant close to it confers 
susceptibility to the disease. When an allelic variant is associated with a trait, this result can be 
interpreted as:  
a) a direct association, if the variant has a causal role in the phenotype susceptibility;  
b) an indirect association, if the variant is in Linkage Disequilibrium with the causal variant (LD is 
a phenomenon arising from alleles at linked loci, that tend to co-segregate more often than expected 
by chance and forming “haplotypes blocks”);  
c) a false positive, that may be due to chance or to problems such as population stratification or 
inappropriate statistical methods.  
Generally, association studies require a higher density of markers than linkage studies, but they 
identify candidate chromosome regions with a better resolution. 
Results of association studies are usually expressed as P values or –log10(P): very low P values 
provide strong evidence for association. The significance threshold depends on the number of 
markers: as the number of markers increases, the required number of tests increases and the 
significance threshold becomes more stringent. 
International projects, such as the HapMap Project (http://hapmap.ncbi.nlm.nih.gov/) and the 1000 
Genome Project (http://www.1000genomes.org/) have been a useful resource for association 
studies, providing a deep characterization on human genetic variation in different populations and 
determining its Linkage Disequilibrium structure. Moreover, the advent of microarrays and the 
availability of sufficiently large samples have allowed to perform genome-wide association studies 
(GWAS).  
Several GWAS in large cohorts of autistic individuals have been carried out (Anney et al., 2012; 
Anney et al., 2010; Wang et al., 2009; Weiss et al., 2009). These studies identified genome-wide 
significant association signals in some genomic regions, suggesting putative molecular pathways 
with a crucial role in ASD pathogenesis. For example, an altered functional connectivity in frontal 
lobe circuits has been associated with common genetic SNP variation in CNTNAP2 (Scott-Van 
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Zeeland et al., 2010), a putative ASD risk gene identified through the study of rare variants. 
However, none of these studies has replicated any of the previous linkage or association findings, 
supporting the hypothesis that only a few common variants have a substantial impact on risk, 
whereas risk alleles with low minor allele frequency or rare variants might be relevant in the 
aetiology of ASD. 
 
2.5 CNVs and ASD 
Screening for CNVs, performed using different microarray platforms (see Chapter 1), has proven to 
be a rapid method to analyse the genomes of large cohorts of ASD cases and controls and to 
quantify the role of rare CNVs in ASD susceptibility.  
Early genome-wide studies performed on ASD families, revealed that CNVs are present in about 6-
10% of individuals with ASD, compared with 1-3% in the general population (Christian et al., 
2008; Jacquemont et al., 2006; Marshall et al., 2008; Sebat et al., 2007). Notably, these studies 
found that  the proportion of de novo CNVs is three-fold to five-fold higher in patients with ASD 
than in unaffected individuals. Moreover, de novo CNVs are larger and affect more genes in 
individuals with ASD compared with their unaffected siblings and controls. However, since 
unaffected siblings display a frequency of de novo variants similar to controls, this enrichment does 
not reflect a higher risk of parents to produce these de novo variants. 
Another interesting finding is that simplex and multiplex families differ in the proportion of de novo 
CNVs. 
Other studies (Marshall et al., 2008; Pinto et al., 2010) confirmed a greater abundance of large de 
novo CNVs in simplex versus multiplex ASD families and highlighted some of the CNVs 
recognized as risk loci and their frequency of occurrence (all individually less than 1%) in ASD 
cases. Further studies, however, failed to replicate the genome-wide differences initially found in 
CNV frequency between ASD patients and controls (Bucan et al., 2009; Glessner et al., 2009; Pinto 
et al., 2010). 
When comparing 996 ASD individuals of European ancestry to 1,287 matched controls, genotyped 
on the Illumina Infinium 1M-single SNP-microarray, Pinto et al. (2010) did not find a significant 
difference between cases and controls. Instead, when focusing on gene-containing segments, a 
significant increase (1.19-fold increase, empirical P=0.012) in the number of genes intersected by 
rare CNVs was discovered in cases; interestingly this difference was more statistically significant 
(1.69 fold, P= 3.4×10
-4
) restricting the analysis to loci previously implicated in either ASD and/or 
intellectual disability (Figure 2.3). 
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Figure 2.3 (Pinto et al., 2010). CNV burden in known ASD and/or ID genes. Proportion of samples with rare CNVs 
overlapping genes known to be associated in ASD with or without ID or ID only. A higher proportion of cases with rare 
CNVs overlapping “ASD implicated” genes was observed compared to controls (4.3% versus 2.3%, Fisher exact test 
P= 5.4×10−3). Combining the “ASD implicated” and “ID” gene-sets result that 7.6% of cases has rare CNVs 
preferentially affecting ASD/ID genes compared to 4.5% in controls (Fisher exact test P= 1.2×10−3, Fig. 2a). 
 
A total of 226 de novo and inherited CNVs not observed in controls and affecting single genes were 
found, and among these CNVs, some of them implicated many novel ASD genes, such as SHANK2, 
SYNGAP1 and DLGAP2. Moreover in order to identify groups of genes affected by CNVs that 
share a common function or operate in the same pathway (gene-sets), a functional enrichment 
mapping approach was used. Both gene-sets known to be involved in ASDs and new candidate 
ASD pathways were discovered: for example, gene-sets involved in cell and neuronal development 
and function (including projection, motility, and proliferation) previously reported in ASD-
associated phenotypes, and new groups such as GTPase/Ras signaling, known to be involved in 
regulating dendrite and spine plasticity and associated with ID (figure 2.4).  
AUTISM SPECTRUM DISORDER 
 
 
 
34 
 
 
 
Figure 2.4 (Pinto et al., 2010). A functional map of ASD. The gene-sets of known ASD/ID genes are represented by 
nodes and node size is proportional to the total number of genes in each set. The color indicates the class of gene-set: 
enriched in deletions, red; known ASD and/or ID genes, blue; enriched only in disease genes, yellow. Edge color 
represents the overlap between gene-sets enriched in deletions (green), from disease genes to enriched sets (blue), and 
between sets enriched in deletions and in disease genes or between disease gene-sets only (orange). The major 
functional groups are highlighted by filled circles (enriched in deletions, green; enriched in ASD/ID, blue). 
 
These findings suggest that CNV location and its functional relevance may play a more important 
role instead of mean CNV number and size. Moreover these CNV studies provide strong support for 
the involvement of multiple rare genic CNVs, both genome-wide and at specific loci, in ASD and 
highlight the role of molecules such as NRXN1, NLGN3/4X and SHANK3, in maturation and 
function of glutamatergic synapses. Other network-based functional analyses of rare CNVs have 
confirmed the involvement of these loci in axon targeting, neuron motility and synapse 
development (Gilman et al., 2011). 
Two independent recent studies (D. Levy et al., 2011; Sanders et al., 2011), performed on the same 
large ASD cohorts of simplex cases, have supported the role of de-novo CNVs in idiopathic autism, 
reporting a significant increase in the burden of rare de novo CNVs in ASD cases (5.8%-7.9%) 
compared to unaffected siblings (1.7%-1.9%). Moreover, they confirmed several known ASD loci, 
but identified also many new candidate regions, such as the 16p13.2 and CDH13 loci. 
Therefore, the occurrence of multiple different de novo CNVs identified in the probands, but not in 
their unaffected siblings, indicates that autism is mostly caused by rare mutations with most de novo 
events being unique to each proband. 
More specifically, Levi et al found evidence for a major contribution of inherited „„ultrarare‟‟ 
duplications in cases than in unaffected siblings and showed that relative to males, females have 
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greater resistance to autism, as they have a higher frequency of de novo events than males (11.7% 
versus 7.4%, p value = 0.16) and these genomic imbalances are larger and affect more genes. 
In summary, the studies conducted to date on ASD revealed that a large number of individually rare 
(with a frequency less than 1%) CNVs and encompassing several different genes, are involved in 
the etiology of ASD, further showing the extent of genetic heterogeneity in this disorder.  
Some CNVs have a large impact on ASD expression, cause more severe ASD symptoms, and be 
more prevalent among sporadic ASD cases, whereas other CNVs have moderate or mild effects and 
constitute risk factors, which likely require other genetic (other CNVs, mutations) or non-genetic 
factors to predispose to ASD or to other  disorders. Some of these CNVs show a variable 
phenotypic expression and are observed in non-ASD relatives and in some controls.  
Indeed up to 40% of family-specific CNVs are inherited from an apparently non ASD parent, who 
may display some autistic traits, but without satisfying criteria for autistic disorder and this is 
consistent with incomplete penetrance. 
 
2.6 Next Generation Sequencing Technologies (NGS) and ASD 
The recent introduction of Next Generation Sequencing (NGS) technologies such as whole-exome 
and whole-genome sequencing, had an enormous impact on gene discovery, accelerating the 
characterization of genomic variation and allowing the mapping of both CNVs and single 
nucleotide variants. 
In particular, whole exome sequencing has proven to be a powerful tool for discovering risk-
conferring variation, such as de-novo mutations, which are sufficiently rare and may thus provide 
evidence for a causal link to ASD.  
The first large-scale WES (Kong et al., 2012; Neale et al., 2012; O'Roak et al., 2012; Sanders et al., 
2012) have been carried out assessing more than 1000 ASD subjects, in order to estimate the 
contribution of de novo coding sequence mutations, especially de novo loss-of-function (LoF) 
variations (mutations that are predicted to disrupt gene function), which are more deleterious than 
inherited variants. These studies showed that the average rate of de-novo LoF (including missense, 
splicing, frameshift and stop-gain variants) was higher in ASD cases than unaffected siblings, and 
this difference was statistically significant when the analysis was restricted to genes expressed in  
brain. Specifically, females with ASD tend to have more de-novo coding sequence variants than 
affected males (figure 2.5a). Moreover the proportion of these protein-altering point mutations was 
three time more likely to come from paternal chromosome than the maternal one (figure 2.5b) and 
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the rate of these variants increased with paternal age (figure 2.5c) (Kong et al., 2012), suggesting 
that children of older father have a higher autism risk. 
 
 
Figure 2.5 (Huguet, Ey and Bourgeron 2013). The burden of de novo coding-sequence variants in ASD. (a) 
Distribution of de novo coding-sequence variants in individuals with ASD and controls after stratification by sex. Data 
are from Neale et al.2012, O‟Roak et al. 2012, Sanders et al. 2012; Iossinov et al, 2012. (b) Parental origin of de novo 
coding-sequence variants identified in individuals with ASD. Data are from References Kong et al., 2012 and  O‟Roak 
et al. 2012. (c) Relationship between parental age and the number of de novo coding-sequence variants in the child. 
Data are from Reference Kong et al., 2012.  
 
However, only a small number of these variants are causative, and those that confer risk to ASD are 
distributed in many autism-related genes and show an incomplete penetrance. Moreover, many of 
the disrupted genes are involved in important gene networks, including synaptic plasticity or 
catenin/chromatin remodelling, and several de novo variants impact genes previously implicated in 
other neurodevelopmental disorders and in intellectual disability. Therefore, these findings further 
support the involvement of synaptic pathways in ASD susceptibility.  
Another interesting result originating from WES is that ASD risk was increased when two 
extremely rare (≤ 5%) damaging variants, such as nonsense and essential splice site, affect both 
copies of a protein coding gene, suggesting a role of recessive non-synonymous changes in ASD 
susceptibility. Similarly, rare hemizygous mutations on the X chromosome, which truncate the 
protein in males, were enriched in ASD males compared to controls (Lim et al., 2013). These results 
provide thus evidence that homozygous or compound heterozygous LoF variants play an important 
role in ASD pathogenesis.  
A further evidence supporting a role of biallelic mutations comes from WES applied to 
consanguineous and/or multiplex families with ASD (Yu et al., 2013), which are extremely useful 
to identify inherited mutations responsible for rare heritable conditions. These approach allowed the 
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identification of many hypomorphic mutations that partially impair gene function and could result 
in atypical milder forms of some diseases, associated with a ASD phenotype. Interestingly these 
rare variants have been detected in genes not directly implicated in synaptic activity, but involved in 
neurometabolic disorders, such as AMT and PEX7, suggesting that unexpected pathways may be 
involved in ASD aetiology. Alternatively, these new candidate genes may be implicated in synaptic 
pathways that have yet to be characterized: for example AMT encodes for an enzyme essential for 
glycine degradation and it is known that glycine is a crucial inhibitory neurotransmitter (Baer, 
Waldvogel, Faull, & Rees, 2009), whereas PEX7 encodes for a receptor required for import of 
proteins into the peroxisomes, which are abundant in dendrites (J. Kou et al., 2011)  
Therefore, since ASD is an etiologically and phenotypically heterogeneous disorder that involved 
hundreds of genomic loci, identifying highly penetrant variants in very large sample size is likely 
the better approach to understand the biological pathways linked to ASD.  
To this end two recent WES have been performed (De Rubeis et al., 2014). 
By sequencing more than 2500 ASD simplex families Iossifov et al (Iossifov et al., 2014) estimated 
that 13% of de novo missense mutations and 43% of de novo likely gene-disrupting (LGD) 
mutations (including non sense, frameshift and splice site) contribute to 12% and 9% of ASD 
diagnoses, respectively. Moreover de novo variants occur three time as often in the paternal 
background and mutation rates are increased with age of either parent, confirming thus previous 
findings (Kong et al., 2012; O'Roak et al., 2012).  
When comparing probands and unaffected siblings, probands were found to carry a significant 
enrichment for de novo LGD in certain functional categories, including FMRP targets, chromatin 
modifiers and genes expressed in embryonic development. Specifically, affected individuals with 
higher IQs had a greater incidence of LGD mutations than unaffected siblings, but a lower 
incidence than affected females or males with lower IQs. Moreover, in comparison with males with 
higher IQ, females and males with lower IQ showed an enrichment of these variants in the FMRP-
associated genes, chromatin modifiers, embryonically expressed genes and in published targets for 
intellectual disability and schizophrenia. 
Additional gene-sets implicated in ASD susceptibility have been discovered by the largest ASD 
WES study conducted so far (De Rubeis et al., 2014) in more than 3800 autistic cases and in about 
10.000 ancestry-matched or parental controls. By analysing the distribution of relative risks across 
genes for three particular classes of sequence changes, including de novo LoF, de novo probably 
damaging missense (Mis3) variants and transmitted LoF, 22 autosomal genes at a false discovery 
rate (FDR) ˂ 0.05, plus a set of 107 autosomal genes strongly enriched for those likely to affect risk 
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(FDR ˂ 0.30), were discovered. These 107 genes include 21 candidate genes for intellectual 
disability, 3 for epilepsy, 17 for schizophrenia, 9 for congenital heart disease and 6 for metabolic 
disorders (figure 2.6). 
 
 
Figure 2.6 (De Rubeis et al., 2014). Venn diagram showing the overlap in  disease involvement for the ASD genes.  
 
As previously observed, male and female ASD subjects showed a difference in the effect on risk for 
a class of variants: females have greatly reduced rates of ASD relative to males (a „female 
protective effect‟) and a higher liability threshold, requiring a larger genetic burden before being 
diagnosed. Moreover, three critical pathways were found to be damaged by risk variation: 
chromatin remodelling, which involves histone-modifying enzymes and chromatin remodellers that 
recognize specific histone post-translational modifications and orchestrate their effects on 
chromatin; transcription and splicing, which includes the RBFOX splicing factors; synaptic 
function, which involves multiple classes and components of synaptic networks, from receptors and 
ion channels to scaffolding proteins. These findings suggest that alterations of the chromatin 
dynamics and transcription may affect the synaptic function, that is essential for neural physiology. 
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CHAPTER 3: 
ASD CANDIDATE GENES 
 
3.1 ASD candidate genes 
Many ASD loci and genes have been identified and are just beginning to be connected in functional 
networks. Moreover, several databases, such as Autism KB (http://autismkb.cbi.pku.edu.cn) and 
SFARI Gene (https://gene.sfari.org), are providing functional annotation of genes associated with 
ASD.  
The genes implicated in ASD susceptibility are numerous and involved in multiple cellular 
functions. Most of them encode proteins involved in the development and function of neural circuits 
(figure 3.1), including neuronal differentiation, migration and circuit formation (CDH10, CDH9, 
SEMA5A, RELN, PTEN), regulation of synaptic adhesion (NRXN1, CNTNAP2, NLGN3, and 
NLGN4X), synaptic transmission (CADPS2, CACNA1C, GABRB3 and SHANK3), and transcription 
and translation (TSC1, TSC2, FMR1, and MECP2) (Bill & Geschwind, 2009; O'Roak et al., 2012; 
Pinto et al., 2010). 
 
 
Figure 3.1 (Sadakata, Shinoda, Sato, et al., 2013). Many ASD-associated genes and gene candidates are involved in 
synapse function and structure. ASD-associated genes and gene candidates (indicated by underlining) are involved in 
synaptic connections, synaptic transmission, synaptic plasticity, activity-dependent gene expression, and local 
translation in synapses. 
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3.2 ASD-related syndromes 
The first genetic causes of ASD were identified in monogenic disorders which occur in 
approximately 10% of all ASD cases and include known genetic syndromes, such as tuberous 
sclerosis (associated with TSC1 and TSC2), neurofibromatosis (associated with NF1), Rett 
syndrome (associated with MECP2), and Cowden syndrome (associated with PTEN).  
Fragile X syndrome (FXS) is the second most common cause of mental impairment after trisomy 21 
(Rousseau, Rouillard, Morel, Khandjian, & Morgan, 1995), accounting for 2% of ASD cases. FXS 
is caused by the unstable expansion of a CGG repeat (>200 repeats) at 5‟ of the FMR1 gene, located 
in Xq27.3, producing abnormal methylation, FMR1 transcription silencing and decreased FMRP 
protein levels in the brain (Bagni & Greenough, 2005). Fragile X syndrome in the ASD cases is 
caused by premutation repeat expansions (55-200 CGG repeats) which can result in RNA toxicity 
and can also lead to aging effects including tremor, ataxia and cognitive decline, called “Fragile X-
associated tremor ataxia syndrome”. ASD in FXS is mainly characterized by deficits in social 
interaction and communication, although impairments in theory-of-mind and pragmatic language 
distinguish FXS with and without ASD (Kaufmann et al., 2004; Losh, Martin, Klusek, Hogan-
Brown, & Sideris, 2012; McDuffie et al., 2010). Recent studies have demonstrated that individuals 
with ASD and FXS have a lower IQ and greater deficits in receptive and expressive language 
compared to patients with FXS alone (McDuffie et al., 2010). 
Tuberous sclerosis (TS) is an autosomal dominant disease with high penetrance, caused by 
inactivating mutations, including nonsense, missense, insertion and deletion mutations, in either of 
two genes, TSC1 or TSC2, located in 9q34 and 16p13.3, respectively. It is characterized by tumor-
like lesions in multiple organs but also by other clinical manifestations such as epilepsy, learning 
difficulties and behavioral problems. In particular, subject with TSC2 mutations are significantly 
more likely to display greater severity compared to those with TSC1 mutations, including autistic 
disorder, infantile spasms and a lower intelligent quotient (Crino, Nathanson, & Henske, 2006; 
Gutierrez, Smalley, & Tanguay, 1998). 
While FMR1 mutations may also contribute to the etiology of non-syndromic ASD, particularly in 
women (Chaste et al., 2012), an enrichment of rare functional variants in the TSC1 and TSC2 genes 
was not reported in a sample of 300 ASD trios, thus excluding that mutations in the TSC1/2 genes 
are rare causes of non-syndromic autism (Bahl et al., 2013). 
Rett syndrome is caused by de novo loss-of-function mutations in  the MECP2 gene, which encodes 
a member of the methyl-CpG-binding domain family of proteins. MeCP2 binds to methylated CpG 
dinucleotides and recruits histone deacetylase 1 (HDAC1) and other proteins involved in chromatin 
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repression at specific gene promoters. Loss of MeCP2 results in a delay of neuronal maturation and 
synaptogenesis, suggesting that this gene play an important role in correct brain function and 
development. Rett syndrome occurs in approximately 70% of affected females, while it is generally 
lethal in males (Amir et al., 1999; Chahrour & Zoghbi, 2007).  
Depending on specific mutation affecting MECP2, genetic background of the affected individual 
and most specifically on X-inactivation pattern which tends to be highly altered in presence of 
mutations affecting X-linked genes, the de novo mutations in MECP2 can result in mild mental 
retardation or relatively asymptomatic phenotypes. Moreover MECP2 variants, most of them are de 
novo, but some are inherited from mothers with borderline cognitive functioning, have also been 
identified in non-syndromic autistic girls (Young et al., 2008).  
Mutations in the PTEN gene (Phosphatase and Tensin homolog), encoding a tumor suppressor 
involved in cell-cycle arrest in G1 and apoptosis, are associated with a broad spectrum of disorders, 
including Cowden syndrome. Moreover genetic syndromes linked to PTEN haploinsufficiency are 
often associated with autism or mental retardation (Goffin, Hoefsloot, Bosgoed, Swillen, & Fryns, 
2001). In particular autistic individuals with mutations in PTEN are characterized by severe to 
extreme macrocephaly and the most of them have a high incidence of de novo mutations and an 
increased risk of developing cancers during adulthood (Lintas & Persico, 2009). 
These ASD-related syndromes are characterized by an aberrant mRNA translation which lead to 
increased synthesis of synaptic proteins, since the proteins encoded by FMR1, TSC1/2, NF1 and 
PTEN normally inhibit translation directly at synapses (FMRP) or through the PI3K-mTOR 
signaling pathway (TSC1, TSC2, NF1, and PTEN). Thus, these findings indicate that abnormally 
increased levels of plasticity-related proteins may affect synaptic connectivity, producing cognitive 
impairment (Kelleher & Bear, 2008). Moreover, it is evident that also these syndromic forms of 
autism show clinical phenotypes highly heterogeneous even in the presence of the same well 
characterized mutation, supporting the hypothesis that differences in genetic background and 
epigenetic influences underlie ASD.  
 
3.3 “Synaptic” genes: neuroligins, neurexins and SHANK family 
Other monogenic causes of ASD, each accounting for less than 1% of the general ASD population, 
are due to rare highly penetrant mutations in some synaptic genes, such as those encoding 
neuroligins, neurexins, and SHANKs, which are crucial proteins for synapse formation, maturation 
and stabilization. 
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Neurexins (NRXN) and neuroligins (NLGN) are cell adhesion molecules present in excitatory and 
inhibitory synapses, and they are required for correct neuron network function. At the extracellular 
level, postsynaptic neuroligins interact with presynaptic α or β neurexins modulating the synaptic 
development and function (Fabrichny et al., 2007; Scheiffele, Fan, Choih, Fetter, & Serafini, 2000), 
whereas at the intracellular level, neuroligins associate with postsynaptic scaffolding proteins, such 
as SHANK3 (Gerrow et al., 2006). In addition to their role in interaction with neuroligins, 
neurexins are important mediators for neurotransmitter release by linking calcium (Ca
2+
) channels 
to synaptic vesicle exocytosis (Missler et al., 2003). 
The involvement of neuroligins in ASD was first reported by Jamain and colleagues, who identified 
deleterious mutations in the NLGN3 (Xq13) and NLGN4 (Xp22.3) genes in siblings with autism or 
Asperger Syndrome (Jamain et al., 2003). Moreover a 2-bp deletion in fifth exon of NLGN4 was 
found in a large family including members affected by nonspecific X-linked mental retardation, 
with or without autism or pervasive developmental disorder in affected male patients (Laumonnier et 
al., 2004). This deletion leads to a premature stop codon in the middle of the sequence and results in 
a protein that is predicted to be truncated by ∼50% of its normal sequence and to lose sequences 
important for the dimerization of neuroligins that are required for cell-cell interaction through 
binding to β-neurexins.  
These results suggest that NLGN4 is not only involved in autism, as previously described, but also 
in mental retardation, indicating that some types of autistic disorder and mental retardation may 
have common genetic origins and highlighting the phenotypic heterogeneity of this X-linked 
condition. However these and others studies have demonstrated that the frequency of NLGN gene 
mutations among idiopathic ASD patients is low (Lintas & Persico, 2009).  
Several studies have reported rare sequence variants or CNVs affecting the NRXN1 gene. Similarly 
to neuroligins, individuals with mutations in NRXN1 show vastly different clinical phenotypes, 
ranging from ASD, ID (Zahir et al., 2008) and schizophrenia (Kirov et al., 2009; Rujescu et al., 
2009) to specific language disorder and muscle hypotonia (Ching et al., 2010). 
Rare mutations have also been identified in the three members of the SHANK gene family, SHANK1 
(Sato et al., 2012), SHANK2 (Leblond et al., 2012) and SHANK3 (Durand et al., 2007). 
The SHANK3 gene maps in the critical region of the 22q13 deletion syndrome, also known as 
Phelan-McDermid Syndrome, which is characterized by hypotonia, ID, severely speech delay or 
absence of speech, mild dysmorphic and autistic traits (Phelan & McDermid, 2012). 
The phenotypic features observed in the Phelan–McDermid Syndrome are likely due to different 
genes involved in the deletion, but SHANK3 haploinsufficiency seems to be the most cause of the 
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autistic traits reported in the ASD patients. Indeed several studies have reported de novo mutations 
(such as microdeletions or loss-of function sequence variants) encompassing only the SHANK3 
locus in ASD individuals. These ASD subjects are characterized by severe language impairment, 
often accompanied by ID and neurodevelopmental delay (Lintas & Persico, 2009). Moreover, two 
de novo mutations, never found in ASD patients, have been found in individuals with schizophrenia 
(Gauthier et al., 2010). Notably, autistic carriers of inherited 22q13 deletions involving SHANK3 
have siblings with partial 22q13 trisomy diagnosed with Asperger‟s syndrome (Durand et al., 2007; 
Moessner et al., 2007). 
Deletions and rare sequence variants, both inherited and de novo, have also recently been reported 
in the SHANK2 gene in subjects with ASD and ID (Berkel et al., 2010). However, while de novo 
mutations have a clear pathogenic effect, the role of inherited variants is difficult to ascertain, since 
they are frequently inherited from an apparently healthy parent and can also be found in unaffected 
siblings of probands with autism and also in controls.  
However, a significant enrichment (P=0.004) of variants affecting conserved amino acids of 
SHANK2 were observed in subject with ASD (3.4%) compared with controls (1.5%) and, notably, 
several variants identified in patients were associated with a reduced synaptic density at dendrites 
compared to the variants only detected in controls (P = 0.0013) (Leblond et al., 2012). 
Interestingly, three patients with de novo SHANK2 deletions also carried inherited 15q11-q13 CNVs 
previously associated with neuropsychiatric disorders. Specifically, two patients carried a 
duplication involving the nicotinic receptor CHRNA7, while the other ASD individual carried a 
deletion encompassing the synaptic translation repressor CYFIP1 (figure 3.1).  
 
Figure 3.1 (Leblond et al., 2012). Inherited 15q11-q13 CNVs identified in three ASD patients carrier of a de novo 
SHANK2 deletion. Genes altered by the CNVs are indicated in blue (duplications) or red (deletions). BP, breakpoint; 
Inh_M, inherited by mother; Inh_F, inherited by father. 
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These results strongly support an oligogenic, “multiple hit” model and suggest that alterations in the 
SHANK2 gene might contribute to ASD risk interacting with other variants involving genes which 
play a role in the same pathway.  
Another study (Sato et al., 2012) has indeed indicated that SHANK1 deletions are associated with 
ASD with higher functioning in males. Interestingly, a stop mutation of the PCDHGA11 gene, a 
member of the protocadherin gamma gene cluster, which have an important role in establishing 
connections in the brain, was found to segregate precisely with SHANK1 deletion, suggesting that, 
similarly to individuals with SHANK2 mutations, additional hits increase the risk of ASD in 
individuals with SHANK1 mutations. 
 
3.4 Candidate genes object of this thesis 
 
3.4.1 The α-catenins 
Other synaptic cell-adhesion proteins implicated in ASD susceptibility are the cadherins (CDH), the 
protocadherin (PCDH), the contactins (CNTN1-CNTN6) and the contactin-associated proteins 
(CNTNAP1–CNTNAP5) (Betancur, Sakurai, & Buxbaum, 2009). 
Specifically, the cadherins regulate the synapse morphogenesis and plasticity within the mammalian 
central nervous system through the binding to their cytosolic partners, the catenins.  
The catenins are subdivided into three separate groups: two β-catenin-like proteins (β-catenin and 
plakoglobin), three α-catenins and four p120 catenin-related proteins (Arikkath & Reichardt, 2008).  
The α-catenins anchor the cadherin/catenin complex to the actin cytoskeleton by binding to β-
catenins or cadherins on one side, and form a direct or indirect (through -actinin) interaction with 
actin filaments on the other side. The cadherin-catenin complex has been proposed to be crucial in 
mediating adhesion between presynaptic and postsynaptic membranes. 
There are three α-catenin genes, which differ in pattern of expression: CTNNA1 (alpha E-catenin) is 
ubiquitously expressed but mainly in epithelial tissues (Nagafuchi, Takeichi, & Tsukita, 1991), 
CTNNA2 (alpha N-catenin) shows a neural specific expression pattern (Hirano, Kimoto, 
Shimoyama, Hirohashi, & Takeichi, 1992) and CTNNA3 (alpha T-catenin) is expressed primarily in 
the heart and testis but at lower levels in the brain (Janssens et al., 2001). 
However, the sequence conservation between the three -catenins is particularly elevated in some 
functional domains, such as binding sites for β-catenin, -actinin and actin. In addition to playing a 
structural role in cell-cell adhesion, α-catenins are also involved in signal transduction, including 
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the Wnt signaling, previously implicated in Alzheimer disease (Sehgal, Gumbiner, & Reichardt, 
1997). 
αE-catenin is a well-known invasion suppressor, as defects in its expression have been observed in 
several invasive cell lines. In vitro experiments have reported that αE-catenin function can be 
substituted by αN-catenin and αT-catenin. However, since αN-catenin and αT-catenin show a 
restricted expression pattern, they likely have other specific functions. N-catenins are localized to 
adherens junctions bordering active zones in developing and mature synapses throughout the brain 
and it has been suggested that they contribute to the maintenance of positional information during 
forebrain development (Park, Falls, Finger, Longo-Guess, & Ackerman, 2002). Moreover αN-
catenin is a key regulator for the stability of synaptic contacts, since it was been shown that in the 
absence of αN-catenin, spine heads were abnormally motile, actively protruding filopodia from 
their synaptic contact sites.  
Alternative splicing generate different α-catenin protein isoforms. A C-terminally truncated isoform 
of aE-catenin (Vanpoucke, Nollet, Tejpar, Cassiman, & van Roy, 2002) or an isoform of aN-catenin 
with in-frame insertion in the C-terminal region (Uchida et al., 1994) have been identified. In 
addition, transcripts of CTNNA2 and CTNNA3 that contain an alternative 5‟ exon instead of the 
conventional initial exon encode isoforms with truncated N-termini (Goossens et al., 2007; Mexal et 
al., 2008). Moreover a testis-specific N-terminally truncated CTNNA3 isoform that does not bind b-
catenin has been detected in mouse (Goossens et al., 2007).  
The role of αT-catenin has been primarily investigated in the heart, due to its high expression in 
cardiac tissue and co-localization with plakophilin 2 (Goossens et al., 2007) and in testis but it is 
expressed also in brain (Busby et al., 2004). Even if its neuronal function remains largely 
unexplored, several evidence have indicated that CTNNA3 is a very promising ASD candidate gene.  
Functional studies performed on mice have shown that overexpression of Ctnna3, similarly to 
Ctnna1 and Ctnna2, causes an increase in spine and synapse density (Abe, Chisaka, Van Roy, & 
Takeichi, 2004), suggesting that all α-catenin isoforms share the same spine-stabilizing activity. 
Moreover, like other α-catenins, Ctnna3 participates in the canonical Wnt signalling pathway 
(Busby et al., 2004), which plays an important role in brain development and synaptic function. 
Specifically, CNV and association studies investigating several genes involved in this pathway have 
provided evidence that Wnt signalling might be affected at least in a subset of individuals with ASD 
(Kalkman, 2012). In addition some studies have reported common single nucleotide polymorphism 
(SNP) association (Wang et al., 2009; Weiss et al., 2009) and the occurrence of rare CNVs 
intersecting CTNNA3 in ASD cases (Girirajan et al., 2012; D. Levy et al., 2011; O'Roak et al., 2012; 
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Prasad et al., 2012). Another study have reported a de novo exonic deletion in this gene associated 
to ASD and in a recent analysis of exon-disrupting CNVs affecting known autism candidate genes, 
CTNNA3 was found borderline enriched in the autism cohort as opposed to controls (22 out of 
2,588 autism cases versus 12 out of 2,670 controls, P = 0.050) (Girirajan et al., 2012). 
Another evidence that support the role of αT-catenin in ASD susceptibility is its genomic 
localization. Indeed, CTNNA3 is located in a common fragile site (FRA10D) and it was suggested 
that some fragile sites, which are considered hot spots for genomic instability, may be associated to 
neuropsychiatric diseases, including autism (Savelyeva, Sagulenko, Schmitt, & Schwab, 2006; 
Smith, Zhu, McAvoy, & Kuhn, 2006).  
Moreover, like the others α-catenins, CTNNA3 contains the antisense oriented leucine rich repeat 
transmembrane 3 gene (LRRTM3) within its seventh intron (Laurén, Airaksinen, Saarma, & 
Timmusk, 2003). The LRRTM genes encode transmembrane proteins that regulate presynaptic 
differentiation (Linhoff et al., 2009). The location of the LRRTM3 genes within α-catenin family 
members suggests that α-catenin genes and the respective LRRTMs share common transcriptional 
regulation mechanisms.  
LRRTM3 is expressed predominantly in the brain, notably in the hippocampus, and, similar to 
CTNNA3, is thought to mediate cell adhesion (Laurén et al., 2003; Majercak et al., 2006). 
Interestingly, a significant association of SNPs in LRRTM3 with ASD was reported, supporting that 
the CTNNA3/LRRTM3 genomic region confers susceptibility to ASD. 
 
3.4.2 The CADPS family 
The CADPS (Ca
2+
-dependent activator protein for secretion) family is a secretory-related protein 
family involved in the regulation of secretory granule exocytosis (Berwin, Floor, & Martin, 1998), 
including monoamines and neuropeptides, as well as in the Golgi traffing (Sadakata & Furuichi, 
2010; Sadakata, Shinoda, Oka, Sekine, & Furuichi, 2013; Shinoda et al., 2011). 
In mammals this family includes two members, CADPS1 and CADPS2. These two isoforms are 
structurally and functionally highly related and show striking difference in their spatial and 
temporal expression patterns: CADPS1 is expressed almost exclusively in neuroendocrine cells and 
in brain and at lower levels before birth, but it increases postnatally, whereas CADPS2 expression is 
restricted to certain brain regions, but also in lung, liver and testis and it expression is constant 
between embryonic and postnatal stage (Speidel et al., 2003).  
Several studies (Sadakata & Furuichi, 2009; Sadakata et al., 2004; Shinoda et al., 2011) have found 
that CADPS2 promotes secretion of brain-derived neurotrophic factor (BDNF), which plays a 
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crucial role in neuronal survival and differentiation and in synaptic development and plasticity 
(Greenberg, Xu, Lu, & Hempstead, 2009) as well as in development of hippocampal GABAergic 
interneuron networks (Hong, McCord, & Greenberg, 2008). CADPS2-KO mice show decreased 
BDNF amounts and significant deficits in hippocampal GABAergic systems at multiple levels, 
ranging from inhibitory synaptic architectures to related behavioral traits, including decreased social 
interaction, increased anxiety-like behaviors and defective circadian rhythms (Sadakata, Kakegawa, 
et al., 2007), suggesting thus that BDNF is involved in psychiatric disorders, such as schizophrenia 
and depression, and developmental disorders, such as autism.  
The human CADPS2 gene is located within 7q31.32. Five transcripts (CAPS2/CADPS2, TAS2R16, 
RNF148, RNF133, and FEZF1) have been annotated in this region, although CADPS2 is the only 
gene with an exon-intron structure and characterized to be expressed as a functional protein (figure 
3.2).  
Comparison between CADPS2 and the mouse homolog, which is located on chromosome 6, showed 
several differences on exonic structure, suggesting that alternative splicing may occur for this gene. 
In mouse brain, the major form of CAPS2 protein (full) consists of approximately 1300 amino acid 
residues (1275-1355 aa). An aberrant alternative splicing of CADPS2 mRNA caused by exon 3 
skipping (CAPS2-dex3), predicting a deletion of 111 aa residues in the human CADPS2 protein, 
was found abnormally increased in some patients with autism compared to healthy controls 
(Sadakata, Washida, et al., 2007). Interestingly, in the Caps2-dex3 mice models the exon 3-skipped 
CADPS2 protein localizes at cell soma and it is not transported to presynaptic terminal, suggesting 
an increased BDNF release from cell soma and a decreased BDNF release from the axon terminal. 
The altered local BDNF secretion patterns thereby affect the correct development of synapses and 
neural circuits. Furthermore, decreased social interaction, increased anxiety, impairment of maternal 
nurturing behavior and circadian rhythm abnormalities were observed, indicating that increased 
CADPS2-dex3 expression leads to increased risk for developing ASD-like behaviors. 
At least 13 CNVs around the 7q31.3 region and at least 12 single nucleotide variations, including 
missense, silence, and insertion mutations in the CADPS2 gene have so far been reported in ASD 
patients (Cisternas, Vincent, Scherer, & Ray, 2003). Some of the CNVs have been identified in 
multiplex ASD families and one CNV (CNV-3 in Figure 2) causes a deletion of 0.75 Mb, including 
four genes (CAPS2, TAS2R16, RNF148, and RNF133) (AGP, 2007). Moreover in a recent study on 
exon-disrupting CNVs in 253 autism candidate genes a paternally inherited duplication of 0.43 Mb 
within the CAPS2 gene was identified (Girirajan et al., 2013). These data suggest that CADPS2 
could be an excellent candidate for neurologic development abnormalities associated with ASD. 
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Figure 3.2 (Sadakata, Shinoda, Sato, et al., 2013) In the figure are represented six CNVs and seven non-synonymous 
single-nucleotide polymorphisms (SNPs) affecting the human CADPS2 gene. Among the six CNVs four CNVs (CNV 
1-4) have been identified in ASD patients, whereas CNV-5 (Bentley et al., 2008) and CNV-6 (S. Levy et al., 2007), 
which delete very short sequences of CADPS2 intron 1, had no evidence for a connection with ASD. CNV-2 causes a 
0.94 Mb deletion which extend from exon 9 to the end of the CADPS2 gene (Christian et al., 2008). CNV-1 deletes 15 
Mb, affecting about 50 genes including also CADPS2. CNV-4 removes CADPS2 intron 2 and the RNF148 and 
RNF133 gene (Bucan et al., 2009). 
 
3.4.3 The CHRNA7 gene 
As discussed in the first chapter, the PB4-PB5 recurrent microdeletion contains six genes 
(MTMR15, MTMR10, TRPM1, KLF13, OTUD7A, and CHRNA7) and an miRNA gene (hsa-mir-
211). Strong evidence supporting CHRNA7 as responsible for the majority of neurodevelopmental 
phenotypes resulting from PB4-BP5 deletion comes from the identification of individuals carrying 
smaller deletions which encompass the entire CHRNA7 gene and the first exon of OTUD7A 
(Shinawi et al., 2009) or even smaller deletions, including only CHRNA7 (Hoppman-Chaney, Wain, 
Seger, Superneau, & Hodge, 2013; Masurel-Paulet et al., 2010; Mikhail et al., 2011) and conveying 
most or all of the phenotypic abnormalities associated with the larger 15q13.3 recurrent deletions. 
CHRNA7 encodes the α7 subunit of the neuronal nicotinic acetylcholine receptor, which is the only 
subunit able to form a homopentameric chloride channel receptor, and is highly expressed in the 
brain. Receptors containing α7 are localized both pre- and post-synaptically and regulate the release 
of both the inhibitory neurotransmitter GABA and excitatory neurotransmitter glutamate in the 
hippocampal formation (Albuquerque, Pereira, Alkondon, & Rogers, 2009). Moreover alpha-7 
nicotinic acetylcholine receptor mediated signaling causes an influx of Ca
2+
 into the cell 
(Vijayaraghavan, Pugh, Zhang, Rathouz, & Berg, 1992). 
Mobilization of intracellular Ca
2+ 
plays a critical role in synaptic plasticity and immediate early 
gene expression associated with learning and memory (Benfenati, 2007). Another evidence 
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supporting CHRNA7 involvement in neuropsychiatric disorders comes from a recent study which 
has reported a significantly reduced CHRNA7 expression in the frontal cortex of individuals with 
Rett syndrome or with typical ASD (Yasui et al., 2011). In addition CHRNA7 has been implicated  
as a candidate gene for schizophrenia and its expression was reported to be reduced in several brain 
regions in schizophrenic subjects compared with control subjects. In particular several 
polymorphisms were identified in the CHRNA7 core promoter in schizophrenic individuals and 
functional analysis of these promoter variants indicated that CHRNA7 transcription was reduced (S. 
Leonard et al., 2002). 
Moreover it is known that the binding of the methyl CpG binding protein 2 (MeCP2), encoded by 
MECP2, influences the chromatin loop organization of the much larger 15q11.2-13.3 region that 
includes the Prader-Willi/Angelmansyndrome region, and is required for optimal expression of AS/ 
PWS region genes implicated in the ASD phenotype.  
Therefore these discoveries suggest that CHRNA7 transcription is modulated by these regulatory 
elements and its reduced expression may be involved in ASD-like phenotypes (Yasui et al., 2011).  
Function and structural organization of the CHRNA7 gene 
The α7 receptor subunit gene, CHRNA7, is a member of a large gene family of neuronal receptors 
which are expressed in mammalian brain as pentameric, ligand-gated ion channels (Vijayaraghavan 
et al., 1992). Two principal classes of these receptors are present in the nervous system:  receptors 
with α2-α6 subunits bind nicotine with high affinity and require an association with β subunits for 
functional expression (Deneris et al., 1989; Goldman et al., 1987), whereas receptors with α7-α9 
subunits, including CHRNA7, bind nicotine with low affinity but they have a high affinity for the 
antagonist, α-bungarotoxin, and can function as homomeric ion channels in vitro. 
The α7 receptors are located both pre- and postsynaptically: presynaptically, they are involved in 
neurotransmitter release, including release of GABA, glutamate, and dopamine from specific 
terminals (Jones & Wonnacott, 2004; Schilström et al., 2000), while postsynaptically they are 
localized in or near the postsynaptic density (PSD), where the calcium flux increases 
phosphorylation and affects gene expression.  
CHRNA7 contains ten exons and it is partially duplicated (figure 3.3a,b). Indeed, the exons 5-10, 
along with a large cassette of DNA (about 300 kb), are duplicated and map approximately 1.6 Mb 
proximal to the full-length CHRNA7 gene (Gault et al., 1998).  
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Figure 3.3 (Araud et al., 2011). Structure of the CHRNA7/CHRFAM7A gene cluster on chromosome 15q13.3. a) Map 
of the partial duplication of CHRNA7 on 15q13.3. Exons 5-10 of CHRNA7 were duplicated in a duplicon of ∼300kb, 
mapping centromeric by 1.6 Mb. The duplicon interrupted a partial duplication of a second gene, ULK4. CHRNA7 
exons, red; ULK4 exons, blue; exon D, pink. b) Schematic representation of the exon organisation of the transcripts 
coding for CHRNA7, CHRFAM7A, CHRFAM7A based on the RefSeq NM_000746.3 and NM_139320.1. c) Putative 
translation products from CHRNA7, CHRFAM7A, and CHRFAM7AΔ2bp mRNAs. Amino acid sequence of α7 is 
represented in green and yellow (for the different domains). Alternative amino acids from CHRFAM7A are indicated in 
red and alternative amino acids from CHRFAM7AΔ2bp in blue.  
 
CHRFAM7A is a chimeric gene derived by the fusion of CHRNA7 (exons 5-10) to one of many 
copies of a novel gene called FAM7A, that encodes exons A-E (Gault et al., 1998; Riley, 
Williamson, Collier, Wilkie, & Makoff, 2002). Exons C-A are the result of a partial duplication of a 
putative kinase-like gene (ULK4) on chromosome 3p22.1, while exon D is of unknown provenance. 
CHRNA7 DNA sequence in CHRFAM7A is 99.9% conserved. Since CHRFAM7A has not been 
found in closely related primates (Locke et al., 2003) and in rodents, it is probably that the 
duplication has a recent origin. The CHRFAM7A gene has a variable copy number: approximately 
30% of individuals have only one copy of CHRFAM7A, while rare individuals (about 5%) are 
missing both copies (Gault et al., 1998; Sinkus et al., 2009). Mutation screening of CHRFAM7A has 
revealed a 2bp deletion in exon 6. This polymorphism has been associated with schizophrenia and 
with a gene inversion (Flomen et al., 2008). The wild type allele is in a head-to-head orientation 
with respect to the full-length CHRNA7 gene, but CHRFAM7AΔ2bp is oriented in the same 
direction (figure 3.4c).  
A recent study  has revealed that expression of CHRFAM7A alone generates a protein product but it 
is not functional, whereas co-expression of α7 subunits and the CHRFAM7A gene results in 
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decreased ACh stimulated current. However, this co-expression does not reduce the ligand binding 
and does not alter CHRNA7 transcription, suggesting thus that CHRFAM7A acts as a dominant 
negative modulator of CHRNA7 function and is critical for receptor regulation in humans (Araud et 
al., 2011). 
 
3.4.4 The kelch-like (KLHL) gene family 
The KLHL (Kelch-like) gene family includes proteins that constitute a subgroup at the intersection 
between the BTB/POZ domain and Kelch domain superfamilies. In the human genome there are 42 
KLHL family members, dispersed on different chromosomes and with a number of exons ranging 
from a single coding exon to 15 coding exons.  
However the number of KLHL genes is conserved between mammalian species and all generally 
contain a BTB/POZ domain, a BACK domain, and five to six Kelch domains. The BTB (Broad 
Complex, tramtrack and bric à brac)/POZ (poxviruses and zinc finger) domain has been found 
primarily in zinc finger proteins (Zollman, Godt, Privé, Couderc, & Laski, 1994). It is present at the 
amino terminus and it is involved in the protein-protein interaction interface (Bardwell & Treisman, 
1994) and in both dimer and heterodimer formation in vitro (Albagli, Dhordain, Deweindt, Lecocq, 
& Leprince, 1995). BTB-containing proteins have different functions such as control of cytoskeletal 
organization (M. I. Kang, Kobayashi, Wakabayashi, Kim, & Yamamoto, 2004), ion channel gating 
(Minor et al., 2000), transcription suppression (Melnick et al., 2000) and protein targeting for 
ubiquitination (Furukawa, He, Borchers, & Xiong, 2003; Xu et al., 2003). 
The central BACK domain does not have a known function yet, but it is likely to be of functional 
significance since mutations in this region have been shown to cause human disease (Bomont et al., 
2000; Liang, Avraham, Jiang, & Avraham, 2004). The Kelch repeats, at the C-terminus, form a 
tertiary structure of β-propellers, which has roles in extracellular communication/interaction, cell 
morphology, gene expression and actin binding.  
KLHL proteins are known to be involved in several cellular processes and are responsible for 
different human diseases, from cancer to Mendelian diseases.  
Mutations in KLHL7 have been found in patients with autosomal dominant retinitis pigmentosa 
(Friedman et al., 2009); a missense mutation in the KLHL9 gene has been associated with 
development of distal myopathy (Cirak et al., 2010), while mutations in KLHL16 are linked to 
human giant axonal neuropathy (Bomont et al., 2000). Other KLHL members are involved in 
cancer. Examples are KLHL20, implicated in prostate cancer progression (Yuan et al., 2011) and 
KLHL37 associated with brain tumors (Liang et al., 2004). 
ASD CANDIDATE GENES 
 
 
 
52 
 
The KLHL genes in neuropsychiatric disorders  
Despite the specific roles for each KLHL family member have not been completely elucidated, as 
they are involved in different biological processes and disease, some KLHL proteins have an 
established role in neurodevelopment (Jiang, Seng, Avraham, Fu, & Avraham, 2007; S. K. 
Williams et al., 2005).  
An example is KLHL2/Mayven, an actin-binding protein constitutively expressed in developing and 
mature oligodendrocytes and neurons, where it binds directly to F-actin through its Kelch repeats 
and plays an important role in the organization of the actin cytoskeleton (Jiang et al., 2005; Jiang et 
al., 2007). Another actin-binding protein is KLHL1/MRP2, mainly expressed in specific brain 
regions, including the cerebellum, the area most affected by spinocerebellar ataxia type 8 (SCA8), 
an inherited disease of the central nervous system caused by a CTG expansion mutation in the 
natural antisense RNA of KLHL1. MRP2 plays an important role in neurite outgrowth and 
colocalizes with the cytoskeletal protein talin at the neuronal growth cones and with actin in 
differentiated primary rat hippocampal neurons (Seng, Avraham, Jiang, Venkatesh, & Avraham, 
2006). MRP2 is also involved in the process elongation of  oligodendrocytes (OLGs) and its 
interaction with actin is significantly increased in differentiated OLGs (Jiang et al., 2007).  
Additional evidences have supported the involvement of some KLHL genes in complex 
neuropsychiatric disorders.  
A partial deletion of the KLHL15 gene was identified in a patient with severe ID, epilepsy and 
anomalies of cortical development in a recent array CGH study (Mignon-Ravix et al., 2014). 
Moreover, proteins containing the kelch domain have been also detected as one of the functional 
categories enriched among de novo genic CNVs in schizophrenia (Malhotra et al., 2011). In 
addition a deletion involving KLHL17 has been identified in a subject with early infantile epileptic 
encephalopathy (Paciorkowski et al., 2011). 
Therefore, the occurrence of CNVs in some KLHL gene family members in multiple unrelated 
patients with the same neuropsychiatric disorder or co-morbid conditions might indicate that these 
genes represent new and interesting candidate for complex disorders. 
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CHAPTER 4: 
INTELLECTUAL DISABILITY 
 
4.1 Intellectual disability 
Intellectual disability (ID), also referred to as mental retardation (MR) is a common 
neurodevelopmental disorder with onset before age 18 years and characterized by social, cognitive, 
and adaptive skill deficits. 
ID diagnosis is based on use of standardized age-dependent tests that measure the intelligence 
quotient (IQ), such as the Wechsler Intelligence Scale for Children (WISC) or Wechsler Adult 
Intelligence Scales Intelligence Scale for Adults (WAIS).  
Depending on the IQ, several degrees of severity are distinguished: mild, moderate, severe, 
profound and unable to classify. However ID is commonly divided into 2 principal categories: mild 
ID (IQ 50-70) and severe ID (IQ<50) (Ropers & Hamel, 2005). 
Mild mental retardation is the most common type of intellectual impairment accounting for about 
85% of cases (Deb & Prasad, 1994). Despite a causative diagnosis of moderate to severe mental 
retardation is established in up to 65% of cases, the underlying cause of mild ID mental remains 
unknown in up to 80% of patients. 
In addition to categorization by severity/IQ level, ID can also be divided into syndromic intellectual 
disability (S-ID), which is characterized by one or multiple clinical features or co-morbidities in 
addition to ID, and non-syndromic intellectual disability (NS-ID), in which intellectual disability is 
the sole clinical feature. However the distinction between S-ID and NS-ID is unclear, since the 
diagnosis is often difficult because of the cognitive impairment of the patients. Moreover recent 
studies have indicated that, in some cases, different mutations in the same gene can result in S-ID or 
NS-ID, depending on their effect on the protein product (complete loss or partial loss of the 
protein), on the X-inactivation pattern in females and on genetic background (Vaillend, Poirier, & 
Laroche, 2008). 
The prevalence of ID is between 1% and 3% (H. Leonard & Wen, 2002) and tends to be higher in 
developing countries or in areas of lower socioeconomic status, likely due to a variety of non-
genetic factors such as malnutrition, cultural deprivation and poor health care (Durkin, 2002), and 
to etiologic factors, such as parental consanguinity (Ropers, 2008), since inbreeding is associated 
with reduced cognitive performance (Bashi, 1977). 
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Mild ID tends to be more prevalent in males. However, the ratio of males to females decreases as 
IQ decreases (McLaren & Bryson, 1987) and some studies have revealed that severe ID may be 
more prevalent among females (Katusic et al., 1996).  
 
4.2 Causes of ID 
ID can be caused by environmental and/or genetic factors.  
Environmental exposure to certain teratogens, viruses or radiation can cause ID, but 25-50% of 
cases are due to genetic factors. However for up to 60% of cases, there is no an identifiable cause 
(Rauch et al., 2006).  
The genetic causes underlying mental retardation include chromosomal abnormalities, autosomal 
trisomies compatible with human viability, aneuploidies of the X-chromosome, and monogenic 
diseases. These genetic factors contribute to about 30% of moderate ID cases, while the 
environmental factors, including malnutrition during pregnancy, preterm birth, cerebral ischemia 
and infections pre and postnatal, play an important role in mild ID pathogenesis. In particular, 
prenatal factors (principally genetic, but also due to threatened abortion and maternal diabetes), are 
the most frequent and are responsible of about 60-75% of cases, while perinatal causes (low birth 
weight and intra-uterine growth retardation), and postnatal factors (for example cerebral  injuries), 
are less common (Aicardi, 1998).  
Given its genetic complexity, still little is known about the genetic factors contributing to mild ID. 
Some forms of mild ID segregate as Mendelian traits, while others are multifactorial. Moreover, 
many single gene causes of NS-ID may also cause not only S-ID, but also autism or other 
neurodevelopmental phenotypes, suggesting thus that other genetic modifiers or environmental 
factors may be involved in disease etiology. 
Cytogenetically visible chromosome aberrations account for approximately 15% of patients with 
severe ID (H. Leonard & Wen, 2002) and recently, also small duplications and deletions, have been 
identified as risk factors for both mild and severe ID. Moreover about 10% of ID found in males are 
caused by X-linked gene defects (Ropers & Hamel, 2005), much less than previously thought 
(Herbst & Miller, 1980), indicating that other factors are responsible for prevalence of cognitive 
impairment in males than females. This has left ample room for autosomal gene defects that appear 
as both dominant or recessive forms of ID in sporadic cases.  
 
4.2.1 Chromosomal aberrations and ID 
With a prevalence of 1/750 to 1/800, Down syndrome (DS, or trisomy 21) is the most common 
known cause of mental retardation (Collins, Muggli, Riley, Palma, & Halliday, 2008). 
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Other numerical and structural aberrations that can be detected by light microscopy are far less 
common, but taken together, cytogenetically visible chromosomal aberrations are found in one out 
of seven individuals with severe cognitive impairment (H. Leonard & Wen, 2002). 
Moreover, submicroscopic rearrangements, including deletions as well as balanced translocations 
and other chromosomal aberrations have been implicated in the etiology of NS-ID. These 
microdeletions include a number of known syndromes, such as Prader-Willi and Angelman 
syndromes, Smith-Magenis, Miller-Dieker, and DiGeorge syndromes.  
After the advent of high-resolution array CGH the identification of submicroscopic subtelomeric 
rearrangements has became more robust and several pathogenic CNVs, both rare and de novo, as 
well as rare inherited mutations, were detected in 10-15% of individuals with idiopathic ID and 
normal karyotype (Koolen et al., 2009). 
Interestingly, mapping the breakpoints of these CNVs was a successful method in determining 
autosomal dominant as well as X-linked causes of ID. 
 
4.2.2 X-linked intellectual disability (XLID) 
X-linked forms of ID (XLID) are common causes of moderate to severe intellectual disability in 
males and are easily identifiable because of their characteristic inheritance pattern.  
XLID is usually subdivided into syndromic (S-XLID) and non-syndromic forms (NS-XLID) and 
generally NS-XLID are more common than syndromic ones (Fishburn, Turner, Daniel, & 
Brookwell, 1983). 
However, some of the genes involved in NS-XLID have also been implicated in syndromic XLID, 
depending on the mutation, or may even vary within families, possibly modulated by additional 
factors, indicating thus that there is no clear separation between S-XLID and NS-XLID.  
For example, defects of OPHN1, one of the first genes implicated in NS-XLID (Billuart et al., 
1998), were later found to be associated with a syndrome including ataxia, epilepsy, and cerebellar 
hypoplasia. Additionally, several genes that classically cause ID syndromes may also cause NS-
XLID, such as the MEPC2 gene, which causes Rett syndrome.  
The human X-chromosome carries only about 4% of the protein-coding genes in the human 
genome, but the X-linked gene defects are responsible for about 10-12% of the ID found in males, 
which means that there must be other factors to explain why cognitive impairment is far more 
common in males than females. These factors include differential imprinting of maternal and 
paternal X-chromosomes, regulatory effects of the Y-chromosome or incomplete X-inactivation in 
females (Nguyen & Disteche, 2006; Skuse, 2007). 
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The most common form of XLID, accounting in 25% of ID cases (Fishburn et al., 1983), is the 
Fragile X syndrome, while ARX mutations rank second giving rise to non-syndromic XLID and to 
a variety of syndromic forms in more than 5% of the families (Gécz, Cloosterman, & Partington, 
2006). Mutations in the CUL4B, JARID1C and SLC6A8 genes are all relatively frequent, each 
accounting for 2-3% of the families, whereas defects of all other known XLID genes seem to be 
significantly less common (about 1%).  
The first mutations identified in patients with syndromic and nonsyndromic forms of XLID impact 
genes which play an important role in neuronal development and synapse formation and function, 
such as genes regulating the activity of small Rho and Ras GTPases (Kutsche et al., 2000). Other 
genes implicated in XLID are involved in many other important cellular processes, such as cell 
adhesion, post-translational modification, signal transduction, transcription regulation, actin 
cytoskeleton modification and ubiquitination (figure 4.1). 
 
Figure 4.1 (Ropers, 2010). Genes implicated in syndromic and/or nonsyndromic forms of XLID, and their position on 
the human X-chromosome. Gene defects that may give rise to non-syndromic XLID are shown on the right, and colors 
relate to different functional classes (gray, cell adhesion; dark blue, transcription regulation; pink, kinase activity, post-
translational modification; light blue, signal transduction; green, ubiquitination; red, regulation of actin cytoskeleton; 
orange, sodium ion transport; and purple, other defects.  
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4.2.3 Autosomal forms of ID 
Autosomal forms of ID (AID) include both autosomal dominant forms (ADID) and autosomal 
recessive forms (ARID). 
Well-known autosomal dominant disorders often associated with ID of varying severity include 
neurofibromatosis, tuberous sclerosis, and myotonic dystrophy. Other ADID, associated with a 
more severe phenotype, are mainly caused by de novo mutations and they are rarely familial 
because in general, affected individuals will not reproduce.  
The first method used to identify autosomal dominant disease causing genes was the 
characterization of chromosomal aberrations by breakpoint analysis, which allowed the discovery of 
several candidate genes for non-syndromic autosomal dominant ID (NS-ADID), such as DOCK8, 
MBD5, CDH15 and KIRREL3 (Bhalla et al., 2008; Griggs, Ladd, Saul, DuPont, & Srivastava, 
2008). Further screening of some of these genes in cohorts of ID patients led to the identification of 
several sequence mutations.  
Others genes that were all identified as autosomal dominant causes of NS-ID using candidate gene 
sequencing  are SYNGAP1, STXBP1, and SHANK2(Hamdan et al., 2009). 
In particular, the SYNGAP1 and SHANK2 (Berkel et al., 2010; Pinto et al., 2010) genes have also 
been associated with autism, suggesting thus that ASD and ID show a genetic overlap. 
In general, all these studies have provide evidence that de novo mutations in autosomal genes are 
common among sporadic patients with idiopathic ID and that some mutations, mainly truncating 
mutations, copy number changes or dominant-negative mutations affecting genes involved in the 
synapses of the central nervous system, have functional consequences not only for X-linked, but 
also for autosomal dominant forms of ID. 
The best strategy to elucidate the molecular defects underlying the autosomal recessive forms of ID  
is microarray technology combined with homozygosity mapping using large consanguineous 
families, followed by mutation screening of candidate genes (Houwen et al., 1994). 
Consanguineous families are common in countries belonging to a consanguinity belt, such as 
Morocco and India, while in the industrialized countries large families and parental consanguinity 
are rare.  
The first studies ruled out the presence of common gene defects that account for more than a few 
percent of the patients and revealed that ARID is highly heterogeneous.  
The largest study published so far for ARID has been performed by Najmabadi et al., (Najmabadi et 
al., 2011) using homozygosity mapping, targeted exon enrichment and next-generation sequencing 
in 136 consanguineous families from Iran and elsewhere.  
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Instead of sequencing entire exomes in consanguineous families, they have focused on the exons 
from homozygous linkage intervals known to carry the genetic defect. Additional mutations in 23 
genes previously implicated in intellectual disability or related neurological disorders, as well as 
single, probably disease-causing variants in 50 novel candidate genes, have been identified (figure 
4.2). 
 
 
Figure 4.2 (Najmabadi et al., 2011). Known and novel intellectual disability genes form protein and regulatory 
networks. Connecting edges indicate protein–protein interactions. Arrows define direction of post-translational protein 
modifications: a, acetylation; ar, ADP-ribosylation; d, demethylation; da, deacetylation; dq, deubiquitination; m, 
methylation. Dotted lines indicate modulation of gene function. a) Transcriptional/translational network. b) Cell-cycle-
related network. c) Ras/Rho/PSD95 network.  
 
Relatively few of the novel defects identified involve synapse- or neuron-specific genes and the 
majority among them are ubiquitously expressed genes with a role in several cellular functions, 
such as DNA transcription, translation, protein degradation and mRNA splicing. However, some 
proteins encoded by these genes interact directly with products of known intellectual disability 
genes and therefore they seem to be pivotal for normal brain development and function.  
This study provides interesting implications for the diagnosis and prevention of intellectual 
disability, and perhaps also for autism, schizophrenia and epilepsy, which often co-exist in 
intellectual disability patients and are frequently associated with mutations in the same genes. 
 
4.3 Co-morbidity of ID with ASD  
In addition to social, cognitive, and adaptive skill deficits, intellectual disability is often 
accompanied by different co-morbidities, ranging from challenging behaviors to anxiety, 
depression, and schizophrenia (Cherry, Matson, & Paclawskyj, 1997). The disorders with the 
greatest overlap with ID are those in the autism spectrum. 
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Several studied have revealed that, besides the heterogenecity of ID and ASDs, they  share 
overlapping risk factors (Betancur, 2011) and both exist together in the majority of patients.  
About 70% of patients with ASD have ID (Fombonne, 2003), while the remaining 30%, in addition 
to cognitive dysfunction, have also speech or behavior disability (Mefford, Batshaw, & Hoffman, 
2012). Conversely, at least 10% of individuals with ID have ASDs, with some ID conditions 
exhibiting a much higher level of co-morbidity. 
 
4.3.1 Phenotypic overlap between ID and ASD 
ID and ASD have multiple overlapping phenotypic domains. Indeed, the three major phenotypes 
that characterize autism (language abnormalities, social deficits and stereotypies) can often be seen 
to varying degrees in ID individuals. Both ASD and ID may present with developmental delay, 
abnormal language and social difficulties and are often associated with medical conditions such as 
epilepsy or autoimmune disorders (Depienne et al., 2007; Schieve et al., 2012). 
Deficits in verbal and non-verbal communication as well as repetitive and restrictive activities are 
more common in persons with autism and ID versus autism alone (Deb & Prasad, 1994). 
Individuals with severe and profound ID show often severe language deficits and stereotypies that 
tend to become more evident than subjects with mild ID. Moreover with increasing of IQ the 
autistic subjects present less improvements in social and daily living skills. In addition, patients 
with severe ID and autism as a comorbid disorder have much greater deficits in social and adaptive 
behavior in comparison with subjects whose comorbid disorder with ID was psychosis (Matson, 
Bielecki, Mayville, & Matson, 2003). In addition, as IQ decreases the rates of challenging behaviors 
became higher, self-injury in particular. Symptoms of psychopathology, such as mania, anxiety, 
psychosis, mood disorder and schizophrenia are present in persons with ID and ASD. Specifically 
these symptoms are evident in severe autism with the fewest symptoms in the ID only group. 
Compared to persons with ID alone, patients with autism and ID show higher rates of inattention, 
hyperactivity, and impulse behaviors. Others common comorbid disorders are depression and 
bipolar disorder (Bradley & Bolton, 2006). What is evident is that this ID and ASD group is 
distinctly different from persons with ID or with normal IQ and ASD and, at present, the clinicians 
are attempting to distinguish between these groups, by developing scales that are specific to this aim  
 
4.3.2 Genetic overlap between ID and ASD 
Although ID and ASD constitute two distinct disorders, they are characterized by some genetic 
overlaps which are difficult to quantify genetically because of the heterogeneity of both conditions 
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and the contribution of rare genetic variants to both diseases. Therefore understanding of the 
molecular mechanisms underlying ID and ASD remain limited, since most deleterious variants in 
the ASD and/or ID-associated genes have a very low prevalence and many rare and inherited 
mutations display often incomplete penetrance. However, several CNVs as well as single gene 
mutations appear to contribute significantly to the etiology of both ID and autism.  
It has recently been reported that 10-20% of ASD cases have an identified genetic anomaly and, 
notably, these genetic anomalies are also found in individuals with ID. Moreover, many patients 
affected by an ID syndrome, such as fragile X Syndrome, Down syndrome, tuberous sclerosis 
(TSC), but also Angelman syndrome and Rett syndrome, have a concomitant autism/PDD diagnosis 
(Fombonne, 2003). 
Several CNVs have been identified in patients with ASD and ID, such as the terminal deletion of 
the long arm of chromosome 2 (Galasso et al., 2008), the 1.5 Mb duplication on chromosome 16p-
13.1 (Ullmann et al., 2007), the deletion at the 7q 11.23 (Depienne et al., 2007) and many others.  
A mutation in NLGN4, a gene known to be associated to autism (Marshall et al., 2008), has been 
identified in a family containing subjects with NS-ID, with or without ASD (Laumonnier et al., 
2004). Others genes that have been implicated both in autism and NS-ID are PTCHD1 (Noor et al., 
2010), SHANK3, IL1RAPL1 (Piton et al., 2008) and JARID1C (Adegbola, Gao, Sommer, & 
Browning, 2008)  
Polymorphisms in GRIK2, one of the genes implicated in non-syndromic autosomal recessive 
intellectual disability (NS-ARID), has been associated with an increased susceptibility to autism 
and it has been found in linkage disequilibrium in an autistic population (Jamain et al., 2002). 
Others independent studies performed on different autistic populations have revealed similar results 
(Kim, Kim, Park, Cho, & Yoo, 2007). However, while in autism mutations in GRIK2 act in a  
dominant pattern of inheritance, in NS-ID they show a recessive inheritance, suggesting that 
polymorphisms in this gene may contribute to the overall ASD susceptibility.  
These findings indicate that ID and ASD may be on the same continuum, as opposed to being 
different clinical entities, sharing common etiologies and showing many genetic similarities. 
Furthermore these observations confirm the involvement of similar cellular and molecular processes 
underlying these two disorders. Indeed, using a combined network and systems biology approach to 
predict candidate genes for ASD and ID, Kou et al (Y. Kou, Betancur, Xu, Buxbaum, & Ma'ayan, 
2012) found that both conditions share common pathways and have similar clusters of genes 
(Figure 4.3). This approach is very useful to understand the cellular and molecular mechanisms 
INTELLECTUAL DISABILITY 
 
 
 
61 
 
underlying pathophysiology of the ASD/ID associated genes, but also to assess the pathogenicity of 
new candidate genes for both diseases. 
 
 
Figure 4.3 (Kou et al 2012). Functional connections between the ASD genes (in green) and the ID genes (in blue).  The 
figure show four distinct clusters of genes, consistent with the accumulating evidence that core pathways, common to 
ASD and ID, are perturbed in a recurrent manner in these related disorders. 
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CHAPTER 5: 
MATERIALS AND METHODS 
5.1 ASD Samples 
5.1.1 Italian ASD Cohort 
The Italian ASD cohort is formed by 228 Italian simplex families recruited at the Stella Maris 
Clinical Research Institute for Child and Adolescent Neuropsychiatry (Calambrone, Pisa, Italy). 
ASD diagnosis was based on the the Autism Diagnostic Interview-Revised (ADIR) (Lord et al., 
1994) and the Autism Diagnostic Observation Schedule (ADOS) (Lord et al., 2000) and a clinical 
evaluation was undertaken in order to exclude known syndromes associated with autism. Standard 
karyotyping, fragile-X testing, EEG, and array-based comparative genomic hybridization (aCGH) 
were obtained for all probands. 
DNA was extracted from blood with the QIAGEN DNA Blood extraction kit. 
80 Italian ASD families were included in the Autism Genome Project (AGP) genome-wide study 
(combined sample of stage 1 and stage 2 families) (Pinto et al., 2014; Pinto et al., 2010) (see 
paragraph 5.1.2). 
The three Italian ASD individuals carrying the CNVs reported in this thesis (3456_3; 3474_3 and 
3423_3) belong to Italian ASD cohort included in the AGP genome-wide study. 
135 ASD subjects belonging to Italian ASD cohort were analysed in the CHRNA7 mutation 
screening. 
 
5.1.2. AGP Cohort 
The AGP collection, including a total of 2,845 ASD families (Pinto et al., 2014), comprises simplex 
families with only one ASD case and multiplex families with at least two ASD individuals. The 
affection status was determined using the diagnostic tools Autism Diagnostic Interview-Revised 
(ADIR) (Lord et al., 1994) and the Autism Diagnostic Observation Schedule (ADOS) (Lord et al., 
2000). Three categories of affected individuals were established (strict, broad and spectrum ASD), 
based on proband diagnostic measures:  
- the strict class included affected individuals who met criteria for autism on both ADI-R and 
ADOS instruments;  
- the broad class included individuals who met full autism criteria on one diagnostic instrument and 
ASD criteria on the other one;  
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- the spectrum class included all individuals who were classified as ASD on both the ADI-R and 
ADOS or who were not evaluated on one of the instruments but were diagnosed with autism on the 
other instrument.  
Given the international and multi-site nature of the project and the range of chronological and 
mental ages of the probands, a range of cognitive tests were administered, and standard scores were 
combined across tests to provide consolidated IQ estimates. 
DNA, extracted from blood, buccal-swabs or cell-lines, has been genotyped with Illumina Human 
1M-single and Illumina Human 1M-Duo BeadChip arrays (Pinto et al., 2014; Pinto et al., 2010). All 
CNVs reported in ASD samples are high-confidence CNVs predicted by intersecting CNV calls 
from at least two algorithms between iPattern, PennCNV and QuantiSNP. This strategy ensures 
maximum specificity because each of these algorithms employs unique strategies for CNV calling, 
allowing their strengths to be leveraged. Previous analysis showed that validation rates were 
approximately 95% for CNVs identified using this method (Pinto et al., 2010). 
CNV data on a total of 2,147 European ASD families from the AGP study were used to examine the 
frequency of CTNNA3 exonic deletions in autism. 
 
5.1.3 IMGSAC Cohort  
The International Molecular Genetic Study of Autism Consortium (IMGSAC) ((IMGSAC), 2001) 
collected multiplex ASD families from different countries (UK, Netherlands, France, USA, 
Germany, Denmark, Greece). The individuals had predominantly a Caucasian origin (>90%). 
Clinical diagnosis of ASD was made using the ADI-R, ADOS or ADOS-Generic (ADOS-G).  
The multiplex families had fragile X testing and were karyotyped whenever possible. The following 
items were used to exclude individuals so as to keep the sample set more homogeneous:  
• Any medical condition likely to be etiological (e.g. tuberous sclerosis, fragile X, focal epilepsy, 
infantile spasms, single gene disorders involving the central nervous system).  
• Any neurological disorder involving pathology above the brain stem, other than uncomplicated 
non-focal epilepsy.  
• Contemporaneous evidence, or unequivocal retrospective evidence, of probable neonatal brain 
damage. Clinically significant visual or auditory impairment after correction.  
• Rearing in adoptive or foster homes.  
• Institutional rearing during the first 4 years when there is any possibility that this led to an autistic-
like picture.  
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• Any circumstances that might possibly account for the picture of autism (e.g. very severe 
nutritional or psychological deprivation).  
• Birth in a place making it difficult to obtain satisfactory obstetric data (this would ordinarily 
exclude those born in a developing country).  
• Autism secondary to some other psychiatric disorder (e.g., schizophrenia), but not psychiatric co-
morbidity.  
• Observational data that cast doubt on the diagnosis.  
• In vitro fertilisation as a means of conception.  
• Cases arising from consanguineous marriage.  
A number of features were not used as exclusion criteria, these are: epilepsy (unless focal); 
psychiatric co-morbidity; head circumference over 97%; mental illness in a parent and belonging to 
an ethnic minority.  
Genomic DNA was extracted from blood using Nucleon® kit (IMGSAC, 1998). In a minority of 
cases in which a blood sample could not be obtained, DNA was extracted from buccal swabs 
(IMGSAC, 1998). In addition, when possible, lymphoblastoid cell lines (LCLs) have been 
generated from peripheral blood leukocytes. 
96 unrelated ASD probands selected from the IMGSAC multiplex families were included in the 
KLHL23 and PHOSPHO2-KLHL23 mutation screening. 
 
5.2 Control samples 
5.2.1 AGP control cohorts 
CNV data from 6,639 European controls belonging to the AGP control cohorts were used to 
examine the frequency of CTNNA3 exonic deletions in control populations.  
Control cohort microarray data include 1,287 unrelated European control subjects from the Study of 
Addiction: Genetics and Environment cohort (SAGE) (Bierut et al., 2010) genotyped with Illumina 
Human 1 M-single BeadChip arrays, 1,123 Northern Europeans from the German PopGen project 
(POPGEN) (Krawczak et al., 2006) genotyped on the Affymetrix 6.0 SNP array (Affymetrix, Santa 
Clara, CA, USA), 1,234 individuals of European decent from the Ottawa River Valley (OHI) 
(Stewart et al., 2009) genotyped on the Affymetrix 6.0 SNP array, 1,320 European control subjects 
routinely seen at primary care and well-child clinic practices within the Children's Hospital of 
Philadelphia (CHOP) Health Care (Shaikh et al., 2009) genotyped with Illumina 550 K BeadChip, 
435 unrelated European control subjects from the Ontario Colorectal Cancer Case-Control study 
(OC) (Figueiredo et al., 2011) genotyped with the Illumina 1 M single array and 1,240 European 
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controls from the NHGR-CIDR Visceral Adiposity Study (Fox et al., 2012) genotyped on Illumina 
1 M-duo BeadChip arrays. For all these control samples (except for the CHOP samples, for which 
the CNV data are available at http://cnv.chop.edu), the heterozygous state of exonic CTNNA3 
deletions has been determined by inspecting the genotypes and/or plotting B allele freq and log R 
ratios for each region.  
Statistical comparison of CTNNA3 exonic deletion frequencies between ASD cases and controls 
was performed using Fisher‟s exact test. 
 
5.2.2 Italian controls  
The Italian control sample consists of 174 unrelated individuals selected from University of 
Bologna with no psychiatric disorders. This sample was used to test the presence of the -86/-241 
variants identified in the CHRNA7 mutation screening. 
 
5.2.3 European controls  
462 Caucasian controls from the European Collection of Cell Culture (ECACC) 
(http://www.hpacultures.org.uk/products/dna/hrcdna/hrcdna.jsp), were instead used to test by 
PCR-RFLP the presence of the non-synonymous variant p.Met65Val detected in the KLHL23 
and PHOSPHO2-KLHL23 mutation screening.  
 
All data from either affected patients or their parents and controls, including informed consent, were 
handled in accordance with the local ethical committee‟s approved protocols and in compliance 
with the Helsinki declaration. 
 
5.3 Identification of CNVs by Illumina Human 1M-Duo BeadChip array 
The Illumina Human 1M-duo BeadChip array generates genotype calls for more than 1 million 
markers using the Infinium HD technology (Figure 5.1) and it is able to genotype two samples per 
Chip. 
This assay is based on a two-step detection process:  
a) fragments of the DNA of interest selectively hybridize to specific probes (50-mer 
oligonucleotides), designed to be complementary to the loci of interest, but stopping one base 
before the interrogated SNP;  
b) an enzymatic single-base extension incorporates a nucleotide labelled with a fluorescent dye, 
complementary to the base present at the SNP site.  
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For each SNP, Cy3 and Cy5 fluorescence signals specify the two alleles (referred to as allele A and 
allele B). Dual-colour staining of the labelled nucleotides is followed by an image scanning 
performed by Illumina‟s iScan imaging system, which detects both colour and signal intensity. 
Homozygous genotypes are specified by red/red or green/green signals, heterozygous genotypes are 
indicated by red/green (yellow) signals.  
 
Figure 5.1. Schematic representation of the Illumina Infinium HD Assay protocol. 
 
The data generated by a SNP genotyping array can be analyzed and visualized with GenomeStudio 
Data Analysis software (Illumina). This program can covert the raw image scan into quantitative 
values and calculate the signal intensities for alleles A and B at each SNP, indicated as X and Y, 
respectively. The allele specific intensities are normalized using a proprietary algorithm of the 
Illumina GenomeStudio software: this procedure adjusts for background and makes markers more 
comparable to each other. Normalized allelic intensities are used to calculate the total fluorescent 
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intensity signal (R) and the allelic intensity ratio (θ). R is calculated as a combined SNP intensity: 
Robserved = X+Y, while θ is calculated as arctan (Y/X)/(π/2). R and θ values are calibrated to 
canonical genotype clusters generated from a large panel of normal samples, used to determine the 
R and theta values expected for each genotype (AA, AB and BB) (Figure 5.2).  
 
Figure 5.2 The graphical display of results in GenomeStudio is a Genoplot with data points color coded for the call 
(red=AA; purple=AB; blue=BB). Genotype are called for each sample (dots)  by their signal intensity (Norm-R; y-axis) 
and Allele Frequency (Norm Theta; x-axis) relative canonical cluster position for a given SNP marker. 
 
R and θ are then converted to two important measures: Log R Ratio (LRR) and B Allele Frequency 
(BAF). LRR, which represents a normalized measure of the total signal intensity at each SNP, 
derives from the comparison of the Robserved with the R obtained from a reference sample population 
(Rexpected) and it is calculated as log2(Robserved/Rexpected). In autosomic regions without CNVs (copy 
number = 2), LRR is ~0: LRR lower than zero may indicate a deletion, LRR higher than zero a 
duplication. BAF, which derives from the normalized θ, represents the proportion contributed by 
allele B to the total copy number. BAF represents an estimate of NB/(NA+NB), where NA and NB are 
the number of A and B alleles, respectively, therefore its value range from 0 to 1. BAF close to 1 
indicate that all alleles for that marker are B alleles (e.g. BB, BBB or B/-), viceversa BAF close to 0 
indicate that all alleles for that SNP are A alleles (e.g. AA, AAA or A/-), values close to 0.5 indicate 
a heterozygous genotype AB.  
These two transformed parameters, LRR and BAF, are plotted along each chromosome for all SNPs 
on the array and can be then visually inspected (Figure 5.3). The exported values of LRR and BAF 
for each SNP in each individual can be used for the identification of changes in copy number by 
QuantiSNP and PennCNV. 
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Figure 5.3. Examples of LRR and BAF plots for a deleted region (1 copy, genotype B/- or A/-), region with 2 normal 
copies (three possible genotypes for each SNP: AA, AB, BB) and duplicated region (3 copies, four possible genotypes 
for each SNP: AAA, AAB, ABB, BBB). 
 
The validation and the resolution of the extension of the three CNVs identified in probands 3456_3 
(CTNNA3 deletion); 3474_3 (CHRNA7 duplication) and 3423_3 (2q31.1 deletion), were carried out 
using the SNP data from the Illumina 1M-duo array generated as part of the large genome-wide 
scan for CNVs performed by the AGP (Pinto et al., 2014). The presence of the CNVs was also 
verified by visual inspection of the log R ratios and B allele frequencies in GenomeStudio. 
 
5.4 Validation of CNVs by Real-Time PCR 
CNVs were validated by real-time quantitative PCR (qPCR) using Fast SYBR Green Master Mix 
(Life Technologies). Briefly, SYBR Green is a non-specific dye that emits fluorescence when it 
intercalates with double stranded DNA. In a qPCR experiment, the fluorescence is measured after 
each extension step and this allows the monitoring of the increasing amount of DNA produced 
during the PCR reaction. The analysis of qPCR data is based on the threshold Cycle (Ct), which 
represents the cycle at which the fluorescence passes the threshold level, within the exponential 
phase, and it is a relative measure of the amount of target in the reaction.  
All the primers used for the CNV validation were designed with Primer3 
(http://bioinfo.ut.ee/primer3-0.4.0/primer3/). Oligonucleotide primers were designed taking into 
account an optimal primer length of 20-22 nucleotides, a GC content of 40–60% and an optimal 
PCR product size of 90-140 bp. In order to evaluate the PCR efficiency, a standard curve was set up 
for each primer pair, using three replicates of a control DNA and 4 template concentrations (four 
DNA template amounts deriving from a 1:2 serial dilution). The primers used for the CNV 
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validation were selected to have a PCR efficiency in the range of 90%-110%. We made sure the 
concentration of the DNA we would be using occurred within the serial dilution range. 
For the relative quantification, the DNA template was used with a concentration of 5 ng/μl. 
Each reaction was set up in triplicate using the following conditions: 
 
qPCR Reaction MIX Amount (μl) 
DNA template 5 
SYBR Green MasterMix (2X) 10 
Primer F (10 μM) 1 
Primer R (10 μM) 1 
H2O 3 
Final volume 20 
 
The qPCR experiments were run on the 7500 fast Real-Time PCR system (Life Technologies) 
according to the following qPCR program, which includes three main stages:  
1) Polymerase activation: incubation at 95°C for 20”;  
2) Anneal/extend: 40 cycles of incubation at 95°C for 3”, at 60°C for 30”;  
3) Melting curve: incubation at 95°C for 15”, followed by an incubation at 60°C for 1‟, with an 
increase of 0.5°C each cycle.  
The melting curve analysis, also called dissociation curve, consists of a step in which the 
temperature is gradually increased while the fluorescence is constantly monitored. When the 
temperature is high enough, the double strands of DNA fragments are denatured and the SYBR 
Green dye dissociates from the ds-DNA, causing a decrease in fluorescence. The melting 
temperature (Tm) depends on primer features (such as sequence complementarity and G-C 
composition) and reaction conditions. Analysis of melting curves allows the detection of primer-
dimers or other non-specific PCR products that could reduce the PCR efficiency and give spurious 
fluorescence signals. Primer-dimers usually have lower Tm compared to the PCR products, since 
they have a smaller size.  
For each sample, the qPCR data were compared against a control gene (FOXP2) (Table 5.16) and a 
control subject predicted to have two normal copies of the tested region. The number of copies of 
each amplified fragment was calculated using the 2
-ΔΔCt
 method (Livak & Schmittgen, 2001):  
ΔCt sampleDNA= Ct fragment of interest - Ct FOXP2 
ΔCt control DNA= Ct fragment of interest - Ct FOXP2 
ΔΔCt = ΔCt sample DNA - ΔCt control DNA 
ratio = 2
-ΔΔCt 
Copy number = 2*ratio
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5.5 Mutation screening 
5.5.1 Primers design 
DNA sequences and genomic organization of the genes analyzed are from the UCSC genome 
Browser (hg 19). All the primers were designed using Primer3 (http://bioinfo.ut.ee/primer3-
0.4.0/primer3/). All coding exons, intron-exon boundaries and the 5-UTR were sequenced by 
Sanger method. 
 
5.5.2 Polymerase Chain Reaction (PCR) assay 
The PCR assays were performed using the kit provided with AmpliTaq Gold DNA Polymerase 
(Life Technologies). AmpliTaq Gold is a Hot Start polymerase, that is inactive at room temperature 
and is activated during the initial denaturing step at 95°C. 
The PCR conditions were optimized for each primer pair using four different Mg
2+
 concentrations 
(1,5 mM; 2 mM; 2,5 mM or 3 mM). The reactions were set up in a final volume of 15 or 20 μl using 
30 or 50 ng of template DNA according to the following PCR reaction setup: 
 
Component 20 μl rxn 15 μl rxn Final conc. 
PCR Buffer (10X) 2 1,5 1X 
MgCl2 (25 mM) variable variable 1,5mM; 2mM; 2,5mM or 3mM 
dNTPs mix (25 mM) 0,16 0,12 0,2 mM each 
Forward primer (10 μM) 0,5 0,4 0,25 mM 
Reverse primer (10 μM) 0,5 0,4 0,25 mM 
Taq Gold Polymerase (5 U/μl) 0,06 0,05 0,015 U/ μl 
H20 variable variable variable 
DNA template variable variable 30-50 ng 
 
The amplification of some fragments containing a high GC content was performed adding to the 
PCR mix the dimethyl sulfoxide (DMSO) and/or 7-deaza-2‟-deoxiguanosina-5‟-trifosfato (Deaza 
GTP), which improve the denaturation of the template DNA, help the reaction and overcome the 
problem of non-specific annealing. The GC pair has a higher number of hydrogen bonds compared 
to the AT pair, therefore, GC-rich stretches are more stable and require a higher melting 
temperature. 
The PCR conditions were optimized for each primer pair used in the screening. For some of them, 
we used a traditional PCR program, with one annealing temperature (Ta): 
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program 
Initial denaturation 95°C for 15 minutes 
Amplification (35 cycles) 
95°C for 30 seconds 
Ta1 °C for 30 seconds 
72°C for seconds/minutes 
 
For other fragments, in order to increase the specificity and the yield of the reaction, we used a 
Touch-Down PCR program (TD) (Korbie & Mattick, 2008). In a TD program, the initial Ta (1) is 
higher to ensure a specific annealing of the primers to the template, then it is progressively 
decreased until it reaches a second, lower Ta (2), which is maintained constant for remaining 
amplification cycles. 
 
TD program 
Initial denaturation 95°C for 15 minutes 
Touch-Down 
(Ta decreases 0,5°C at each cycle) 
95°C for 30 seconds or 1 minute 
Ta1 °C for 30 seconds 
72°C for 30-45 seconds or 1 minute 
Amplification (30 cyles) 
95°C for 30 seconds or 1 minute 
Ta2°C for 30-45 seconds or 1 minute 
72°C for 1 minute 
 
Alternatively, some fragments were amplify using KAPA HiFi HotStart PCR (Resnova), which 
contains a novel HotStart DNA Polymerase, engineered for fast and versatile high-fidelity PCR and 
it is able to amplify fragments up to 15 kb from genomic DNA. The manufacturer‟s protocol is the 
following:  
 
PCR mix 25 μl rxn Final conc. 
5X KAPA HiFi Fidelity Buffer (contains 2.0 mM Mg
2+ 
at 1X) 5 1X 
KAPA dNTP Mix (10 mM each dNTP) 0,75 0,3 mM each 
Forward primer (10 µM) 0,75 0,3 µM each 
Reverse primer (10 µM) 0,75 0,3 µM each 
DMSO (100%) (for amplicons with a GC content >70%) 1,25 5% 
KAPA HiFi HotStart DNA Polymerase (1 U/µl) 0,5 0,5 U/25 μl rxn 
PCR grade water 11 - 
Template DNA (10ng/µl) 5 50 ng 
 
The PCR reaction was performed on the Veriti thermocycle (Life Technologies) using the following 
“touch-down” protocol: 
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KAPA HiFi HotStart cycling protocol 
Initial denaturation 95°C for 5 minutes 
Touch-Down 
(Ta decreases 0,5°C at each cycle) 
98°C for 20 seconds 
Ta1 °C for 15 seconds 
72°C for 15-60 seconds/kb 
Amplification (25 cyles) 
98°C for 20 seconds 
Ta2 °C for 15 seconds 
72°C for 15-60 seconds/kb 
Final extension 72°C for 1-5 minutes 
 
The PCR products were visualized with a UV transilluminator after electrophoresis on a 0,8%, 1%, 
2% or 2,5% agarose gel (the percentage of agarose varies depending on the PCR fragment) and 
GelRed staining (Biotium). The 100 bp and 1kb DNA ladders (NEB) were loaded to check the PCR 
fragment size. 
 
5.5.3 PCR purification 
Prior to sequencing, the PCR products were purified with Exonuclease I (ExoI) and Shrimp 
Alcaline Phospatase (SAP) using the ExoSAP-IT PCR Clean-up Kit (GE Healthcare). The enzyme 
ExoI removes single-strand DNA (primers or intermediate products), the enzyme SAP removes the 
unconsumed dNTPs remaining in the PCR mixture. The PCR cleanup was performed adding the 
Exo-SAP reaction mix to the PCR products, followed by a two-step incubation: 
 
EXOSAP mix Amount (μl) Program 
SAP enzyme 0,5 Treatment  37°C x 15 minutes  
ExoI enzyme 0,5 Enzymatic inactivation  80°C x 15 minutes  
PCR product 6 
Final volume 10 
 
Alternatively, PCR products were purified using a Millipore Multi Screen PCR plate (Millipore) 
according to the following procedure: 
1. at the conclusion of the PCR reaction, pipet 70 ul H20 to the reaction products and transfer the 
final volume into the 96 well Millipore Multiscreen PCR plate; 
2. place the Multiscreen plate on top of the Multiscreen Vacuum and apply vacuum until no liquid 
remains in the wells; 
3. to resuspend PCR products, add 25-30 ml of H20 to each well. Cover plate with cover provided 
and shake vigorously on a plate shaker for 10 min.  
5. remove as much as possible of the resuspended products from each well and place in a new, 96 
well plate for storage.  
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5.5.4 Sanger Sequencing reaction 
The Sanger Sequencing reaction was performed using the BigDye Terminator kit v1.1 (Life 
Technologies) according to the following manufacturer‟s  protocol: 
 
Sequencing mix  Amount (μl)  Program  
Big Dye terminator buffer (5X)  1,75  Initial Denaturation  96°C for 1 minute  
Big Dye terminator  0,5  
Amplification (29 cycles) 
96°C for 10 seconds 
Primer (10 µM) 0,16 50°C for 5 seconds 
H2O  variable 60°C for 4 minutes 
PCR product variable 
Final volume  10 
 
5.5.5 Ethanol-EDTA Precipitation of Sequencing Reactions 
In order to remove unincorporated dNTPs and primers, the products of sequence reactions were 
precipitated using the following procedure:  
1. A “precipitation mix” was prepared and added to each sample (volume of the sequence reaction: 
10 μl). This solution was composed by 10 μl of H2O, 2.5 volumes of 100% EtOH (55 μl), 1/10 of 
the volume of sodium acetate (NaAc) 3M pH 5.2 (2 μl).  
2. The samples were spun in a centrifuge for 30 minutes at 3000 rpm (4°C).  
3. The surnatant was discarded.  
4. The pellet was rinsed with 70 μl of 70% EtOH.  
5. The samples were spun in a centrifuge for 10 minutes at 3000 rpm (4°C).  
6. The surnatant was discarded.  
7. The microplates were spun upside down for 1 minute at 300 rpm, to remove traces of EtOH or 
NaAc.  
8. The pellet was dried at room temperature and stored away from direct light.  
The purified sequencing products were then resuspended in 15 μl of Injection Solution (DNA 
Sequencing Reaction Cleanup kit, Millipore) by pipetting up and down several times and/or using a 
microplate shaker. The sequences products were run on the ABI PRISM 3730 DNA analyser (Life 
Technologies). The sequences were analysed and compared to the reference sequence using the 
software Sequencher 5.0 (Gene Code Corporation). 
 
5.6 Prediction tools 
We used two online bioinformatic tools to predict the possible impact of non-synonymous coding 
SNPs on the structure and function of the human proteins: PolyPhen-2 (Polymorphism 
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Phenotyping v2, http://genetics.bwh.harvard.edu/pph2/) (Adzhubei et al., 2010) and SIFT (Sorting 
Tolerant From Intolerant, http://sift.jcvi.org/) (Kumar, Henikoff, & Ng, 2009). SIFT is a sequence-
based algorithm that uses sequence homology to predict the effect of amino-acid replacements, 
assuming that important positions in a protein sequence have been conserved throughout evolution. 
Polyphen-2 instead is a prediction algorithm, that incorporates sequence conservation information 
and protein structure annotations to predict the impact of the non-synonymous change. For SIFT, 
the score ranges from 0 (damaging) to 1 (neutral); for Polyphen-2, the score ranges from 0 (neutral) 
to 1 (damaging). 
 
5.6 RNA extraction and cDNA synthesis 
Total RNA from human frozen brain tissues (30-40 mg) was extracted using the Qiagen Total RNA 
kit (Qiagen), according to the manufacturer‟s protocol.  
Total RNA from whole blood was instead extracted using the RiboPure™-Blood Kit (Life 
Technologies) according to the manufacturer‟s protocol. 300-500 μl of blood can be processed 
immediately, or they can be stored in RNAlater Solution (a solution for the stabilization of RNA in 
whole blood) for a few days at ambient temperature or for longer periods at -20°C prior to RNA 
extraction.  
RNA quality was assessed on a 1% agarose gel and its concentration and purity was determined by 
UV Spectrophotometry. 
Reverse transcriptase PCR (RT-PCR) was performed using the Superscript III First Strand 
Synthesis SuperMix (Life Technologies) using approximately 1 μg of RNA as template. 
 
5.7 Analysis of the candidate gene CTNNA3 
5.7.1 Characterisation and segregation analysis of CTNNA3 deletions 
The maternal and the paternal exon 11 CTNNA3 microdeletions segregating in family 3456 were 
amplified via several PCR assays using the AmpliTaq Gold polymerase (Life Technologies) (Table 
5.1). The paternal 301-bp and the maternal 949-bp deletion spanning amplicons were purified using 
Exosap (GE Healthcare, Little Chalfont, UK) and then sequenced using BigDye Terminator kit v1.1 
(Life Technologies), as described before, to determine the exact boundaries of the deletions.  
An additional primer pair that amplifies exon 11 of CTNNA3 (not deleted allele) was subsequently 
used to confirm that the identified deletions in family 3456 were in the heterozygous or 
homozygous status (Table 5.1).  
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The experimental validation of CTNNA3 exonic deletions in four other ASD families was carried 
out by qPCR using Fast SYBR Green as reported in section 5.4. Each assay was conducted with at 
least three sets of primers corresponding to the region of interest (Table 5.2) and another mapping 
to the control region on FOXP2 gene (Table 5.16). The number of copies of each amplified 
fragment was calculated using the 2
-ΔΔCt
 method. The parents and additional affected or unaffected 
siblings were also tested for inheritance and segregation of CNVs, respectively. 
Numbering for CTNNA3 exons is based on the Reference Sequence (RefSeq) NM_013266. 
 
5.7.2 CTNNA3 and LRRTM3 exon sequencing 
All coding exons, intron-exon boundaries and the 5‟-UTR of the long isoforms of CTNNA3 
(NM_001127384; NM_013266) and the nested gene LRRTM3 (NM_178011.4) have been amplified 
by PCR in all members of four families carrying CTNNA3 exonic deletions .  
Primer sequences and PCR conditions used for amplification (20 amplicons for CTNNA3 and 5 
amplicons for LRRTM3) are listed in tables 5.3 and 5.4. PCR products were purified using Exosap 
(GE Healthcare) and then sequenced using BigDye v1.1 (Life Technologies).  
 
5.7.3 CTNNA3 expression  
Human brain samples from the frontal cerebral cortex and cerebellum were obtained from deep 
frozen (-80°C) slices of two informative heterozygous adult control subjects for a CTNNA3 exon 13 
coding SNP (rs4548513; p.Ser596Asn).  
Total RNA from human frozen brain tissues (30-40 mg) was extracted using the Qiagen Total RNA 
kit (Qiagen) and RT-PCR was performed using the Superscript III First Strand Synthesis SuperMix 
(Life Technologies) as described in section 5.6. Two microliters of complementary DNA (cDNA) 
was used for testing CTNNA3 expression in the human frontal cerebral cortex and cerebellum using 
a forward primer designed in exon 10 and a reverse primer mapping in exon 15, in order to amplify 
a cDNA fragment including the coding SNP rs4548513 (pSer596Asn). PCR products were purified 
and sequenced as described before using primers mapping in exon 12 and exon 14. (Table 5.5) 
 
5.7.4 Western blot analysis 
The hippocampus and cortex were dissected from three mice (C57Bl/6 N) at each time point (from 
P0 to P90) pooled together. Samples were lysed with lysis buffer containing 1% SDS and boiled. 
Forty micrograms of total proteins were loaded onto a 4%–12% polyacrylamide gel (Life 
Technologies) and then transferred to a nitrocellulose membrane (Whatman). Filters were 
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hybridized with antibodies against N-catenin (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) or 
T-catenin [30] or GAPDH (Millipore, Billerica, MA, USA) as housekeeping control and then 
revealed by using HRP-conjugated specific secondary antibodies (BioRad, Hercules, CA, USA) and 
ECL (GE Healthcare). ImageJ was used to quantify bands. Experiments were done according to the 
animal protocols approved by the Institutional Animal Care and Use Committee San Raffaele 
(IACUC) (San Raffaele, Milan, Italy) and were approved by the National Ministry of Health, 
IACUC ID 470. All experiments were carried out in accordance with the guidelines established by 
the European Community Council Directive of 24 November 1986 on the use of animals in research 
(86/609/EEC). All efforts were made to minimize animal suffering and to use only the number of 
animals necessary to produce reliable results. 
 
5.8 Analysis of the candidate gene CHRNA7 
5.8.1 Validation of the CHRNA7 duplication 
All members of the discovery family 3474 were analyzed for the CHRNA7 microduplication by 
qPCR as described in section 5.4. A primer pair mapping in exon 3, specific for CHRNA7 was used 
to confirm the predicted duplication (Table 5.6). 67 additional ASD probands were tested by qPCR 
using the same probe on exon 3. 
 
5.8.2 CHRNA7 sequencing 
All 10 exons and intron-exon boundaries of CHRNA7 were sequenced by Sanger method in 135 
ASD individuals.  
The first four exons, which are specific for CHRNA7, were amplified using exon specific primers 
corresponding to flanking intronic sequences using the AmpliTaq Gold polymerase (Life 
Technologies), purified with Exosap (GE Healthcare) and then subjected to Sanger sequencing. 
The amplification of the fragments containing exon 1 and exon 2 was particularly problematic, 
since these regions are located in a CpG island extending to intron 2, and therefore they were 
amplify adding to the PCR mix 7-deaza-2‟-deoxiguanosina-5‟-trifosfato (Deaza GTP) and/or 
DMSO (5%). The primers and the PCR conditions used for amplification of the first four exons are 
listed in table 5.7. 
To selectively amplify the CHRNA7 exons 5-10, which are duplicated in the CHRFAM7A gene, two 
long range PCRs (LR-PCRs) were performed to amplify: a) a segment encompassing exon 5 to 
exon 8 (x5-x8 LR-PCR) using a primer F outside the duplication (mapping to CHRNA7 specific 
intron 4) and a primer R in the duplicated region (mapping to intron 8); b) a segment encompassing 
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exon 9 to exon 10 (x9-x10 LR-PCR) using primer F in the duplicated region (mapping to intron 8) 
and a primer R mapping in a CHRNA7 specific region located at 3‟UTR. LR-PCR was performed 
using KAPA HiFi HotStart PCR (Resnova) according to the manufacturer‟s protocol, as described 
in section 5.5.2. The primers and the PCR conditions used for amplification of the two LR-PCRs 
are listed in table 5.8. 
All LR-PCR products were purified using a Millipore Multi Screen PCR 96 well (section 5.5.3) and 
then they were directly sequenced by Sanger method using specific primers for each exon (Table 
5.10). In particular to sequence the CHRNA7 exon 10, we carried out an additional PCR assay with 
the AmpliTaq Gold polymerase using 3 μl of the purified product from x9-x10 LR-PCR and 
primers specific for exon 10 (Table 5.9).  
The CHRNA7 intron 5 and intron 9 were amplified using primers flanking these two regions, 
purified with Exosap and then sequenced with the same primers (this protocol leads to co-
amplification of both CHRNA7 and CHRFAM7A) or they were amplified using 3 μl of the purified 
product from the x5-x8 and x9-x10 LR-PCRs (Table 5.7). 
 
5.9 Analysis of the microdeletion on chromosome 2q31.1 
5.9.1 Validation of the microdeletion in the discovery pedigree 
The presence of the deletion was validated in blood-derived genomic DNA from family 3423 by 
qPCR using Fast SYBR-green as described in section 5.4. The copy number was normalized against 
the father 3423_1. 
Eight primer pairs were used (Table 5.11): two qPCR fragments, mapping to KLHL23 exon 3 and 
METTL5 intron 7, are located outside the deletion, whereas six probes, mapping to intron 3 and 
exon 4 of KLHL23, to intron 9 and intron 11 of SSB, and to intron 6 and exon 6 of the METTL5 
gene, are inside the deletion.  
 
5.9.2 KLHL23 and PHOSHO2-KLHL23 expression analyses  
Total RNA from all member of family 3423 was extracted from peripheral blood using the 
RiboPure™-Blood Kit (Life Technologies) and cDNA was synthesized using the Superscript III 
First Strand Synthesis SuperMix (Life Technologies). KLHL23 expression in family 3423 was 
tested by quantitative RT-PCR with Sybr Green using 1 µl of cDNA. Two qPCR fragments were 
used: one spanning exons 2-3 (outside of the microdeletion) and another one spanning exons 3-4 
(exon 4 maps inside the microdeletion) (Table 5.12). All the data were normalized using the 
housekeeping gene GUSB as reference gene (Table 5.16). Expression levels were also normalized 
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against a control individual. The 2
-ΔΔCt
 method was applied to estimate the difference in the gene 
expression between samples: 
ΔCt sample cDNA= Ct fragment of interest - Ct GUSB 
ΔCt control cDNA= Ct fragment of interest - Ct GUSB 
ΔΔCt = ΔCt sample cDNA - ΔCt control cDNA 
Expression level = 2
-ΔΔCt 
 
KLHL23 and PHOSPHO2-KLHL23 expression was analysed in a multiple tissue cDNA panel 
(Human MTC Panel I, Clontech) by PCR with the TaqGold polymerase using 1μg of cDNA from 
each tissue and two primer pairs: one primer pair specific for KLHL23 and another primer pair 
specific for the PHOSPHO2-KLHL23 gene. PCR primers and condition are reported in Table 5.13. 
 
5.9.3 KLHL23 and PHOSHO2-KLHL23 mutation screening 
The entire open reading frames of KLHL23 (NM_144711.5) and PHOSPHO2-KLHL23 
(NM_001199290.1) were screened in the 3423_3 individual and in 96 additional unrelated ASD 
probands using primers and reaction conditions reported in tables 5.14 and 5.15. Probands were 
selected from the International Molecular Genetic Study of Autism Consortium (IMGSAC) 
multiplex families (see paragraph 5.1.3). 
Bioinformatic analysis of novel non synonymous variants was carried out using Poly-Phen2 
(http://genetics.bwh.harvard.edu/pph2) and SIFT (http://sift.jcvi.org/) (section 5.6). 
 
5.9.4 PCR-Restriction Fragment Length Polymorphism (RFLP) analysis 
PCR-Restriction Fragment Length Polymorphism (RFLP)-based analysis was used for SNPs 
genotyping. The first step in a PCR-RFLP analysis is the amplification of a fragment containing the 
variation. Since the presence or absence of the restriction enzyme recognition site results in the 
formation of restriction fragments of different sizes, allele identification can be done by 
electrophoretic resolvement of the fragments. 
We used the bioinformatic program INSIZER (http://zeon.well.ox.ac.uk/git-bin/insizer, not 
available anymore) to find a restriction endonuclease that could specifically discriminate between 
the two allelic variants (A>G) located in exon 2 of KLHL23. 
The PCR fragment containing exon 2 was amplified with the same primer pair used for KLHL23 
mutation screening (Table 5.14). Subsequently, the digestion reaction was assembled using the 
enzyme BtsI (NEB, New England Biolabs) and the following conditions: 
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Digestion mix  Amount (μl)  Program  
NEB buffer 10X 1,5 Digestion  55°C for 3 hours  
BtsI enzyme (2 U/μl)  0,2 Heat inactivation  80°C for 20 minutes  
BSA (10X)  1,5   
H2O  8,8   
PCR product  3   
Final volume  15   
 
The restriction fragments were separated by electrophoresis on a 2,5% agarose gel (0,7 g of agarose 
and 0,8 g of Nusieve). 
 
5.10 Analysis of the CADPS2 gene 
5.10.1 Microsatellite analysis 
Two microsatellite markers mapping to CADPS2 intron 1 (CADPS2_21xAC, genomic position: 
chr7:122,414,324-122,414,365) and intron 2 (CADPS2_26xAT, genomic position: 
chr7:122,348,575- 122,348,626) were genotyped from blood-derived DNA of father, proband, and 
affected sister according to the following PCR conditions:  
 
Component 10 μl rxn Final conc. 
PCR Buffer (10X) 1 1X 
MgCl2 (25 mM) 1 2,5mM 
dNTPs mix (2 mM) 1 0,2 mM each 
Forward primer FAM-labeled (10 μM) 0,25 0,5 μM 
Reverse primer FAM-labeled (10 μM) 0,25 0,5 μM 
Taq Polymerase (5 U/μl) 0,03 0,015 U 
H20 3,47 Up to  
DNA template 3 30 ng 
 
The following touch-down program was used:  
 
TD program  
Initial denaturation 95°C for 15 minutes 
Touch-Down 
(Ta decreases 0,5°C at each cycle) 
95°C for 30 seconds  
62°C for 30 seconds 
72°C for 30 seconds 
Amplification (30 cyles) 
95°C for 30 seconds  
57°C for 30 seconds  
72°C for 7 minutes 
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Samples were diluted 1/10 and 1 μl of dilution was run onto the automated 3730 ABI sequencing 
machine with LIZ(500) size marker (Life Technologies, Foster City, CA, USA). Genotype call was 
performed with GeneMapper v3.7. 
 
5.10.2 CADPS2 expression analysis 
Human brain samples from frontal cerebral cortex, amygdala, entorhinal cortex and cerebellum 
were obtained from deep-frozen (-80°C) slices of 3 adults showing either no significant 
histopathological changes or neurodegenerative histopathological lesions of variable severity. Total 
RNA from these brain tissues (30-40 mg) was extracted using with the QIAGEN Total RNA kit 
(QIAGEN) and cDNA was synthesized using the Superscript III First Strand Synthesis SuperMix 
(Life Technologies) according to the manufacturer‟s protocol.  
PCR was performed using a forward primer designed in CADPS2 exon 3 and a reverse primer 
mapping in exon 5 (Table 5.17), in order to amplify a cDNA fragment including the SNP 
rs2251761. PCR products were purified and sequenced as described before using the same PCR 
primers. 
 
5.10.3 MALDI-TOF MS methylation analysis 
DNA methylation of CADPS2 gene was determined with the MassARRAY platform Sequenom, 
which uses the EpiTYPER assay, a tool for the detection and quantitative analysis of DNA 
methylation using base-specific cleavage and MALDI-TOF MS (Matrix-Assisted Laser 
Desorption/Ionization Time-of-Flight Mass Spectrometry). This technology consists of four main 
steps (Figure 5.4): 
1) The first step is the bisulfite treatment of genomic DNA, where nonmethylated cytosine is 
converted to uracil, while methylated cytosine remains unchanged.  
2) The second step is PCR amplification with a T7-promotor tagged primers and the neutralization 
of unincorporated dNTPs using shrimp alkaline phosphatase (SAP).  
3) The third step is the generation of a single strand RNA molecule by in vitro RNA transcription 
followed by base-specific cleavage using RNase A. In this step the reverse strand of both 
methylated and not methylated regions is cleaved at every U to produce fragments containing at 
least one CpG site each. 
4) The different cleavage products have a mass difference of 16 dalton for each CpGs between the 
methylated and un-methylated regions and they can be analyzed by mass spectrometry. In analyzing 
the mass spectrum, the relative amount of methylation can be calculated by comparing the 
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difference in signal intensity between mass signals derived from methylated and nonmethylated 
template DNA.  
 
Figure 5.4 Protocol of the MALDI-TOF MS methylation analysis 
 
The EpiDesigner BETA software was used to design primers for PCR amplification of bisulfite 
treated DNA. This tools allows to design PCR amplicons which must cover the majority of CpG 
dense areas in close proximity to or overlapping with the annotated transcription start. The figure 
5.5 shows an overview of a genomic region submitted to software for predicting the CpG islands: 
the blue bars are the CpG covered by MS analysis, while the red bars are the CpG connot be 
analyzed; all possible primer combinations to cover the area of interest are also represented.  
 
 
Figure 5.5 Overview of the genomic area submitted to the EpiDesigner BETA software, with a pictorial view of the GC 
content and all possible primer combinations to cover the area of interest.  
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PCR amplification is carried out using a forward primer with a 10mer-tag sequence and a reverse 
primer with a T7 promoter-tag that is incorporated into the amplification product for in vitro 
transcription (Figure 5.6). 
 
 
 
Figure 5.6 Primers used for the T7-promoter-tagged PCR amplification of bisulfite-converted DNA 
 
The software also displays the mass spectrum for all analyzed amplicons and identifies the selected 
CpG site. The software matches the reference spectrum (green lines) with the mass of the fragments 
generated by each amplicon (black lines) once they are run in the MassArray. The output is a 
graphical representation (epigram) where a series of individual CpGs are represented by circles on 
the same line and they are arranged in ascending numerical order from left to right. The numbers 
indicate the base pairs relative to the amplified PCR product and the position of the CpGs. Per 
amplicon, the color within the circle denotes the level of methylation found at this particular site in 
the selected sample. The color ranges from red (0% methylation) to yellow (100% methylation) 
(Figure 5.7).  
 
MATERIALS AND METHODS 
 
 
 
83 
 
 
Figure 5.7 Outputs of the EpyTYPER BETA sortware. At the top panel is shown the spectrum pane for a specific 
amplicon; the reference spectrum is indicated by green lines, while the spectrum of mass of the fragment of interest is 
indicated by black lines. At the bottom panel is shown the epigram tab pane: this pane provides graphical 
representations of  the CpG sites within the selected amplicon. 
 
 
One microgram of genomic DNA was submitted to bisulfite conversion, using the EZ DNA 
Methylation Kit (Zymo Research, CA, USA), according to the manufacturer‟s protocol, except for 
the conversion step consisting of 21 cycles at 95°C for 30 s and 50°C for 15 min. Universal 
unmethylated and methylated DNAs (Millipore, MA, USA) were used as internal controls. In 
addition, a 477-bp amplicon for the IGF2 region was included in the assay for quality assessment of 
bisulfate treated DNA. A region length spanning 1.9 kb of promoter and 1.8 kb of intron 1 of 
CADPS2 gene (corresponding to genomic coordinates chr7: 122,524,253-122,528,311, hg19) was 
submitted to EpiDesigner BETA software (Sequenom) for predicting the CpG islands. Four 
amplicons including 92 CpGs were selected; 63 of these CpGs were analyzable through this 
methodology (Table 5.18). 
25 μl H2O MilliQ and 4 μg resin were added to the cleaved fragments. 20 μl of the analytes was 
nanodispensed onto 384-element silicon chips preloaded with matrix. Mass spectra were collected 
by using a matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS, and 
spectra‟s methylation ratios were generated by EpiTYPER software V.1.2.22. Samples were run 
in duplicate/triplicate when possible. 
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5.10.4 PCR and sequencing of CADPS2 intron 1 
The CADPS2 intron 1 fragment containing SNP rs981321 (g.122,525,329 G>A) was amplified with 
primers flanking this region using the AmpliTaq Gold DNA Polymerase (Life Technologies) with 
30 ng of genomic DNA in a final volume of 15 µl. The PCR products were purified using a 
Millipore Multi Screen PCR 96 well (section 5.5.3) and then sequenced as described in section 
5.5.4. The PCR primers and conditions are reported in table 5.19. 
 
5.10.5 Colony screening 
To analyzed the methylation status of four control individuals heterozygous for the SNP rs981321, 
we performed colony analysis of an intron 1 fragment containing both the SNP rs981321 and the 
three CpG sites (CpG_14, CpG_15, CpG_16).  
1) Producing PCR products. 
One microgram of genomic DNA was submitted to bisulfite conversion, using the EZ DNA 
Methylation Kit (Zymo Research, CA, USA), according to the manufacturer‟s protocol. 
Six microliters of bisulfite-treated DNA was used for PCR amplification using the KAPA2G 
ReadyMix (KAPA Biosystems) in a final volume of 50 µl. KAPA2G ReadyMix allows the 
amplification of DNA fragments with high GC- or AT content and it contains a HotStart DNA 
Polymerase (1 U per 25 µl reaction) in a proprietary reaction buffer containing dNTPs (0.2 mM of 
each dNTP at 1X), MgCl2 (2 mM at 1X) and stabilizers. The PCR was protocol is the following:  
 
Component 50 μl rxn Final conc. 
KAPA 2G (2X)
  25 1X 
MgCl2 (25 mM) 1 0,5mM 
DMSO 100% 2,5 5% 
Forward primer (10 μM) 2,5 0,5 μM 
Reverse primer (10 μM) 2,5 0,5 μM 
H20 10,5  
DNA template 6  
 
The PCR primers and PCR program are reported in table 5.20. 
All 50 µl of the PCR products were purified using the GenElute Gel Extraction Kit (Sigma) 
according to the manufacturer‟s protocol. 
2) Cloning into pCR®2.1 vector. 
The PCR products were then cloned into pCR®2.1 vector using the Original TA cloning kit (Life 
Technologies). This vector contains the lacZ gene, encoding β-galactosidase, and it allows the for 
blue-white screening. The following ligation reaction was used: 
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Component Amount (µl) 
10X Ligation Buffer 1 
pCR®2.1 vector (25 ng/µl) 2 
T4 DNA Ligase (4.0 Weiss units) 1 
H20 7 
PCR product 10 
 
The ligation reaction was incubated at 14°C overnight.  
3) Transforming Competent Cells. 
After the ligation of insert  into pCR®2.1, the construct was transformed into competent DH5α E. 
coli strains according this protocol: 
1. Thaw on ice one 50 µl vial of frozen Competent Cells for each transformation.  
2. Pipette 2 µl of each ligation reaction directly into the vial of competent cells and mix  
3. Incubate the vials on ice for 30 minutes.  
4. Heat shock the cells for 30 seconds at 42°C without shaking.  
5. Immediately transfer the vials to ice for 5 minutes.  
6. Add 300 μl of room temperature LB medium. 
7. Shake the vials horizontally at 37°C for 1 hour  
8. Spread the entire volume on LB agar plates containing  ampicillin (10mg/ml). 
9. Incubate plates overnight at 37ºC. 
 
White colonies were grown and the plasmid DNA was purified and sequenced with universal M13 
forward and reverse primers (Table 5.21) using the BigDye v1.1 kit (Life Technologies). Sequences 
were run onto the ABI 3730 automated sequencing machine, and electropherograms were analyzed 
with Sequencher 5.0 (Gene Code Corporation). 
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Table 5.1: CTNNA3 deletion in family 3456 (validation by PCR) (* primers used for sequencing) 
Primer name Sequence (5’-3’) 
Prime
r size 
(bp) 
Product size 
(pb) 
Fragment position (hg19) 
PCR with TaqGold 
[Mg
2+
] PCR program 
CTNNA3_father_del_5F TCTCCGAACTCCCAAAAGAA 20 
301 bp chr10:68227982-68327931 2,5 mM 
95°C-60°C-72°C (30'',30'',1'30'')             
for 35 cycles CTNNA3_father_del_5Rseq* GTCAAGCATCACTTCTTGGCTA 22 
CTNNA3_mother_del_1F TCGCTTTCAGAGGTTGGAGT 20 
949 bp chr10:68272399-68333091 2,5 mM         
 95°C-60°C-72°C (30'',30'',6')                 
for 35 cycles CTNNA3_mother_del_1Rseq* GGATTGTGCTTCTGGCATTT 20 
CTNNA3_delx11_rt_F ACCAGATACAGCAAGGAAGTCA 22 
91 bp chr10:68280373-68280463 2,5 mM           
TD 65-58°C (30'',30'',30'')              
for 30 cycles CTNNA3_delx11_rt_R GTACAAGCGTACATGGGAGAAT 22 
 
Table 5.2: CTNNA3 deletions in four ASD families (validation by qPCR) 
Primer name Sequence (5’-3’) 
Primer 
size (bp) 
Product size 
(pb) 
Fragment position (hg19) Name in the figure 7.5 
CTNNA3_del3093_1F TCTGTGCCTTTGTCCTATCACT 
 
22 
107 chr10:68373163-68373269 
Intron 10_1 
CTNNA3_del3093_1R GGTGGTCCGTAAGTATTTGTTG 22  
CTNNA3_del3093_2F AGTGCCTTCACACATTTCCA 20 
100 chr10:68372197-68372297 
Intron 10_2 
CTNNA3_del3093_2R GGGCTACAACTTACCTTTCCA 21  
CTNNA3_del3093_3F TTTCATTGCTTCTGGCCTCT 20 
105 chr10: 68352567-68352671 
Intron 10_3 
CTNNA3_del3093_3R CAAAGTGTCTGCACAGGGTAA 21  
CTNNA3_del3311_1F CTTTCAGTTGACTCCTTGTGCT 22 
114 chr10:68065197-68065310 
Intron 12 
CTNNA3_del3311_1R GACTCTGCATTTGGCTCATT 20  
CTNNA3_del3311_2F CCTCCTCTTGTGTATCCCATTT 22 
116 chr10:68031618-68031733 
Intron13 
CTNNA3_del3311_2R TCACTAACTAGCGCGGCTTT 20  
CTNNA3_del3476_1F GGCTTAGTTTATGGCTCTCCAA 22 
111 chr10:68547946-68548056 
Intron7_1 
CTNNA3_del3476_1R TTAATGACCACCACCCTCCT 20  
CTNNA3_del3476_2F TTTGGTATGCTTCTGCTGCT 20 
107 chr10:68537601-68537707 
Intron7_2 
CTNNA3_del3476_2R ACTCCTGTTGTGTTGGCTGT 20  
CTNNA3_delx11_rt_F ACCAGATACAGCAAGGAAGTCA 22 
91 chr10:68280373-68280463 
Exon 11 
CTNNA3_delx11_rt_R GTACAAGCGTACATGGGAGAAT 22  
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Table 5.3: CTNNA3 mutation screening (* primers used for sequencing) 
Primer name Sequence (5’-3’) 
Primer 
size (bp) 
Product 
size (pb) 
Fragment position (hg19) 
PCR with TaqGold 
[Mg2+] [DMSO] PCR program 
CTNNA3_x1F* TGTTTGTAGGTCTCTAGGCAAAG 23 
394 chr10:69455688-69456081 2 mM  TD 67-60°C  (1',30'',1') for 30 cycles 
CTNNA3_x1R CACAGGAATTCAATGCAGAA 20 
CTNNA3_x1alt_F* GCTCTGGGCTATGCAGAAAG 20 
476 chr10:69408315-69408791 2,5 mM  TD 67-60°C (1',30'',1') for 30 cycles 
CTNNA3_x1alt_R CAGGGTGGCTACAATTCCTT 20 
CTNNA3_x1bF* TACCCTTCACTGGCATGTTG 20 
340 chr10:69425192-69425531 2 mM  TD 62-57°C (30",30",30") for 30 cycles 
CTNNA3_x1bR CCTTTCATTTCCCCCAAAGT 20 
CTNNA3_x2F TTTTGTAGCCTGGTCCTCTGA 21 
467 chr10:69406956-69407422 2 mM 5% TD 67-60°C (1',30'',1') for 30 cycles 
CTNNA3_x2R* AAAGAGAATGTGGGGGAAACT 21 
CTNNA3_x3F TCCCAGGACTGTGTTCTCCT 20 
467 chr10:69366850-69367317 2 mM,  TD 67-60°C (1',30'',1') for 30 cycles 
CTNNA3_x3R* GGGGACCGAGCAACTAAAA 19 
CTNNA3_x4F* TCAGCAAATGCAGAAGTTGG 20 
542 chr10:69299171-69299712 2 mM  TD 67-60°C (1',30'',1') for 30 cycles 
CTNNA3_x4R GCCAAGATGCACTAGGATCG 20 
CTNNA3_x5F GAGGCTCATTATCGACTCTTCG 22 
350 chr10:69281462-69281811 2 mM  TD 67-60°C (1',30'',1') for 30 cycles 
CTNNA3_x5R* GATCAGCACAGCACAACCTG 20 
CTNNA3_x6F* TGTAGAAATAATAGATGCCCTTGA 24 
567 chr10:68979217-68979783 2,5 mM  TD 62-55°C (1',30'',1') for 30 cycles 
CTNNA3_x6R TTTGGAAGACTCAAGAAGGTGA 22 
CTNNA3_x7F* AGCCGAGGCAGTAAAACACA 20 
499 chr10:68939912-68940410 2,5 mM  TD 67-60°C (1',30'',1') for 30 cycles 
CTNNA3_x7R TTCCCTGTAAATAACCAAGCAGA 23 
CTNNA3_x8F* GCTCTGCCTATTGTCACACTG 21 
435 chr10:68535107-68535541 2 mM  TD 67-60°C (1',30'',1') for 30 cycles 
CTNNA3_x8R TGAAAGGAACAAAACAAGAAACA 23 
CTNNA3_x9F TTTCTTTTTGCCTGGATATTTTG 23 
513 chr10:68525851-68526363 3 mM; 5% TD 67-60°C (1',30'',1') for 30 cycles 
CTNNA3_x9R* TGGAGTGATCTATACAATCGGACA 24 
CTNNA3_x10F* CATTGAGATTCTTGATGAATGTGT 24 
585 chr10:68381063-68381647 3 mM ; 5% TD 67-60°C (1',30'',1') for 30 cycles 
CTNNA3_x10R GGACAATTCTGTCTTCCATGC 21 
CTNNA3_x11F* TGTTTTTCCTATTGTCGATGATG 23 
582 chr10:68280297-68280878 2,5 mM 5%, TD 67-60°C (1',30'',1') for 30 cycles 
CTNNA3_x11R ACCATGCCTGTCCCAGTATT 20 
CTNNA3_x12F* AGTCTTCCATTTCCAATGTGC 21 
471 chr10:68138763- 68139233 2,5 mM   TD 67-60°C (1',30'',1') for 30 cycles 
CTNNA3_x12R CGCATAACCAAAGTGTGCAA 20 
CTNNA3_x13F CAGAAGCCTGGGGTTTAGAA 20 
467 chr10:68040148- 68040614 3 mM   TD 67-60°C (1',30'',1') for 30 cycles 
CTNNA3_x13R* AGCATTTCTTGCAGTCATCC 20 
CTNNA3_x14F TAAGGTACTGCCGCGTTGTT 20 
305 chr10:67862781-67863085 3 mM  TD 67-60°C (1',30'',1') for 30 cycles 
CTNNA3_x14R* TTTCTCCATGTGCTTCACAGA 21 
CTNNA3_x15F* TGGATTTAAGTATGTTGGACACC 23 
546 chr10:67828960-67829505 2,5 mM   TD 67-60°C (1',30'',1') for 30 cycles 
CTNNA3_x15R CCACCTGATTTTTGGCACTT 20 
CTNNA3_x16F GATGGATGGACGCATAGATT 20 
459 chr10:67748199-67748657 3 mM   TD 67-60°C (1',30'',1') for 30 cycles 
CTNNA3_x16R* TTTGATGCTGAAGAGCTGATACT 23 
CTNNA3_x17F* GAAGCTACTTGGTCCTGTATGAA 23 
350 chr10:67726290-67726639 2,5 mM   TD 67-60°C (1',30'',1') for 30 cycles 
CTNNA3_x17R TGGTCATGTAAACAAGGGTGT 21 
CTNNA3_x18F AACAAAACCTCCTGGAATAATAGC 24 
479 chr10:67679946-67680424 2,5 mM   TD 67-60°C (1',30'',1') for 30 cycles 
CTNNA3_x18R* TTGATTTAGCGCCCAATATTTTA 23 
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Table 5.4: LRRTM3 mutation screening (* primers used for sequencing) 
Primer name Sequence (5’-3’) 
Primer 
size (bp) 
Product 
size (pb) 
Fragment position (hg19) 
PCR with TaqGold 
[Mg
2+
] PCR program 
LRRTM3_x1F* GTGCTCATCACGGGAACTG 19 
587 chr10:68685905-68686491 2,5 mM TD 65-60°C (30",30", 1') 
for 30 cycles LRRTM3_x1R GGAAACATGCCACTAAGCAAA 21 
LRRTM3_x2Fa TTTGCTTAGTGGCATGTTTCC 21 
845 chr10:68686471-68687315 2,5 mM TD 65-60°C (30",30", 1') 
for 30 cycles LRRTM3_x2Ra TGCTCCAGGTGAAGTTCTTTG 21 
LRRTM3_x2Fb GAACCATCCCTGTGCGAATA 20 
645 chr10:68687183-68687827 2,5 mM TD 65-60°C (30",30", 1') 
for 30 cycles LRRTM3_x2Rb GGAGCTTGGGCTTAAACGTC 20 
LRRTM3_x2Fc ATATGGGAATGCAGCAGAAA 20 
690 chr10:68687611-68688300 2,5 mM TD 65-60°C (30",30", 1') 
for 30 cycles LRRTM3_x2Rc CATCGCGTTCCCTTGATAGT 20 
LRRTM3_x3F* GCGGGATAATATAGGGACACC 21 
473 chr10:68857201-68857673 2,5 mM TD 65-60°C (30",30", 1') 
for 30 cycles LRRTM3_x3R TTTGAACAGGGGATTTTGTG 20 
LRRTM3_x2RaSeq* TGGAACTAAGAATCAGCTCTTTGA 24     
LRRTM3_x2RbSeq* TGAAAGCTTCGATCTCATTGC 21     
LRRTM3_x2FcSeq* CCGAGCACATCTCTTTCCAT 20     
 
Table 5.5: CTNNA3 expression (* primers used for sequencing) 
Primer name Sequence (5’-3’) 
Primer 
size (bp) 
Product 
size (pb) 
Fragment position (hg19) 
PCR conditions (Kapa HiFi) 
[Mg
2+
] PCR program 
CTNNA3_express_x10F CCAATCATTTGGAAACCTTGTG 22 
731 chr10:68381457- 68857673 2,5 mM 
TD 65-60°C (20",15", 45") for 35 
cycles CTNNA3_express_x15R CTCAATCTCAGCATCCAGCTTA 22 
CTNNA3_express_x12F GTTACGAGCCAGGGGCTTAC* 20 
     
CTNNA3_express_x14R CAAGGTCAGAAACATCCTCCA* 21 
 
Table 5.6: CHRNA7 duplication (validation by qPCR) 
Primer name Sequence (5’-3’) 
Primer size 
(bp) 
Product size 
(pb) 
Fragment position (hg19) 
CHRNA7_x3F GGCTGCAAATGGTAAGTTAAGAG 23 
111 chr15:32393540-32393650 
CHRNA7_x3R AACAGGACCTCTCAGAAGCAAG 22 
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Table 5.7: CHRNA7 mutation screening exons 1-4 (* primers used for sequencing) 
Primer name Sequence (5’-3’) 
Primer 
size (bp) 
Product 
size (pb) 
Fragment position (hg19) 
PCR with TaqGold 
[Mg
2+
] 
[Deaza 
GTP] 
[DMSO] PCR program 
CHRNA7_x1F AGTACCTCCCGCTCACACCT 20 
480 chr15:32322529-32323009 
1,5 
mM 
0.1mM 5% 
TD 65-60°C (30",30", 
30") for 30 cycles CHRNA7_x1R* GTGCAGCCCAGACAAGCA 18 
CHRNA7_x2F CTCCGGGACTCAACATGC 18 
578 chr15: 32322784-32323008 
1,5 
mM 
0.1mM 5% 
TD 65-60°C (30",30", 
30") for 30 cycles CHRNA7_x2R* AGCTTGGGGCCAACTAGAG 19 
CHRNA7_x3F CCACACACAACAACGCTCTC 20 
252 chr15:32393397-32393646 
2,5 
mM 
  
TD 65-60°C (30",30", 
30") for 30 cycles CHRNA7_x3R* GGACCTCTCAGAAGCAAGCA 20 
CHRNA7_x4F TGGAATTCTCTTTGGTTTTGC 21 
388 chr15:32403893-32404280 
2,5 
mM 
  
TD 65-60°C (30",30", 
30") for 30 cycles CHRNA7_x4R* GCTGGCTTACAGGGACAGAG 20 
CHRNA7_intron5F GACTTGACCATAACATGACTTTCC 24 
252 chr15:32448127-32448507 
2,5 
mM 
  
TD 65-60°C (30",30", 
30") for 30 cycles CHRNA7_intron5R* CAGACAATCCCCCTCCATTA 20 
CHRNA7_intron9F AGTGCCGCCTGCTTGTAA 18 
298 chr15:32458604-32458902 
2,5 
mM 
  
TD 65-60°C (30",30", 
30") for 30 cycles CHRNA7_intron9R* TTCCCTGAAATTATCCAGATCCT 23 
 
Table 5.8: CHRNA7 long range PCR 
 
Primer name Sequence (5’-3’) 
Primer 
size (bp) 
Product 
size (pb) 
Fragment position (hg19) 
PCR with KAPA HiFi 
 [DMSO] PCR program 
x5-x8 
LR-PCR 
CHRNA7_intron4F CACCTGCAGTTCAGTCATTCAA 22 
6752  chr15:32445306-32452057 5% 
TD 65-60°C (20",15",7) 
for 35 cycles CHRNA7_intron8R AAAGTCAAACCTCAAAGCTGAA 22 
x9-x10 
LR-PCR 
CHRNA7_intron8F AGTGCATGGAAGTGCAATGA 20 
7475  chr15:32455200-32462675  
TD 65-60°C (20",15",7) 
for 35 cycles CHRNA7_3‟-UTR CACTTCTACTTGTTTCTAAAGACACTG 27 
 
Table 5.9: CHRNA7 mutation screening exon 10 
Primer name Sequence (5’-3’) 
Primer 
size (bp) 
Product 
size (pb) 
Fragment position (hg19) 
PCR with TaqGold 
[Mg
2+
] PCR program 
CHRNA7_x10F AATGAAGCAGGGCTTGTATTG 21 
728 chr15:32460047-32460774 1,5 mM 
TD 65-60°C (30",30", 30") 
for 30 cycles CHRNA7_x10R AGGGAACACTGGAGTTGTGG 20 
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Table 5.10: CHRNA7 sequencing (Primer used for sequencing specific exons from the x5-x8 LR-PCR and the x9-x10 LR-PCR products) 
Primer name Sequence (5’-3’) 
Primer size 
(bp) 
Primer position (hg19) 
CHRNA7_x5F CAAGGTCTTTGCTGCTCCAT 20 chr15:32446012-32446031 
CHRNA7_x5R TCTGGGGGTAGAAAGCACAC 20 chr15:32446341-32446360 
CHRNA7_x6F GGCTGAAGGAACTGCTGTGT 20 chr15:32449730-32449749 
CHRNA7_x6R TGTTTCTCCTCCTGTAGCTCTCA 23 chr15:32450107-32450129 
CHRNA7_x7F ATGGCTCCTTCTCTCCTCCT 20 chr15:32450583-32450602 
CHRNA7_x7R AATCCCCAGGAACCCTGAT 19 chr15: 32446333-32446360 
CHRNA7_x8F GGAGCCCTCGTTAGACAGAA 20 chr15:32451695-32451714 
CHRNA7_x8R TCTAGTTTCATCTGCTGGGAAAT 23 chr15:32451918-32451940 
CHRNA7_x9F GGTGTGCCTGTCCTGTGAC 19 chr15: 32455356-32455376 
CHRNA7_x9R AATTGGCCAGGTGTGGTG 18 chr15: 32455802-32455819 
CHRNA7_x10F AATGAAGCAGGGCTTGTATTG 21 chr15:32460047-32460067 
CHRNA7_x10R AGGGAACACTGGAGTTGTGG 20 chr15:32460755-32460774 
 
Table 5.11: KLHL23 deletion in the discovery pedigree (validation by qPCR) 
Primer name Sequence (5’-3’) 
Primer 
size 
Product 
size (pb) 
Fragment position (hg19) 
Name in the 
figure 8.14 
KLHL23del_x3F ACGTAGGTGTGGGAAATGCTAC 22 
117 chr2:170,597,889-170,598,005 1 
KLHL23del_x3R CGGAATTGTAGCTCTGAACTTTG 23 
KLHL23del_intron3F AGGACAAGCTGAAGGATAATGG 22 
104 chr2:170,605,701-170,605,804 2 
KLHL23del_intron3R ATTCAGGCACACAATACTGCAA 22 
KLHL23del_x4F AAGGGAACGTATCTTCAGAGCA 22 
108 chr2:170606123-170606230 3 
KLHL23del_x4F CACACAAACACACCCATGAGAC 22 
SSBdel_intron9F AAAGACATGGAAGGTTTGCAG 21 
92 chr2:170,667,262-170,667,353 4 
SSBdel_intron9R GAAAACAAAAGCCATACCCTTG 22 
SSBdel_intron11F CGATTTACCTCGGTTATGCTGT 22 
113 chr2:170,667,962-170,668,074 5 
SSBdel_intron11R ACTTCCTTGCACCAATGAGAAA 22 
METTL5del_intron7F GCTATTGACGATGGGCCTTT 20 
91 chr2:170,668,636-170,668,726 6 
METTL5del_intron7R TTCTAGTGTTACCAACTTTCCTGTG 25 
METTL5del_intron6F AAGTGTTAAGTGCTGGTAAGCTGAA 25 
112 chr2:170,669,106-170,669,217 7 
METTL5del_intron6R GGCCATAATAACAGAAATGCCAAG 24 
METTL5del_exon6F TCAGGCTAAGTGTTCATTCTGC 22 
105 chr2:170,671,819-170,671,923 8 
METTL5del_exon6R CATGCAGGTGCTGAGAAGATAA 22 
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Table 5.12: KLHL23 expression in family 3423 by qPCR 
Primers name Sequence (5’-3’) 
Primer size 
(bp) 
Product 
size (pb) 
Fragment position (hg19) 
KLHL23_expr_x2F GCAGAAGAGGCTGAGTTCTATGA 23 
123 chr2:170,592,671-170,597,950 
KLHL23_expr_x3R GCCACCAATGACGTAGATAACA 22 
KLHL23_expr_x3F AACGAATGGAGCCTCATCAC 20 
125 chr2:170,598,011- 170,606,019 
KLHL23_expr_x4R TGTTCAGGGTCATAGCATTCTG 22 
 
Table 5.13: KLHL23 and PHOSPHO2-KLHL23 expression in a multiple tissue cDNA panel 
 
Primers name Sequence (5’-3’) 
Primer 
size (bp) 
Product 
size 
(pb) 
Fragment position (hg19) 
PCR with TaqGold 
 
[Mg
2+
] 
PCR 
program 
PCR fragment specific 
for KLHL23 
KLHL23_expr_x1F CCTCTTCCAAAGATGGTCAGA 21 
156 chr2:170,590,503-170,591,583 
2,5 
mM 
TD 63-58°C 
(30",30", 30") 
for 30 cycles PHOSPHO2_expr_x4R ACTGGATGTGTTGAATCCTTGA 22 
PCR fragment specific 
for PHOSPHO2-
KLHL23 
PHOSPHO2_expr_x3F CCAGAAGACTCTGTTCCCTGTA 22 
200 chr2:170,553,903-170,591,583 
2,5 
mM 
TD 63-58°C 
(30",30", 30") 
for 30 cycles PHOSPHO2_expr_x4R ACTGGATGTGTTGAATCCTTGA 22 
 
Table 5.14: KLHL23 mutation screening (* primers used for sequencing; 
a 
primers used also for mutation screening of PHOSPHO2-KLHL23 exons 4,5,6; 
b 
primers used for exon 
2 PCR-RFLP) 
Fragment name Sequence (5’-3’) 
Primer 
size (bp) 
Product 
size (pb) 
Fragment position (hg19) 
PCR with TaqGold 
[Mg
2+
] PCR program 
KLHL23_x1F* GTCTCCTGGGGAAGCAGTC 19 
474 chr2:170590262-170590735 2,5 mM 
TD 65-60°C (30",30", 45") 
for 30 cycles KLHL23_x1R CATTGTCTGCGCTCCTCTC 19 
KLHL23_x2aF* 
a,b
 TCCGATGATAGTCAAGTTATTTAGC 25 
565 chr2:170591436-170592000 2,5 mM 
TD 65-60°C (30",30", 45") 
for 30 cycles KLHL23_x2aR
 a,b
 CGAGATTCCTTCTCTAGTTCTGG 23 
KLHL23_x2bF*
 a
 TTCAGTAAAGAAGGCTTGTGAGC 23 
552 chr2:170591884-170592435 2,5 mM 
TD 65-60°C (30",30", 45") 
for 30 cycles KLHL23_x2bR
 a
 TCTGCTCCCTGAATCCAAAC 20 
KLHL23_x2cF*
 a
 GCCTGCTCACCGAAAATAAG 20 
580 chr2:170592258-170592837 2,5 mM 
TD 65-60°C (30",30", 45") 
for 30 cycles KLHL23_x2cR
 a
 TCCTAGATAGCATCCCAAAGTGA 23 
KLHL23_x3F
 
*
a
 CAGTACCTTGCATTTTACCATCA 23 
465 chr2:170597779-170598243 2,5 mM 
TD 65-60°C (30",30", 45") 
for 30 cycles KLHL23_x3R
 a
 TGTAGATGTGACCCAATCAGAA 22 
KLHL23_x4F
 
*
a 
 AGCCTCAGCGTTGCAGTATT 20 
584 chr2:170605773-170606356 2,5 mM 
TD 65-60°C (30",30", 45") 
for 30 cycles KLHL23_x4R
 a,b
 TCCCCTATCATGTGCCAGAC 20 
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Table 5.15: PHOSPHO2-KLHL23 mutation screening (* primers used for sequencing) 
Fragment name Sequence (5’-3’) Primer 
size (bp) 
Product 
size (pb) 
Fragment position (hg19) 
PCR with TaqGold 
[Mg
2+
] PCR program 
PHOSPHO2-KLHL23_x1F* CGTACCAGCATCTCTGACGA 20 
423 chr2:170550809-170551232 2,5 mM 
TD 65-60°C (30",30", 45") 
for 30 cycles PHOSPHO2-KLHL23_x1R GTAGGCATCGGACCCAATC 19 
PHOSPHO2-KLHL23_x2F* AACAAGTTGGCTCTGACGTG 20 
260 chr2:170550809-170551866 2,5 mM 
TD 65-60°C (30",30", 45") 
for 30 cycles PHOSPHO2-KLHL23_x2R CCCCCAGTTCTTGACACTTT 20 
PHOSPHO2-KLHL23_x3F* CCATTTCCTGACCTCGTGAT 20 
394 chr2:170553745-170554139 2,5 mM 
TD 65-60°C (30",30", 45") 
for 30 cycles PHOSPHO2-KLHL23_x3R GTTCCCCTGCTGATCTGAAA 20 
 
Table 5.16 Control genes (Real time PCR) 
Fragment name Sequence (5’-3’) 
Primer 
size (bp) 
Product 
size (pb) 
Fragment position (hg19) 
FOXP2_F TGCTAGAGGAGTGGGACAAGTA 22 
139 chr7:114121559-114121698 
FOXP2_R GAAGCAGGACTCTAAGTGCAGA 22 
GUSB_8F CACCTAGAATCTGCTGGCTACT 22 
93 chr7:65435290-65439310 
GUSB_9R AGAGTTGCTCACAAAGGTCACA 22 
 
Table 5.17: CADPS2 expression analysis SNP rs2251761 
Fragment name Sequence (5’-3’) 
Primer 
size (bp) 
Product 
size (pb) 
Fragment position (hg19) 
CADPS2_express_x3F GACTTGTGCAAACAGCCAAA 20 
393 chr7: 122261603-122303431 
CADPS2_express_x5R AAAATGCAGAGTTCTGTGAACG 22 
 
Table 5.18: primer sequences for CADPS2 MS analysis and CpG content details for each amplicons.  
Amplicon 
position from 
CDS 
Target 
length 
(bp) 
Primer Forward Primer reverse Strand 
CpGs 
contained 
CpGs 
analyzable 
-1421; -927 (a)
 a
 495 GAAAGTGGTTTGAAAAAGTTAAAATTG ACAAAATAATACTAATTCAACTCAAACA Forward 12 10 
-911; -486 (b) 426 TTTGTTTTGAGTTTGTAGGATTAGAA CCTAAAACCCTAACACACAATTTACA Forward 22 13 
-515; -112 (c) 404 GAAAGGAAAATTGGTTAGGGT CCTTTACAAACTATATACTAAAACTCCAAA Reverse 41 31 
+550; +973 (d) 424 GGGTTGGTAGGAGTTGTTAGTTTATT CAAACCTACCCAAACCAAAAATTAC Forward 17 9 
a 
(a) to (d) refers to positions indicated in Figure 9 
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Figure 5.19: CADPS2 intron 1 (primers used for PCR amplification on genomic DNA) (* primer used for sequencing) 
Fragment name Sequence (5’-3’) 
Primer 
size (bp) 
Product 
size (pb) 
Fragment position (hg19) 
PCR with TaqGold 
[Mg
2+
] PCR program 
rs981321_F* GGCAGGCCTGATTAATGAAA 20 
186 chr7: 122525243-122525428 2,5 mM 
TD 63-58°C (30",30", 30") 
for 30 cycles rs981321_R CCCTGGGGTCTTGTTTTGA 19 
 
Figure 5.20: CADPS2 intron 1 (primers used for PCR amplification on bisulfite treated DNA) (* primers used for sequencing) 
Fragment name Sequence (5’-3’) 
Primer 
size (bp) 
Product 
size (pb) 
Fragment position (hg19) 
PCR with KAPA2G 
PCR program 
CADPS2_int1bisF+* GGGTTTGAATGAGTGTTGTAG 21 
366 chr7: 122525285-122525650 
95°C 1‟; 95°C 15"; 56°C 15"; 72°C 20" 
(for 47 cycles) CADPS2_int1bisG-* AAAAGGTAAGAAGTTTGTTTTAGG 24 
 
Figure 5.21: CADPS2 colony screening 
Fragment name Sequence (5’-3’) 
Primer 
size (bp) 
M13_F GTAAAACGACGGCCAGT 17 
M13_R CAGGAAACAGCTATGAC 17 
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CHAPTER 6: 
AIM OF THE STUDY AND PRELIMINARY RESULTS 
 
6.1 Aim of the study 
Intellectual disability (ID) and autism spectrum disorders (ASDs) are complex neuropsychiatric 
conditions with a clinical and genetic heterogeneity.  
Despite high heritability estimates and the identification of many monogenic and chromosomal 
causes of both these two disorders, their genetic basis remains poorly explained. Genome-wide 
association studies (GWAS) have so far provided only tenuous evidence for individual common 
variants that affect risk of complex neurological traits, shifting the attention to rare variation. Indeed 
several recent studies have revealed that a number of different causes (SNPs or CNVs), each of 
them with low frequency in the population and typically highly penetrant, could collectively 
account for a large proportion of attributable (McClellan & King, 2010). 
Considerable progress in detection of risk genes underlying ASD and ID has been made after the 
advent of array-based approaches (array-CGH and SNP arrays), which have allowed the discovery 
of a large number of pathogenic Copy Number Variants, both de novo and inherited, and the 
genomic analysis of large cohorts of affected subjects and controls. One of the most interesting 
findings emerging from these CNV screenings is that ASD cases carry a higher number of rare 
genic CNVs in comparison with healthy controls, and that the affected genes converge on common 
pathways including cell-adhesion and synaptic function (Pinto et al., 2010). Furthermore, these 
findings have indicated that, besides the high heterogeneity,  ID and ASD share overlapping risk 
factors (Betancur, 2011) and they can co-occur in many patients. 
My PhD project has started from the discovery of CNVs impacting ASD/ID candidate genes, which 
were identified in two genome wide CNVs studies (SNP array and CGH-array) performed by two 
International Projects, the Autism Genome Project (AGP) and the CHERISH.  
The AGP is an ongoing international project which gathers more than 50 research groups from 
different countries in North America and Europe, and is aimed at searching autism-susceptibility 
genes.  
The CHERISH includes clinicians and research groups from Central Asia and Eastern Europe in 
order to collect a large sample of ID patients and to understand the molecular causes underlying this 
complex disease. 
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Specifically, I analyzed three rare genic CNVs detected by the AGP study in Italian ASD 
individuals (see Table 6.1) (Pinto et al., 2014) and an intragenic deletion in CADPS2 in individuals 
with either ASD/ID identified by the CHERISH project (see paragraph 6.2.2) 
The aim of this study was to validate and characterize these rare CNVs, in order to understand their 
contribution and their role in ASD/ID susceptibility.  
 
6.2 Preliminary results 
6.2.1 Analysis of three CNVs identified in ASD Italian families 
In order to investigate the role of de novo and inherited CNVs in the genetic risk for ASD, the 
International Consortium Autism Genome Project (AGP) has recently performed the largest 
genome-wide scan for CNVs reported to date on over 2,845 ASD families and 4,768 control 
subjects (Pinto et al., 2014).  
The samples were genotyped on the Illumina Human 1M-single and Illumina Human 1M-Duo 
BeadChip arrays and three CNV prediction algorithms, namely, QuantiSNP (Colella et al., 2007), 
PennCNV (Wang et al., 2007) and iPattern (Pinto et al., 2011), were used to obtain high-confidence 
CNV call and to minimize the number of potential false discoveries. Specifically, CNVs were 
identified by using QuantiSNP and iPattern, while PennCNV was used to confirm inheritance status 
of the resulting CNV calls in trios families (parents and affected proband). Array data of each 
family were exploited by manual inspection of Log R ratio and B allele frequency in Illumina‟s 
GenomeStudio software, as described in Materials and Methods.  
80 out of 2,845 ASD families included in the AGP study belong to the Italian ASD cohort. 
Among the CNVs indentified in the Italian cohort, three interesting rare CNVs impact promising 
ASD candidate genes (Table 6.1).  
 
Table 6.1 CNVs identified in the Italian ASD Cohort in the AGP study 
AGP ID CNV Coordinates (hg 19) Length (bp) Ref Seq genes Inheritance 
3456_3 
Homozygous 
deletion 
chr10:68228166-68332668 104,503 CTNNA3 Maternal/paternal 
3476_3 
Heterozygous 
duplication 
chr15: 32,005,348-32,515,973 510, 626 CHRNA7, OTUD7A Paternal 
3423_3 
Heterozygous 
deletion 
chr2:170,603,578-170,666,813 63,236 
PHOSPHO2-KLHL23, 
KLHL23, SSB 
Maternal 
 
The first CNV is a compound heterozygous deletion involving the CTNNA3 gene, encoding αT-
catenin (see paragraph 3.4.1). αT-catenin is a member of the α-catenin family and it has a crucial 
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role in cell adhesion, one of the major pathways implicated in ASD (Bucan et al., 2009). The 
deletion, identified in a male proband (3456_3) with ASD and borderline cognitive impairment, is 
inherited from both parents, each heterozygote for a deletion of slightly different length, and causes 
the homozygous loss of a coding exon (exon11) in the affected individual. His younger sister has 
normal cognition, with normal social and communication skills, while both parents do not show any 
evident cognitive or behavioural impairment.  
The second CNV is a small duplication on chromosome 15q13.3, spanning a region of 
approximately 500 kb, including exon 1 of the longer isoform of OTUD7A and the entire CHRNA7 
gene. The duplication was detected in a male proband with ASD and epilepsy (3476_3). His father, 
who transmitted the microdeletion, as well as his mother are both apparently normal. However, the 
paternal grandfather‟s sister was affected by ID, while the paternal grandfather‟s brother had speech 
delay. The CHRNA7 gene, encoding for the alpha7 subunit of the neuronal nicotinic acetylcholine 
receptor (see paragraph 3.4.3), is considered the likely culprit gene in mediating neurological 
phenotypes in cases with 15q13.3 recurrent microdeletions. Even if the reciprocal microduplication 
has a less certain clinical significance in comparison with the deletions (see paragraph 1.5), de novo 
and inherited duplications involving this genomic region are associated with a wide spectrum of 
neuropsychiatric disorders, including ASD.  
The third CNV is a rare maternal inherited microdeletion of about 63 kb encompassing three 
neighbouring genes on the chromosome 2q31.1, KLHL23, PHOSPHO2-KLHL23 and SSB. This 
deletion, mapping in a region previously found to be in linkage with ASD, the AUTS5 locus 
((IMGSAC), 2001; Maestrini et al., 2010), was identified in a male subject with ASD and 
borderline cognitive impairments (3423_3).  
 
6.2.2 Analysis of the CADPS2 gene in subjects with ID and/or ASD  
Identification and validation of a rare deletion in the CADPS2 gene 
During an array-CGH analysis with the Agilent platform 44 K, performed on ID patients recruited 
in the framework of the CHERISH project, an intragenic deletion of ~285 kb in the CADPS2 gene 
was identified in a pair of siblings (male and female) with behavioral problems, borderline ID, and 
epilepsy (Figures 6.1 and 6.2). The deletion is likely to be inherited from the deceased mother, 
since the father did not carry it.  
CADPS2 is an excellent candidate gene for neurologic development abnormalities (see paragraph 
3.4.2) and maps to the “autism susceptibility locus 1” on chromosome 7q31-q33 (Lamb et al., 
2005).  
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Figure 6.1 (Bonora et al., 2014). Family tree of the ID sibs carrying the novel intragenic deletion. 
 
Figure 6.2 Results of CGH array in family ID_004. A) Identification of the CADPS2 deletion in a subject with ID 
and autism. B) When the analysis was performed on patient vs sister CGH cannot detect it because it is present in both 
affected siblings; this suggest that also the affected sister has the same alteration. C) When the patient vs father were 
compared the deletion is seen only in the patient suggesting that the father does not carry the deletion.  
 
The deletion was validated in father and in the two affected siblings by quantitative PCR and the 
deletion boundaries were mapped between intron 3 and intron 28 of CADPS2. Moreover, the 
deletion breakpoints were defined by long-range PCR between bp 121,984,852-122,270,267 of 
chromosome 7 (hg19) (Figure 6.3). 
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Figure 6.3 (Bonora et al., 2014)  A) Fine mapping of CADPS2 deletion by real-time qPCR using different probes across 
the region. All data were normalized using as reference gene FOXP2. B) CADPS2 deletion breakpoint mapping, 
showing the insertion of 3 base pairs at the breakpoint (upper panel) and the corresponding location on chromosome 7q 
(UCSC Genome Browser). 
 
 
CADPS2 mutation screening in ASD/ID patients 
To test whether rare variants in CADPS2 could contribute to ASD and/or ID risk, all 30 exons and 
exon-intron boundaries of the CADPS2 gene (NM_017954.10) were screened in 36 Italian patients 
with ID and in 187 probands with ASD, of which 94 from Italy and 93 from the International 
Molecular Genetic Study of Autism Consortium (IMGSAC) collection (IMGSAC, 2001). Two 
synonymous and five missense heterozygous rare variants were identified (Table 6.2). The most 
interesting variant is a novel missense variant p.Asp113Ans, never observed in databases and in 
Italian controls. This variant is  predicted to be damaging by PolyPhen‐2 (PolyPhen score=0.936), 
and it has a functional effect since it disrupts CADPS2 binding to the dopamine receptor type 2, one 
of its few known interactors (Bonora et al., 2014).  
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Table 6.2 (Bonora et al., 2014). Coding variants in CADPS2 identified either in ASD or in ID patients. The 
p.Asp1113Asn missense variant is indicated in red. 
Position on chr7 
(hg19) 
Type of change  
(N_060424.9) 
NM_017954.10 
PolyPhen-2 score  
(HumDiv) 
SIFT 
prediction 
(cutoff=0.0
5) 
Parental 
origin 
Het a 
in 
ASD/ID 
(N=223) 
Het a 
in Italian 
controls 
(N=250) 
Het a in EVS 
(European-
American) 
P value b 
(Fisher‟s t-
test) 
g.122,526,314G>A 
none c 
p.Ala26= na na Maternal 1/223 
(ASD) 
0 0 0,0467 
g.122,255,252G>C 
none c 
p.Ala402= na na Paternal d 1/223 
(ASD) 
0 0 0,0467 
g.122,114,544A>G 
rs199713510 c 
p.Met630Thr 0,917 (possibly 
damaging) 
0 
(damaging) 
Paternal d 1/223 
(ASD) 
2/250 10/4113 0,477 
g.122,114,500A>C 
rs201536376c 
p.Phe645Val 0,001 (benign) 0,531 
(tolerated) 
Maternal 1/223 
(ASD) 
0 9/4128 0,392 
g.122,027,130C>T 
rs76528953c 
p.Asp1088Asn 1 (probably 
damaging) 
0,001 
(damaging) 
Paternal 2/223 e 
(ASD) 
0 28/4145 0,429 
g.122,019,472C>T 
nonec 
p.Asp1113Asn 0,936 (probably 
damaging) 
0,039  
(tolerated) 
Maternal 1/223 
(ASD) 
0 0 0,0467 
g.122,001,046C>T 
rs200984050c 
p.val1137Met 0,997 (probably 
damaging) 
0,003 
(damaging) 
Maternal 1/223 
(ID) 
0 6/4122 0,294 
a Het = number of heterozygous individuals. 
b Fisher's exact test calculated considering the number of heterozygous individuals in the total control group [Italian and 
European‐American from EVS (http://evs.gs.washington.edu/EVS/ accession March 2013]. 
c dbSNP entry reported for the corresponding variant; none = not present in dbSNP. 
d The two paternal changes were present in the same ASD individual. 
e The two individuals from multiplex ASD families inherited the change from the father; however in both cases, it did not 
co‐segregate with the phenotype 
SNVs not found in dbSNP and EVS are shown in bold. 
 
CADPS2 allelic expression analysis in blood 
CADPS2 maps on a region of chromosome 7 containing a cluster of imprinted genes (Schneider et 
al., 2012); moreover, the CADPS2 deletion and the majority of rare missense variants were of 
maternal origin. Thus CADPS2 was tested for a possible parent‐of‐origin regulation.  
In order to test this hypothesis the gene expression was analyzed in blood of seven informative 
heterozygous controls for two CADPS2 coding SNPs: rs2251761 (exon 3) and rs2074589 (exon 17) 
(figure 6.4A). The results showed that only one allele is expressed in blood cDNA, suggesting that 
CADPS2 shows a monoallelic expression in blood. 
Moreover, in order to establish if the expressed allele was of maternal origin, three different 
families with heterozygous individuals for three SNPs (rs2251761; p.Ala402=; p.Val1137Met) were 
analyzed (Figure 6.4B,C). Since in each family the expressed allele in blood cDNA was the 
maternal one, these findings suggest that CADPS2 is maternally expressed in blood.  
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Figure 6.4 (Bonora et al., 2014). CADPS2 allelic expression in blood. A) Allelic expression in blood cDNA of SNP 
rs2251761 (A/G alleles) and rs2074589 (A/C alleles) in two heterozygous individuals for the two SNPs. Upper panel: 
sequence electropherograms from genomic DNA (gDNA) showing the heterozygous state, lower panel: sequence 
electropherograms from blood cDNA; the SNP position is shown by the underscore marking. B) Allelic expression 
from blood cDNA of SNP rs2251761 in an informative control family: the expressed A allele in the offspring inherits it 
from the mother. C) Allelic expression of the variant p.402Ala=: the change is inherited from the heterozygous father, 
who expresses only the variant allele in blood, whereas the affected child expresses only the maternal allele in blood. D) 
Allelic expression of the variant p.Val1137Met: the maternally inherited variant is the only one expressed in blood 
cDNA of the affected son, whereas the healthy mother expresses the wild‐type allele. The healthy brother does not 
inherit the change. 
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CHAPTER 7: 
RESULTS 
 
Characterization of three CNVs identified in ASD Italian families 
Given the discovery in our Italian cohort of three interesting CNVs involving promising ASD 
candidate genes (see preliminary results, paragraph 6.2.1), we investigated their pathogenic role in 
ASD susceptibility performing expression analyses and assessing the contribution of rare sequence 
variants in these genes by mutation screening. 
 
7.1 Analysis of the CTNNA3 gene 
7.1.1 Fine-mapping and segregation analysis of CTNNA3 deletion in family 3456 
Manual inspection of the log R ratios and B allele frequencies of family 3456 in GenomeStudio 
demonstrated that one copy of the microdeletion was transmitted to the proband (3456_3) from each 
parent, who were both heterozygotes. Indeed the mother (3456_2) and the father (3456_1) show a 
decrease in the log R ratio and values of B-allele frequency around 0 and 1 (there is a lack of 
heterozygous variants), while in the proband the region is deleted on both alleles (Figure 7.1B).  
Using several PCR assays with primers designed to flank the predicted breakpoints, we defined and 
sequenced the breakpoints of the two slightly different microdeletions carried by the parents of 
family 3456: the maternal microdeletion is of about 60 Kb and it encompasses chr10:67,942,931-
68,002,674 (Figure 7.1A), while the paternal one has a length of about 100 Kb and it spans  
chr10:67,898,172-67,997,846 (National Center for Biotechnology Information build 36 
coordinates); both the deletions remove the exon 11 of the CTNNA3 (Figure 7.1C).  
Sequencing of the breakpoints showed the presence of 2 and 5 bp microhomology at the junctions 
of the maternal and paternal deletions, respectively, as well as the insertion of a 26-bp A-T rich 
sequence at the paternal deletion junction (figures 7.1A,C and 7.2). These observations, together 
with the non-recurrent nature of the deletions and the absence of flanking low copy repeats (LCR), 
suggest that these deletions are likely to be generated through a microhomology-mediated repair 
mechanism.  
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Figure 7.1 (Bacchelli et al., 2014). Detection and breakpoint definition of CTNNA3 deletions in the discovery 
pedigree. (A, C) Sequence electropherograms with breakpoint-spanning sequences in the mother and in the father, 
respectively (NCBI build 36 coordinates). In (A) the two base pairs (AT), common to both ends, are highlighted in blue. 
B) GenomeStudio plots of the log R ratio and B allele frequency data from the 1 M-Duo SNP array for family 3456. 
The deletions result in a decrease in the log R ratio and a lack of heterozygous variants (the expected allelic ratio for 
heterozygous variants is 0.5). The deleted SNPs are depicted in red, and the red rectangle indicates the region deleted 
on both alleles in the proband. 
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Figure 7.2 (Bacchelli et al., 2014). Junction fragments of maternal and paternal deletions in family 3456. DNA 
sequences, obtained from direct sequencing of the junction fragments, were aligned to the normal wild-type proximal 
and distal sequences. The presence of bases with perfect microhomology to the normal proximal and distal wild-type 
sequences is shown in red. 
 
The same PCR assay were also used to analyse the segregation of the two microdeletions in the 
discovery pedigree. Three PCR assays were performed: two PCR assays with primers designed 
across the paternal and maternal microdeletion and one PCR with primers within the deleted exon 
11. Visualization of the PCR products on agarose gel showed that the proband inherits both the 
microdeletions, one heterozygous deletion from the father and one from the mother, resulting in the 
homozygous loss of exon 11; instead the unaffected sister inherits only the paternal microdeletion 
(Figure 7.3A,B). 
Exon 11 is present in both the two full-length CTNNA3 isoforms (NM_013266 and 
NM_001127384), which are two transcript variants that differ only for the first 5‟ non-coding exon 
and encoding the same protein of 895 aminoacids (Figure 7.3C).  
The absence of exon 11 causes a frameshift in the ORF and the introduction of 12 novel amino 
acids followed by a premature stop codon (Figure 7.4), resulting in a truncated protein with a 
length of 470 aminoacids. Given the likelihood of nonsense-mediated mRNA decay, this 
homozygous microdeletion would thus be predicted to result in a complete lack of functional 
protein in the affected individual. 
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Figure 7.3 (Bacchelli et al., 2014). Further characterisation of CTNNA3 deletions in the pedigree 3456. (A) From the 
left, results of PCR across father's and mother's deletion breakpoints, respectively: only the allele with the deletion can 
be amplified and visualized as a band of 301 bp in the father (3456_1), in the proband (4356_3) and the unaffected 
sister (3456_4), and as a band of 949 bp in the mother (3456_2) and in the proband. On the right, the amplification with 
primers mapping in the deleted exon of CTNNA3 indicates the presence of at least one allele without the deletion. At 
both extremities of the gel, 1-kb Plus and 100-bp DNA ladder were loaded. (B) The segregation pattern for these two 
deletions involving CTNNA3 in the discovery pedigree. Autism is indicated in black filling. (C) Schematic from the 
UCSC genome browser. The figure shows the position of the two CTNNA3 deletions in the pedigree 3456. The region 
shown corresponds to approximately 1.8 Mb on 10q21.3 (NCBI build 37 coordinates). 
 
 
 
Figure 7.4 At the top are shown the wild type sequence and protein of the CTNNA3 gene; the red box indicates the exon 
11 that is deleted on both alleles in the proband. At the bottom are shown the sequence without exon 11 and truncated 
protein; the premature stop codon is indicated as a red circle.  
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7.1.2 CTNNA3 exonic deletion frequency in ASD cases and controls 
To compared the frequency of CTNNA3 exonic deletions between ASD cases and controls, we used 
the existing CNV data on a total of 2,147 European ASD families from the AGP genome-wide 
study (combined sample of stage 1 and stage 2 families) (Pinto et al., 2014) and CNV data on 6,639 
European controls (Bierut et al., 2010; Figueiredo et al., 2011; Fox et al., 2012; Krawczak et al., 
2006; Shaikh et al., 2009; Stewart et al., 2009). 
We identified a total of 14 additional heterozygous exonic deletions in ASD probands (allelic 
frequency = 0.37%) (Table 7.1; Table 7.2a), thus showing a modest deviation from the Hardy-
Weinberg equilibrium (exact test P = 0.028). Instead, in the control population, we found 43 
CTNNA3 exonic deletions (allelic frequency 0.32%) (Table 7.1; Table 7.2b), indicating a 
comparable frequency between ASD cases and controls ( P = 0.62).  
 
Table 7.1 (Bacchelli et al., 2014). Frequency of CTNNA3 exonic deletions in ASD cases and controls. 
 Number of 
subjects 
Exonic 
deletions 
Exonic deletion 
frequency (%) 
P value
a
 Frameshift 
deletions 
Frameshift deletion 
frequency (%) 
P value
a
 
ASD cases 2,147 16
 b
 0,37 0,62 6
 b
 0,14 0,56 
Controls 6,639 43 0,32  14 0,11  
a  Fisher‟s exact test; b Including the two exon 11 deletions in family 3456 
 
Table 7.2a CTNNA3 exonic deletions in ASD cases 
Sample ID Inheritance Array_platform Genomic coordinates (hg18)a Length (bp) Deleted exonsb Effect on CDS 
5237_3 paternal illumina 1Mv1 single chr10:67628183-67752490 124308 x13 frameshift 
3311_003 maternal illumina 1Mv1 single chr10:67688367-67759307 70941 x13 frameshift 
3456_3 maternal/paternal Illumina 1Mv3 duo chr10:67898172-68002674c 104502 x11 frameshift 
4196_1 mother illumina 1Mv1 single chr10:67912678-67976820 64143 x11 frameshift 
4527_1 mother illumina 1Mv1 single chr10:67947835-67968052 20218 x11 frameshift 
4228_1 N/A illumina 1Mv1 single chr10:67957765-68226404 268640 x10 in frame 
6372_3 maternal (father N/A) Illumina 1Mv3 duo chr10:67979174-68114740 135567 x10 in frame 
14299_4200 paternal illumina 1Mv1 single chr10:67987089-68056520 69432 x10 in frame 
3093_004 maternal illumina 1Mv1 single chr10:67987089-68067310 80222 x10 in frame 
5013_3 paternal illumina 1Mv1 single chr10:68023745-68071037 47293 x10 in frame 
3169_004 maternal illumina 1Mv1 single chr10:68029140-68183933 154794 x10 in frame 
4211_1 father illumina 1Mv1 single chr10:68029140-68183933 154794 x10 in frame 
4291_1 N/A illumina 1Mv1 single chr10:68052141-68210655 158515 x8-x9 in frame 
5065_3 maternal illumina 1Mv1 single chr10:68138586-68227559 88974 x8-x9 in frame 
3476_3 paternal Illumina 1Mv3 duo chr10:68154851-68247375 92525 x8-x9 in frame 
a
 The size of CNV shown is as detected by microarrays; 
b
 Exons numbering according to RefSeq NM_013266; 
c
 Exact breakpoint 
coordinates; 
d
 The deletion includes also exon1 of LRRTM3; 
e
 The deletion includes also exon1 and exon2 of LRRTM3. 
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Table 7.2b CTNNA3 exonic deletions in controls 
Sample ID 
Control 
cohort 
Array_platform 
Genomic coordinates 
(hg18) 
Length (bp) Deleted exons 
Effect on 
CDS 
B601040_1007870358 SAGE illumina 1Mv1 single chr10:67628183-67752490 124308 x13 frameshift 
B782997_1007853703 SAGE illumina 1Mv1 single chr10:67628183-67754983 126801 x13 frameshift 
B974175_1007875270 SAGE illumina 1Mv1 single chr10:67748487-67889985 141499 x12 in frame 
CONSPC2_f_179516 POPGEN Affy6 chr10:67754797-67871675 116879 x12 in frame 
B355026_0067942568 SAGE illumina 1Mv1 single chr10:67820257-68046869 226613 x11 frameshift 
B291548_1007841762 SAGE illumina 1Mv1 single chr10:67834450-68127819 293370 x11 & x10 frameshift 
CONSPC_m_183371 POPGEN Affy6 chr10:67911535-67975943 64409 x11 frameshift 
HABC_900384_900384 HABC Illumina 1Mv3 duo chr10:67912678-67968052 55375 x11 frameshift 
HABC_900268_900268 HABC Illumina 1Mv3 duo chr10:67920659-68059454 138796 x11 & x10 frameshift 
CONT1635 OHI Affy6 chr10:67937332-67971629 34298 x11 frameshift 
CONT-1870 OHI Affy6 chr10:67938271-68044090 105820 x11 frameshift 
110036018737 OC illumina 1Mv1 single chr10:67938287-68059454 121168 x11 & x10 frameshift 
Caucasian CHOP Illumina 550K chr10:67944050-68069165 125116 x10-x11 frameshift 
Caucasian CHOP Illumina 550K chr10:67944050-68077867 133818 x10-x11 frameshift 
Caucasian CHOP Illumina 550K chr10:67944050-68088852 144803 x10-x11 frameshift 
CONT1792 OHI Affy6 chr10:67955244-68119974 164731 x10 in frame 
Caucasian CHOP Illumina 550K chr10:67960600-68052141 91542 x10 in frame 
CONT2294 OHI Affy6 chr10:67981580-68139445 157866 x10 in frame 
B431282_1007873513 SAGE illumina 1Mv1 single chr10:67987089-68088852 101764 x10 in frame 
Caucasian CHOP Illumina 550K chr10:67997021-68053979 56959 x10 in frame 
HABC_900966_900966 HABC Illumina 1Mv3 duo chr10:67997021-68091312 94292 x10 in frame 
CONT-2085 OHI Affy6 chr10:68009168-68066669 57502 x10 in frame 
HABC_901209_901209 HABC Illumina 1Mv3 duo chr10:68013385-68156906 143522 x10 in frame 
CONSPC_f_186937 POPGEN Affy6 chr10:68020146-68070424 50279 x10 in frame 
B779950_1007875276 SAGE illumina 1Mv1 single chr10:68023745-68071037 47293 x10 in frame 
B941932_1007873623 SAGE illumina 1Mv1 single chr10:68023745-68071037 47293 x10 in frame 
HABC_900941_900941 HABC Illumina 1Mv3 duo chr10:68023745-68127819 104075 x10 in frame 
NCA07346 OHI Affy6 chr10:68024710-68070424 45715 x10 in frame 
CONT1593 OHI Affy6 chr10:68024710-68075715 51006 x10 in frame 
Caucasian CHOP Illumina 550K chr10:68034046-68088852 54807 x10 in frame 
CONBSP_m_213905 POPGEN Affy6 chr10:68037680-68109008 71329 x10 in frame 
Caucasian CHOP Illumina 550K chr10:68040186-68088852 48667 x10 in frame 
CONSPC2_m_195755 POPGEN Affy6 chr10:68050416-68077020 26605 x10 in frame 
B764705_1007853643 SAGE illumina 1Mv1 single chr10:68091312-68222395 131084 x9 & x8 in frame 
HABC_902495_902495 HABC Illumina 1Mv3 duo chr10:68113705-68200470 86766 x9 in frame 
Caucasian CHOP Illumina 550K chr10:68127614-68216254 88641 x8-x9 in frame 
Caucasian CHOP Illumina 550K chr10:68160982-68305039 144058 x8-x9 in frame 
Caucasian CHOP Illumina 550K chr10:68180377-68268934 88558 x8-x9 in frame 
Caucasian CHOP Illumina 550K chr10:68190451-68252582 62132 x8-x9 in frame 
NCA07559 OHI Affy6 chr10:68197491-68520899 323409 x8d in frame 
CONT-1970 OHI Affy6 chr10:68211267-68626505 415239 x7e frameshift 
CONBSP_f_186933 POPGEN Affy6 chr10:68622864-68770434 147571 x6 in frame 
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Parental information was available for 13 out of 15 ASD families, and in none of these cases, 
CTNNA3 exonic microdeletions were de novo. The observed exonic deletions are different in 
position, size, sequence junctions and genomic content, removing one or two exons, spanning from 
exon 6 to exon 13 of CTNNA3 (Table 7.2). This is in accordance with CTNNA3 being located in a 
common fragile site (Smith et al., 2006), a region characterised by increased genomic instability 
(Dillon, Pierce, Ng, & Wang, 2013). 
Since deletions that result in a frameshift cause unambiguous loss-of-function alleles, we focused 
our attention to this class of deletions. Among the observed exonic CTNNA3 deletions in cases and 
controls, only deletions that remove exon 7, exons 10-11, exon 11 and exon 13 (NM_013266) are 
predicted to induce frameshifts, but their frequency is not significantly different between cases and 
controls (Table 7.1, P = 0.56). 
 
7.1.3 Segregation analysis of CTNNA3 exonic deletions and mutation screening of CTNNA3 
and LRRTM3 in four ASD families  
To investigate if CTNNA3 exonic deletions segregate with the ASD phenotype we performed a 
quantitative real time PCR in three ASD multiplex families (3093, 3169 and 3311) and one 
singleton family (3476) with heterozygous CTNNA3 deletions. All deletions segregate with the 
ASD phenotype except for the deletion in exon 13 that is transmitted from the mother to only two 
out of three affected children (figure 7.5).  
Moreover, in order to test the hypothesis that the CTNNA3 deletions could act by unmasking rare 
variants in the not deleted allele, we sequenced the entire coding sequence and intron-exon 
boundaries of CTNNA3 and of the nested gene LRRTM3 (leucine-rich repeat transmembrane 
neuronal 3) in all members of these four ASD families.  
We did not detect any novel exonic variants in CTNNA3, while a previously undescribed missense 
change (p.Arg275Ser; G>A) was identified in the LRRTM3 exon 2 in family 3476 (figure 7.6); 
however, this missense variant was transmitted from the unaffected father, who also carries the 
CTNNA3 deletion, to the affected child. This result is thus not compatible with a two-hit model, 
since both the CTNNA3 deletion and the LRRTM3 missense variant are present in the unaffected 
father. 
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Figure 7.5 Pedigree of four ASD families carrying CTNNA3 exonic deletions. Black filling indicates ASD diagnosis. 
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Figure 7.6: Pedigree of family 3476 carrying the CTNNA3 deletion of exons 8 and 9 and the missense change 
p.Arg275Ser in the LRRTM3 gene. 
 
7.1.4 CTNNA3 expression analysis  
In order to test the functional effect of the heterozygous and homozygous loss of exon 11 in family 
3456, we analysed the CTNNA3 expression in blood RNA or Epstein Barr virus (EBV)-transformed 
cell lines from family 3456 by RT-PCR. However, since CTNNA3 is expressed in blood at very low 
levels, we were unable to obtain a reliable amplification of the CTNNA3 transcript.  
It has been previously reported that CTNNA3 is subject to genomic imprinting, with preferential 
monoallelic expression of the maternal allele in placental tissue (Van Dijk et al., 2004). Therefore, 
to investigate whether CTNNA3 is also monoallelically expressed in brain, we analyzed the allelic 
expression in the cerebellum and cerebral cortex of two informative heterozygous controls for a 
coding SNP (rs4548513, p.Ser596Asn) located in exon 13.  
RT-PCR analysis showed high expression levels in these two brain tissues and Sanger sequencing 
of the PCR products revealed a biallelic gene expression, thus excluding the hypothesis of a 
monoallelic expression of CTNNA3 in brain (figure 7.7). 
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Figure 7.7. (Bacchelli et al., 2014). CTNNA3 biallelic expression in the cerebellum and cerebral cortex. Sanger 
sequencing of rs4548513 (p.Ser596Asn) from genomic DNA (gDNA) and brain cDNA (cortex and cerebellum) of two 
adult controls showing the heterozygosity of the SNP and demonstrating biallelic expression of CTNNA3 in both brain 
areas. 
Since the mouse Ctnna3 cDNA encodes a protein showing 95% identity to human CTNNA3 and the 
genomic structures of the mouse Ctnna3 and human CTNNA3 genes are completely conserved, a 
Western blot analysis was performed to get a quantitative characterisation of Ctnna3 expression 
during early brain mouse development compared with the neural specific Ctnna2. 
Protein extracts of mouse cortex and hippocampus at different developmental stages (from P0 to 
P90) were probed with anti-N-catenin antibody that recognizes specifically the C-terminus of 
Ctnna2 as a doublet band and a rabbit polyclonal anti-αT-catenin antibody (#952), which recognizes 
a specific peptide corresponding to the C-terminus of Ctnna3. As shown in Figure 7.8, not only 
Ctnna2 is highly expressed at all brain developmental stages analysed, but also Ctnna3 is present in 
both brain areas analysed. Noticeably, Ctnna3 showed a higher expression in the hippocampus and 
cortex at P0, suggesting a specific neuronal role in very early developmental stages. 
The Western blot experiment was performed at San Raffaele Scientific Institute of Milan in 
collaboration with Dr. M. Giannandrea and Dr. P. D‟Adamo.  
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Figure 7.8 (Bacchelli et al., 2014). Expression analysis of ctnna3 in mouse brain. Western blot analysis of αT-catenin 
and αN-catenin in mouse hippocampus (A) and cortex (B) at different developmental stages (from P0 to P90). (C, D) 
Histograms showing the band intensity normalised by GAPDH as internal loading control. 
 
 
7.2 Analysis of rare variants in the CHRNA7 gene 
7.2.1 Validation of the CHRNA7 microduplication in family 3474 
The presence of the microduplication identified in the proband 3474_3 by SNP array (see 
preliminary results) was verified by visual inspection of the 1M Illumina SNP data, by plotting 
intensities (logR ratio) and allelic ratios (B allele frequency) of all members of the family 3474 
(Figure 7.9A). This CNV, including exon 1 of the longer isoform of OTUD7A and the entire 
CHRNA7 gene (chr15: 32,005,348-32,515,973 NCBI build 37 coordinates), is transmitted from the 
father (3474_1) to the affected son. The duplication was also validated by quantitative PCR in all 
family members. As shown in Figure 7.9B, the father and the proband have 3 copies of CHRNA7, 
while the mother (3474_2) has a normal number of copies. 
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Figure 7.9 (Bacchelli et al., 2015) A) GenomeStudio screenshot showing B-allele frequency and log R ratio for family 
3474. The duplication results in an increase to the Log R ratio and deviation in the allelic ratio for heterozygote variants 
away from the expected 0.5. The SNPs included in the duplication are boxed. B) qPCR results for the CHRNA7 
duplication in family 3474.  
 
CNV analysis of family 3474 led also to the identification of a ~55 kb paternal deletion of 
ARHGAP11B, which is known to accompany the majority of CHRNA7 microduplications 
(Szafranski et al., 2010) and a rare maternal gain of unknown significance on chromosome 5q13.2 
(chr5:68,594,539-68,638,941). This duplication involves the first seven exons of CCDC125 
(Coiled-coil domain-containing protein 125), a gene with a putative role in controlling the cell 
motility of immune systems (Araya et al., 2009).  
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Table 7.3 Other CNVs identified in proband 3474 by CNV analysis 
CNV Gene Position (hg19) Lenght Inheritance 
del15q13.2 ARHGAP11B chr15:30,913,207-30,968,006 54,800 paternal 
dup5q13.2 CCDC125 chr5:68,594,539-68,638,941 44,402 maternal 
 
7.2.2 CNV analysis and mutation screening in 135 ASD subjects  
In order to investigate if rare variants in CHRNA7 could play an important role in ASD, we 
performed CNV analysis and sequence mutation screening of the coding sequence of the CHRNA7 
gene in a sample of 135 Italian ASD probands. The main clinical features of the 135 Italian ASD 
cases included in the study are shown in Table 8.4. 
 
  
Total 
 
Sex   
Epilepsy 
 
Intellectual disability 
    Male Female     
severe 
(20<IQ<34) 
moderate 
(35<IQ<49) 
Mild 
(50<IQ<69) 
BCI 
(70<IQ<85) 
normal 
(IQ>85) 
Unknown 
Autism 98 
 
76 22 
 
2 
 
0 11 27 20 17 23 
Atypical autism 34 
 
28 6 
 
0 
 
2 3 11 3 7 8 
Asperger syndrome 3 
 
2 1 
 
0 
 
0 0 0 1 1 1 
Total 135 
 
106 29 
 
2 
 
2 14 38 24 25 32 
BCI, borderline cognitive impairments 
 
7.2.2a CNV analysis 
68 out of 135 Italian ASD probands have been already included in the CNV screening performed by 
the AGP. Instead, 67 individuals that were not previously analysed by SNP array, were tested by 
qPCR to identify CNVs in CHRNA7 using a probe mapping in exon 3, specific for CHRNA7. The 
proband of family 3474 was included as positive control. No additional deletion or duplication was 
identified in this sample. 
 
7.2.2b CHRNA7 mutation screening 
All 10 exons and intron-exon boundaries of CHRNA7 were sequenced by Sanger method in all 135 
ASD individuals . 
The first four exons, which are specific for CHRNA7, were amplified using exon specific primers 
corresponding to flanking intronic sequences and then subjected to Sanger sequencing. 
The genomic sequence comprising CHRNA7 exons 5-10 is duplicated and nearly identical (>99%) 
in the CHRFAM7A gene, complicating the mutation screening (Gault et al., 1998) (chapter 3, 
paragraph 3.4.3). Therefore, to selectively amplify CHRNA7 exons 5-10, we performed two 
different long range PCRs (LR-PCRs): x5-x8 LR-PCR encompasses exon 5 to exon 8 and amplifies 
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a segment of 6752 bp; x9-x10 LR-PCR encompasses exon 9 to exon 10 and amplifies a segment of 
7500 bp. For the x5-x8 LR-PCR we used a primer F outside the duplication (mapping to CHRNA7 
specific intron 4) and a primer R in the duplicated region (mapping to intron 8), while for the x9-
x10 amplicon we used a primer F in the duplicated region (mapping to intron 8) and a primer R 
mapping in a CHRNA7 specific region located at 3‟UTR which contains a 36 bp insertion (Figure 
7.10 and 7.11C). These two LR-PCR products were sequenced with primers specific for each exon. 
 
Figure 7.10 (Bacchelli et al., 2015). Genomic structure of the human CHRNA7 gene, with the position of the primers 
used for the x5-x8 and x9-x10 LR-PCRs and the qPCR probe. The dashed rectangle indicates the region duplicated in 
CHRFAM7A.  
 
By aligning the genomic sequences of CHRNA7 and CHRFAM7A as reported in human genome 
reference sequence (GRCh37, hg19) we noted that, in addition to 36 bp at the 3‟ end of CHRNA7 
(chr15:32,462,638-32,462,673) (Figure 7.11C), these two genes differ for the presence/absence of 
some bp located in intron 5 and intron 9. As shown in Figure 7.11A,B, intron 5 and intron 9 of 
CHRNA7 contain the 4 bp GTCT (chr15:32,448,389-32,448,3929) and the 5 bp AAGAT (chr15: 
32,458,725-32,458,729), respectively, which are absent in the duplicate gene CHRFAM7A.  
 
 
Figure 7.11 (Bacchelli et al., 2015) Sequence differences in the duplicated regions of CHRNA7 and CHRFAM7A, 
according to NCBI human build 37 (hg19). The genomic position indicate the first and to the last nucleotide of each 
line. The exact coordinates of the 3 small insertions present in CHRNA7 and absent in CHRFAM7A are: A) chr15: 
32,448,389-32,448,392 for the 4 bp in intron 5; B) chr15: 32,458,725-32,458,729 for the 5 bp in intron 9; C) chr15: 
32,462,638-32,462,673 for the 36 bp at the 3‟ end of CHRNA7. 
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To verify the specificity of our two LR-PCR reactions, we amplified the genomic DNA of 30 
patients with  primers flanking intron 5 and intron 9 and we checked for the presence of these two 
CHRNA7 specific sequences. This PCR reaction leads to co-amplification of both CHRNA7 and 
CHRFAM7A. For each patient, we sequenced and compared the co-amplification product and the 
LR-PCR product.  For the exon 5-exon 8 fragment, sequencing of the LR-PCR product shows the 4 
bp CHRNA7 specific insertion (Figure 7.12A), while sequencing of the coamplification products 
leads to overlapping sequence peaks. This result confirmed thus that our x5-x8 LR-PCR is specific 
for CHRNA7 (Figure 7.12B). However, we did notice that in a minority of individuals the LR-PCR 
sequence showed overlapping peaks, suggesting that the 4 bp insertion in intron 5 is actually 
polymorphic in CHRNA7. This hypothesis is supported by comparison of the coamplification 
sequence in these heterozygote individuals, which is compatible with the presence of one allele with 
the 4 bp insertion and three alleles without the insertion, thus still confirming the specificity of this 
LR-PCR (Figure 7.12C,D)  
 
 
Figure 7.12 (Bacchelli et al., 2015). Sequence of the CHRNA7 intron 5 region in two different samples. A) Sample 1 
sequence from LR-PCR; B) Sample 1 sequence from CHRNA7-CHRFAM7A coamplification; C) Sample 2 sequence 
from LR-PCR; D) Sample 2 sequence from CHRNA7-CHRFAM7A coamplification. 
 
For the exon 9-exon 10 fragment, sequencing of the 5 bp specific region in intron 9 did not reveal 
the expected differences between the LR-PCR and the co-amplification products, as the 5 bp 
insertion was always present. However, using the same strategy, we compared the genotypes of two 
common SNPs in exon 10 (rs1042724, rs2253967), by sequencing the x8-x9 LR-PCR versus the 
coamplification product in all ASD individuals. Since we obtained different genotypes (Figure 
7.13) we concluded that our x9-x10 LR-PCR is indeed specific for CHRNA7, while the 5 bp 
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insertion in intron 9 as reported GRCh37 is actually present in both CHRNA7 and CHRFAM7A, at 
least in most individuals. 
 
Figu
re 7.13 (Bacchelli et al., 2015). Genotypes of rs1042724 and rs2253967 in two different probands, obtained by 
sequencing the x8-x9 LR-PCR (A, C) versus the coamplification product (B, D). 
 
By sequencing the entire open reading frame of CHRNA7 we identified four putatively functional 
rare (<1% minor allele frequency) variants: a non-synonymous variant in exon 10 and three 
variants located in the proximal promoter region (S. Leonard et al., 2002) (Table 7.5a). 
 
Table 7.5 (Bacchelli et al., 2015). Rare variants identified in the CHRNA7 gene by mutation screening. 
Region (bp  
distance from  
ATG) 
hg19 position (SNP ID) 
Protein 
NP_000737.1 
(cDNA) 
135 ASD cases 
Genotype Count 
(MAF) 
Controls (1000 Genomes) 
98 TSI 
Genotype 
Count (MAF) 
85 CEU 
Genotype 
Count (MAF) 
379 EUR* 
Genotype 
Count (MAF) 
a) Rare putative functional variants 
Promoter (-241) 
g.32322557A>G 
(rs188889623) 
(c.1-129A>G) AA=132;AG=3 (0,011) 
AA=96; AG=2 
(0,010) 
AA=85 (0) 
AA=374; AG=5 
(0,006) 
Promoter (-191) g.32322607G>A (c.1-79G>A) GG=134;GA=1 (0,004) - - - 
Promoter (-182) g.32322616 delG (c.1-70_1-69delG) 
GG=134;G/delG=1 
(0,004) 
- - - 
Exon 10 
g.32460504 G>A 
(rs199504752) 
p.E452K                
(c.1466G>A) 
GG=134;GA=1 (0,004) - - - 
b) 5'-UTR variant found in the same individual carrying the -241 variant 
5'-UTR(-86) 
g.32322712C>T 
(rs149637464) 
(c.27C>T) 
CC=112;CT=23 
(0,085) 
CC=85;CT=13 
(0,066) 
CC=75; CT=10 
(0.059) 
CC=336; CT=43 
(0.057) 
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The non-synonymous variant in exon 10 causes an amino acid substitution from Glutamate to 
Lysine (p.E452K, rs199504752) and it has been identified in only one ASD proband who inherited 
it from the unaffected mother. Since this variant is located in CHRNA7 exon10, which is duplicated 
in the CHRFAM7A gene, it was not possible to estimate the frequency of this non-synonymous 
variant from public databases. 
Therefore we have sequenced CHRNA7 exon 10 by LR-PCR in a control sample consisting of 125 
Italian unaffected individuals and we detected the p.E452K variant in three unrelated individuals. 
However, since the frequency of this non-synonymous variant is not different between our ASD 
sample and the control sample (1/135 in ASD vs. 3/125 in controls, two sided Fisher exact test P-
value.0.35) and in silico analysis using PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) and 
SIFT (http://sift.jcvi.org/) does not predict any deleterious effect on the protein, it is unlikely that 
this variant contributes to ASD risk.  
The three variants identified in the proximal promoter region are located at -241 bp (rs188889623, 
c.1-129A>G), at -191 bp (c.1-79G>A), and at -182 bp from ATG (c.1-70_1-69delG) (Table 7.5a). 
One out of the three individual with the -241 bp variant (proband 3377_3) also carries another more 
frequent variant in the 5‟ UTR region (g.32322712C>T, rs149637464, -86 bp from ATG) (Table 
7.5b). Interestingly, these two variants have been previously reported to have a functional effect on 
CHRNA7 gene transcription, being strongly associated with a significant decrease of promoter 
activity (P<0,0001) (S. Leonard et al., 2002). Although these two variants have been individually 
found in the sample of 174 Italian unaffected individuals and are separately reported in the 1000 
Genome project (Table 7.5), none of the 174 Italian controls or the 379 EUR patients carry both 
variants. 
Segregation analysis of the -86/-241 variants in the Italian family showed that the -86 bp variant 
was inherited from the mother, while the -241 bp variant was inherited from the father (Figure 
7.13), indicating thus that these two variants are not on the same chromosome  and suggesting that 
CHRNA7 expression might be significantly decreased in proband 3377_3. Unfortunately, we were 
not able to test this hypothesis, since CHRNA7 mRNA is not detectable in blood. 
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Figure 7.13. Segregation  analysis of the -86/-241 variants in family 3377 
 
7.3 Analysis of a rare microdeletion on chromosome 2q31.1 
7.3.1 Fine mapping of a rare microdeletion on chromosome 2q31.1 
The presence of the microdeletion encompassing three neighbouring genes on the chromosome 
2q31.1, KLHL23, PHOSPHO2-KLHL23, SSB, was checked by manual inspection of the log R 
ratios and B allele frequencies of family 3423 in Genome Studio: the mother (3423_2) and the 
affected son (3423_3) show a decrease in the Log R ratio and values of B-allele frequency around 0 
and 1, while the father (3423_1) shows values of log R ratio around zero and values of B-allele 
frequency around zero, 0.5 and 1, as he does not carry the deletion (Figure 7.14A).  
The minimum and the maximum deleted regions were determined to be from rs6745705 to 
rs3754913 (chr2:170603578-170666813, GRCh37) and from rs6725295 to rs10190853 
(chr2:170599690-170672843, GRCh37), respectively, in the mother and the affected subject 
(Figure 7.14B). 
However, at the  distal end, this resolution was not sufficient to determine if the deletion affect also 
the METTL5 gene. Therefore, in order to validate and fine map the deletion further, we performed a 
quantitative PCR in the family 3423 using eight different probes, encompassing KLHL23, SSB and 
METTL5. The results showed that in the mother and in the affected son the last exon of KLHL23, 
the entire SSB gene and the last two exons of the METTL5 gene are deleted, resulting in one copy of 
this genomic region (Figure 7.14C). 
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Figure 7.14: Fine-mapping of the deletion in family 3423. A) GenomeStudio screenshot showing B-allele frequency 
and log R ratio for family 3423. SNP data are from the Illumina Infinium 1M-Single SNP array. SNPs within the 
deletion are boxed and highlighted in red. B) Schematic representation from the UCSC genome browser 
(GRCh37/hg19) showing the PHOSPHO2-KLHL23, KLHL23, SSB and METTL5 loci with respect to chromosome 2. 
The red bar represents the minumum deleted region identified by Pinto et al. (2014) in proband 3423_3 
(chr2:170603578-170666813), whereas the maximum deleted region (chr2:170599690-170672843), which extends also 
to the METTL5 gene, is indicated as a dotted line. The probes used for qPCR validation are depicted in red (deleted 
probes) and in green (not-deleted probes). C) qPCR results for the exonic deletion in family 3423. The eight qPCR 
fragments map to exon 3, intron 3 and exon 4 of KLHL23, to intron 9 and intron 11 of SSB, and to intron 6, exon 6 and 
intron 7 of the METTL5 gene (probes 1-8, respectively). The number of copies of each amplified fragment was 
calculated using the 2
-ΔΔCt
 method. The qPCR data were compared against a control gene (FOXP2) and the copy 
number has been normalized against the father 3423_1.  
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7.3.2 CNV search in the 2q31.1 locus  
In order to investigate the frequency of CNVs overlapping the 2q31.1 locus, we searched CNVs 
data published in the SFARI AutDB database (Basu, Kollu, & Banerjee-Basu, 2009), an evolving 
database containing different kinds of genetic data about autism. While no CNVs affecting SSB 
and/or METTL5 are present, an intragenic deletion in PHOSPHO2-KLHL23, a read-through 
transcript between the neighbouring PHOSPHO2 and KLHL23 genes which encodes the same 
KLHL23 protein, has been reported (Prasad et al., 2012).  
Therefore, given the presence of another CNV impacting only KLHL23 and considering the 
biological function of the KLHL (Kelch-like) family members and their involvement in 
neuropsychiatric disorders (see paragraph 3.4.4), we focused our attention on KLHL23 performing 
expression analyses and mutation screening. 
 
7.3.3 KLHL23 and PHOSHO2-KLHL23 expression analyses  
To investigate if KLHL23 haploinsufficiency  may influence the autism phenotype, we tested the 
KLHL23 expression in family 3423 by quantitative RT-PCR. Expression analysis revealed 
decreased levels of the wild type KLHL23 transcript, assessed using a probe extending across exon 
3 and the deleted exon 4 (probe 2), in  the mother and the proband, while no difference in 
expression was shown by the other probe (probe 1) mapping across the two non-deleted exons 2 and 
3 (Figure 7.15A). 
Moreover, in order to get a global overview of the expression of KLHL23 and the PHOSPHO2-
KLHL23 fusion gene, we tested their expression across multiple tissues using a commercially 
available cDNA panel (Human MTC Panel I, Clontech). Both transcripts are ubiquitously expressed 
in all the tested tissues (Figure 7.15B), thus not supporting the hypothesis of a tissue-specific 
expression of one of them. 
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Figure 7.15 Expression analyses. A) Two qPCR fragments were tested to analyse the KLHL23 transcript levels: one 
spanning exons 2-3 (probe1, outside of the microdeletion) and another one spanning exons 3-4 (probe 2, exon 4 maps 
inside the microdeletion). All the data were normalized using the housekeeping gene GUSB as reference gene. 
Expression levels were also normalized against a control individual. The 2
-ΔΔCt
 method was applied to estimate the 
difference in the gene expression between samples. B) KLHL23 and PHOSPHO2-KLHL23 expression in a multiple 
tissue cDNA panel. The different tissues are indicated by numbers:1) Lung; 2) Heart; 3) Kidney; 4) Placenta; 5) 
Pancreas; 6) Liver; 7) Skeletal muscle; 8) Brain; 9) Human control; 10) Negative control. The KLHL23-specific 
amplicon is visualized as a band of 156 bp, while amplicon specific for the PHOSPHO2-KLHL23 gives a band of 200 
bp. 
 
 
7.3.4 KLHL23 and PHOSHO2-KLHL23 mutation screening 
We sequenced the entire coding region of KLHL23 (NM_144711.5) and PHOSPHO2-KLHL23 
(NM_001199290.1) in proband 3423_3, in order to test the hypothesis that the deletion could act by 
unmasking rare variants in the not-deleted allele, and in 96 additional unrelated ASD probands from 
the IMGSAC multiplex families, in order to identify rare sequence variants which may have an 
etiological role in ASD. 
No rare point mutations were found in proband 3423_3, while two new non-synonymous rare 
variants, p.Met65Val (g.chr2:170,591,717 A>G, GRCh37) and p.Thr522Met (g.chr2:170,606,130 
C>T , GRCh37), were detected in exon 2 and exon 4 of KLHL23, respectively, in two ASD 
unrelated individuals, 12-0269.2  and 13-5008.5 (Table 8.6). The other variants were identified in 
the non coding region of PHOSPHO2-KLHL23 and they were reported in dbSNP. 
Bioinformatic analysis predicted that both the missense changes are likely to have a damaging 
effect (PolyPhen2 score: 0.999 for p.Met65Val and 0.796 for p.Thr522Met; SIFT score: 0 for both 
p.Met65Val and p.Thr522Met).  
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Segregation analysis in these two multiplex families showed that the p.Met65Val variant is 
transmitted from the father (12-0269.5) to both two affected children (12-0269.2; 12-0269.3), but 
not to the non-affected one (12-0269.7) (Figure 7.16A). Instead, the p.Thr522Met variant is 
inherited from the father (13-5008.1) by one affected (13-5008.5) and non-affected child (13-
5008.3), but not by the other affected son (13-5008.4) (Figure 7.16B)  
 
 
Figure 7.16 Electropherograms showing the segregation analysis in the two multiplex families (family 12 02269 and 
family 13 5008) of the two missense variants, p.Met65Val and p.Thr522Met, respectively.  
 
Table 7.6 Variants identified in PHOSPO2-KLHL23 and KLHL23 mutation screening. The two missense changes are 
indicated in red. 
 
Region (bp distance 
from ATG) 
hg 19 position 
(SNP ID) 
97 ASD cases 
Genotype Count  
Type of 
change 
(NP_653312) 
PolyPhen-2 
score 
(HumDiv) 
SIFT 
prediction 
(cutoff=0.05) 
-328 
(NM_001199290.1) 
g.170551011C>G 
(rs115888469 ) 
CC=96; CG=1    
-290 
(NM_001199290.1) 
g.170551049 A>G 
(rs76102705) 
AA=85; AG=10; 
GG=2 
   
-207 
(NM_001199290.1) 
g.170551132 G>A 
(rs77728018) 
GG=86; GA=9; 
AA=2 
   
-191 
(NM_001199290.1) 
g.170551740 T>G 
(rs542956085) 
TT=95; TG=2    
Exon 2 
(NM_144711.5) 
g.170,591,717 A>G 
none 
AA=96; AG=1 p.Met65Val 
0.999 (probably 
damaging) 
0 (damaging) 
Exon 4 
(NM_144711.5) 
g.170,606,130 C>T 
none 
CC=96; CT=1 
p.Thr522Val 
 
0.796 (possibly 
damaging) 
0 (damaging) 
 
Since the p.Met65Val segregates with the ASD phenotype in the family, we genotyped 462 
Caucasian controls from the European Collection of Cell Culture (ECACC) by endonuclease 
restriction analysis using the BtsI enzyme, that is able to cut a PCR fragment containing the minor 
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allele G of the p.Met65Val variant. In our case, the PCR fragment used to amplify the exon 4 and 
the surrounding intronic regions had a size of 565 bp and a unique target site for BtsI (figure 7.17). 
In the presence of the minor allele G, the PCR fragment was cut in three fragments of 565 bp, 282 
bp and 283 bp, while in the presence of the wild type site the restriction site was not recognized by 
the enzyme BtsI and the PCR fragment was not cut.  
Visualization of the restriction products on a 2% agarose gel allowed the discrimination of 
homozygous individuals of the reference allele (A/A), who presented one band of 565 bp and the 
and heterozygotes individuals (A/G), who displayed two bands: the 565 bp fragment derived from 
the reference allele A and one band of about 280 bp (282 bp and 283 bp fragments) from the minor 
allele G (Figure 7.18).  
By PCR-RFLP the p.Met65Val  variant was not detected in the 924 Caucasian control 
chromosomes.  
 
 
Figure 7.18: Example of genotyping of the p.Met65Val variant using the restriction endonuclease BtsI in Caucasian 
controls. The red arrow indicates the heterozygous individual (12-0269.2) carrying the variant p.Met65Val. The ladder 
100 bp was loaded in the last lane.  
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CHAPTER 8: 
RESULTS 
 
Analysis of the CADPS2 gene in subjects with ID and/or ASD 
Given the discovery of  a novel intragenic deletion and of a new functional SNV (p. Asp1113Asn), 
both of maternal origin, encompassing the CADPS2 gene in individuals with either ASD/ID, and 
considering that this gene shows a maternal monoallelic expression in blood (see preliminary 
results, chapter 6), we have tested whether CADPS2 might be subjected to a parent of origin 
regulation. 
 
8.1 Maternal inheritance of the CADPS2 deletion 
In order to confirm the maternal inheritance of the CADPS2 intragenic deletion, we performed a 
microsatellite markers and single nucleotide polymorphisms (SNPs) analysis on blood derived DNA 
of father, proband and affected sister. The haplotype analysis showed that both the affected siblings 
inherit two different chromosome by the father, while they share the same maternal chromosome 
carrying the deletion (Figure 8.1).  
 
Figure 8.1 (Bonora et al., 2014). Microsatellite and SNP analysis showing the maternal inheritance of CADPS2 
intragenic deletion. The two microsatellite markers map to CADPS2 intron 1 and intron 2 (CADPS2_21xAC; 
CADPS2_26xAT), while the two SNPs (rs2074589; rs20745889) map to CADPS2 exon 17 and intron 21.  
8.2 CADPS2 allelic expression analysis in brain tissues 
In order to test if CADPS2 is also monoallelically expressed in brain, we analysed the gene 
expression in four different human brain regions (amygdala, cerebellum, cerebral cortex and 
enthorinal cortex) of three informative heterozygous controls for SNP rs2251761. Sequencing of the 
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PCR products showed that CADPS2 is always monoallelically expressed in the amygdala, whereas 
it is biallelic in the other areas (Figure 8.2). CADPS2 expression analysis in blood cDNA of the 
same individuals confirmed the monoallelic expression and indicated that the same allele was 
expressed in both amygdala and blood, suggesting that CADPS2 might be subjected to 
tissue‐specific monoallelic expression and putative imprinting.  
 
Figure 8.2 (Bonora et al., 2014). CADPS2 allelic expression in different human tissues. Electropherograms showing 
CADPS2 allelic expression in different brain areas of one control individual heterozygous at SNP rs2251761. In the 
lower panel, it is shown that the allele expressed by amygdala and blood cDNA is the same. gDNA = genomic DNA. 
8.3 Quantitative methylation analysis of CADPS2 CpG regions 
In order to analyze the methylation pattern of the CADPS2 gene we performed a quantitative 
epigenetic analysis of CADPS2 CpG regions located in the promoter and first intron, using the 
Sequenom‟s mass array system. It uses the EpiTYPER assay for the detection and quantitative 
analysis of DNA methylation using base-specific cleavage and Mass Spectrometry (paragraph 
5.10.3). The EpiDesigner BETA software was used to design primers for PCR amplification of 
bisulfite-treated DNA. This tool allows to design amplicons which must cover the majority of the 
CpG sites. Four amplicons (namely a,b,c,d) including 92 CpGs were selected; 63 of these CpGs 
were suitable for analysis by gene‐specific amplification using in vitro transcription coupled with 
mass spectrometry (MS) (Figure 8.3).  
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Figure 8.3 (Bonora et al., 2014). Methylation analysis of CADPS2 promoter and intron 1 CpG regions. Upper 
panel: Epidesigner beta output of CpG prediction in the promoter and intron 1 of CADPS2 genomic region; blue 
bars = CpG covered by MS analysis, red bars = CpG that cannot be analyzed by MS analysis, (a,b,d) sequences covered 
in the MS analysis using a forward primer in the in vitro transcription, (c) sequence covered by MS analysis using a 
reverse primer in the in vitro transcription; lower panel: transcription factors, CpG island prediction, and regulatory 
sites in the corresponding genomic region as reported in UCSC Genome Browser (hg19). 
 
Epityper beta output is a graphical representation where a series of individual CpGs are represented 
by circles on the same line and the color within the circle denotes the level of methylation from 0% 
to 100%. The numbers indicate the base pairs relative to the amplified PCR product and the position 
of the CpGs. Analysis was performed on bisulfite‐treated DNA from blood, amygdala and 
cerebellum of 9 different individuals (3 ID and 6 controls individuals). The results showed that the 
promoter region was unmethylated across all the three regions analyzed (Figure 8.4A), whereas in 
the first intron of CADPS2 we identified two differentially methylated sites, (CpG_15, 
chr7:122,525,608) and (CpG_16, chr7:122,525,525). For these two sites, cerebellum DNA showed 
a complete unmethylated status, whereas in blood and amygdala a consistent hemimethylated 
pattern was observed (Figure 8.4B). 
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Figure 8.4 (Bonora et al., 2014). Methylation analysis of CADPS2 promoter and intron 1 CpG regions. A,B) 
Epityper beta output of CADPS2 promoter and intron 1 quantitative methylation analysis via MS in cerebellum, 
amygdala, and blood genomic DNA bisulfite‐ treated from different individuals; the percentage of differential 
methylation is indicated by the different shades of gray as shown in the corresponding box; numbers indicate the base 
pairs relative to the amplified PCR product (upper lane) and the position of the CpG (lower lane); the differential 
methylation pattern is appreciable for CpG_15 and CpG_16 in intron 1. 
 
 
These data were corroborated by cloning the PCR products of intron 1 obtained from 
bisulfite‐ treated blood and cerebellum DNA of the same individual (cnt1) and colony screening for 
the presence of either C (methylated) or T (unmethylated) alleles at the CpGs. This approach led us 
to analyze also CpG_14 (position chr7:122,525,624) that was not possible to study with MS.  
Out of 39 colonies from blood, we found 43.58% methylation at position chr7:122,525,624 
(CpG_14), 48.72% methylation at position chr7:122,525,608 (CpG_15), and 41.03% methylation 
allele at position chr7:122,525,525 (CpG_16), confirming the hemimethylated pattern of the blood. 
Instead, the percentage of colonies derived from the PCR products of bisulfite‐ treated cerebellum 
DNA carrying the methylated allele was 2.56% at bp122,525,624 (CpG_14), 5.13% at 
bp122,525,608 (CpG_15), and 2.56% at bp122,525,525 (CpG_16), confirming the extensive 
unmethylation observed by MS analysis (Figure 8.5). 
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Figure 8.5 (Bonora et al., 2014). Methylation analysis of CADPS2 promoter and intron 1 CpG regions. Colonies 
carrying either the T (unmethylated, white circle) or the C (methylated, black circle) alleles at CpG_14, CpG_15, and 
CpG_16 of CADPS2 from the colonies obtained by cloning the intron 1 PCR products from bisulfite‐ treated DNA of 
cerebellum and blood of individual cnt1. 
 
In order to detect whether these sites (CpG_14, CpG_15, CpG_16) show a parent-of-origin specific 
differential methylation, we analyzed the methylation status of four control individuals 
heterozygous for an adjacent SNP (rs981321, g.122,525,329 G>A), by performing colony analysis 
of an intron 1 fragment containing both the SNP rs981321 and the three CpG sites.  
In one control individual, we could detect a statistically significant preferential methylation of the A 
allele of the SNP rs981321 at CpG_16, while CpG15 and CpG14 did not show a differential 
methylation pattern for the two alleles; however, it was not possible to test the parental origin of the 
two alleles in this individual (Figure 8.6A,B). Instead, for the three other heterozygous controls, the 
parental origin of the alleles was known, but we did not detect a difference in the methylation level 
at any of the three CpGs (Figure 8.6C). 
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Figure 8.6 (Bonora et al., 2014). Colony screening for parent‐of‐origin methylation analysis. A) Colonies carrying 
either the T (unmethylated, white circle) or the C (methylated, black circle) alleles at CpG_14, CpG_15, and CpG_16 
and either G (green) or A (red) alleles at SNP rs981321 (A/G in CADPS2 intron 1 PCR product; sequencing analysis 
performed on the colonies carrying the PCR product for intron 1 obtained from bisulfite‐treated blood DNA of a 
heterozygous individual for SNP rs981321. B) Histogram showing the ratio of colonies with the C methylated allele, for 
each CpG, for each rs981321 allele. Lower line: number of colonies carrying the C methylated allele out of the total 
number of colonies with the same allele at rs981321. Significant P‐values are marked with star (Fisher's exact test). C) 
Parental origin of the methylated and unmethylated alleles at CpG_14, CpG1_15, and CpG_16 for three individuals for 
whom parental origin of alleles at rs981321 was known as shown in the figure. 
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CHAPTER 9: 
DISCUSSION 
 
9.1 Analysis of rare CNVs implicated in ASD and ID susceptibility 
Autism spectrum disorder (ASD) and intellectual disability (ID) are complex neuropsychiatric 
disorders with an extensive clinic and genetic heterogeneity and a prevalence of 0.7-1.1% 
(Elsabbagh et al., 2012) and of 1-3% (van Bokhoven, 2011), respectively, in the general, 
population. 
Despite high heritability estimates for both ASD and ID, relatively few common risk variants have 
been convincingly associated with these diseases (Marshall et al., 2008), drawing attention to the 
contribution of rare genetic variation to susceptibility of complex traits.  
Indeed, recent studies have highlighted the involvement of rare (<1% frequency) inherited or de 
novo Copy Number Variants (CNVs) and single nucleotide variants (SNVs) in 5-10% of idiopathic 
ASD cases and in 10-15% of individuals with idiopathic ID (Devlin & Scherer, 2012). Despite the 
heterogeneous genetic landscape for both ASD and ID, the genes impacted by rare variants seem to 
converge in common pathways affecting neuronal and synaptic homeostasis and many 
susceptibility genes involved in ASD are also involved in intellectual disability, indicating that ID 
and ASD may be on the same continuum, sharing common aetiologies and showing many genetic 
similarities (Y. Kou et al., 2012). 
My PhD project focused on the further characterization of rare genic CNVs previously identified in 
individuals with ASD or ID by two International Consortia, the Autism Genome Project (AGP) and 
the CHERISH project. 
 
9.2 Analysis of a compound heterozygous deletion in CTNNA3 
The compound heterozygous deletion involving the CTNNA3 gene appeared to be an interesting 
finding to follow-up as it causes the homozygous loss of a coding exon, predicted to result in a 
complete lack of CTNNA3 functional protein.  
The role of rare recessive inherited variants in ASD risk has been highlighted in recent studies 
which applied whole-exome sequencing and homozygosity mapping to consanguineous and/or 
multiplex families with ASD (Yu et al., 2013) and in a case-control study (Lim et al., 2013), which 
estimated a 3% contribution to ASD risk from recessive mutations. The proposed involvement of 
recessive mutations in ASD susceptibility is also in accordance with the high heritability of ASD 
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(Constantino & Todd, 2005) and with the observation that the majority of parents of ASD 
individuals are unaffected.  
CTNNA3 represents an interesting candidate gene for ASD based on its biological function. Indeed 
it encodes αT-catenin, a member of the α-catenin family, and it has a crucial role in cell adhesion, 
one of the major pathways implicated in ASD (Betancur et al., 2009). 
Several genetic findings have provided evidence for a potential role of CTNNA3 in ASD 
susceptibility. Some studies have reported common single nucleotide polymorphism (SNP) 
association (Wang et al., 2009; Weiss et al., 2009) and the occurrence of rare CNVs intersecting 
CTNNA3 in ASD cases (D. Levy et al., 2011; O'Roak et al., 2012; Prasad et al., 2012). Moreover, in 
a recent analysis of exon-disrupting CNVs affecting known ASD candidate genes, CTNNA3 was 
found borderline enriched in ASD cases in comparison with controls (Girirajan et al., 2012).  
Even if we did not observed a statistically significant difference for CTNNA3 exonic deletions 
between ASD cases and controls, no homozygous or compound heterozygous exonic deletions were 
found in a sample of over 6,600 controls, suggesting that CTNNA3 is haplosufficient and that only a 
recessive loss of function may play a role in ASD susceptibility. This hypothesis is consistent with 
the segregation of CTNNA3 deletions in the discovery family, as the unaffected sister inherited the 
exonic deletion in the heterozygous form.  
Mutation screening of coding region of CTNNA3 and the nested gene LRRTM3 in four ASD 
families carrying exonic CTNNA3 deletions did not reveal any sequence variants in the non-deleted 
allele, but we cannot exclude the presence of point mutations in non coding regions disrupting gene 
regulation or splicing.  
Linkage and association studies have indicated that the CTNNA3/LRRTM3 locus may play a role in 
susceptibility to late-onset Alzheimer‟s disease and plasma amyloid β levels (Ertekin-Taner et al., 
2003; Martin et al., 2005) but the role of CTNNA3 in brain remains largely unexplored. Western 
blot characterisation of mouse Ctnna3 expression,, have suggested that Ctnna3 has a specific 
neuronal function in very early developmental stages, as it displays higher expression in the 
hippocampus and cortex at P0. Interestingly other functional studies have revealed that, similarly to 
other α-catenins, overexpression of Ctnna3 in dendrites causes an increase in spine and synapse 
density, suggesting that all α-catenin isoforms share the same spine-stabilizing activity (Abe et al., 
2004). The role of αT-catenin has been primarily investigated in the heart, due to its high expression 
in cardiac tissue and co-localization with plakophilin 2 (Goossens et al., 2007). An experiment 
performed on a CTNNA3 loss of function murine model has revealed that the loss of αT-catenin 
alters the adhering junctions in the heart and leads to dilated cardiomyopathy and to increased risk 
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of ventricular arrhythmia following acute ischemia (Li et al., 2012). Notably, the affected proband 
3456_3 with the compound heterozygous CTNNA3 deletion had a normal EKG and heart 
ultrasound, suggesting that CTNNA3 loss of function does not lead to cardiac dysfunction in human. 
Another feature that makes CTNNA3 particularly interesting is the presence of the nested gene 
LRRTM3, a member of leucine-rich repeat transmembrane neuronal (LRRTM) gene family, which 
are transmembrane proteins highly expressed in brain and involved in synaptic organization during 
synapse development (Linhoff et al., 2009). LRRTM3 displays expression predominantly in the 
hippocampus and, similar to CTNNA3, plays a role in cell adhesion (Laurén et al., 2003). Since all 
three α-catenins harbour a LRRTM gene within their largest intron, it is possible that α-catenin 
genes and the respective LRRTMs share common transcriptional regulation mechanisms. Therefore, 
if would be interesting to investigate if deletions in CTNNA3 could cause dysregulation of LRRTM3 
expression.  
In conclusion, our findings point to involvement of α-catenins in ASD pathogenesis, given their 
crucial role in both the development and maintenance of the nervous system. Specifically, the 
recessive inheritance pattern seen in the discovery pedigree, together with the absence of exonic 
homozygous microdeletions in CTNNA3 in over 6,600 control subjects and the high expression of 
Ctnna3 in developing mouse brain, led us to hypothesize that the identified compound heterozygous 
exonic deletion in CTNNA3 contributes to ASD phenotype in family 3456.  
In order to understand the potential role for recessive CTNNA3 defects in other neuropsychiatric 
disorders, alone or co-occurring with ASD, we are currently sequencing CTNNA3 coding region in 
two subjects, one with early infantile epileptic encephalopathy, developmental delay and ASD and 
the other one with language delay, learning disability associated to dysmorphic features, both of 
them carry two different CTNNA3 exonic deletions.  
Further studies in larger cohort with point or structural mutations affecting α-catenin‟s function will 
be very useful to elucidate their contribution to ASD and other neuropsychiatric disorders 
pathogenesis. 
 
9.3 Analysis of a microduplication in the CHRNA7 gene 
The identification of a small 15q13.3 duplication, which involves the entire CHRNA7 gene, 
encoding the alpha7 subunit of the neuronal nicotinic acetylcholine receptor, was of particular 
interest as CHRNA7 is considered the likely culprit gene in mediating neurological phenotypes in 
patients with 15q13.3 recurrent CNVs.   
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The 15q13.3 microdeletion is highly but not always fully penetrant, and it is significantly enriched 
in cases of intellectual disability, autism, epilepsy, schizophrenia, and bipolar disorder (Pagnamenta 
et al., 2009; Sharp et al., 2008; Stefansson et al., 2008; van Bon et al., 2009). Instead, the 
significance of the15q13.3 reciprocal microduplications has been more challenging to interpret, 
given that they have been detected across the same spectrum of neuropsychiatric disorders of the 
microdeletions, but with high variability in expressivity and reduced penetrance compared with 
deletions.  
In order to capture the entire spectrum of genetic variation in CHRNA7 contributing to ASD risk, it 
is essential to integrate both CNV and sequence data. However, given the existence of a fusion 
gene, CHRFAM7A, which includes a nearly identical partial duplication of CHRNA7, sequence 
variation in CHRNA7 remains largely unexplored. Hence, attempts to sequence coding exons must 
distinguish between CHRNA7 and CHRFAM7A, making next-generation sequencing approaches 
unreliable for this purpose.  
No additional duplications or deletions were detected in CHRNA7 by our CNV analysis, while 
mutation screening led to the identification of three rare variants located in the proximal promoter 
region. Notably, one of these promoter mutations (-241 bp from ATG) was found in one ASD 
individual (3377_3) who also carries a more frequent 5‟-UTR variant (-86 bp from ATG) on the 
other chromosome. Both variants has been previously associated with CHRNA7 decreased 
transcription in vitro (S. Leonard & Freedman, 2006; S. Leonard et al., 2002) suggesting that the 
presence of the compound variants (-241 bp and -86 bp from ATG) in proband 3377_3 might lead 
to a marked reduction of CHRNA7 expression. Unfortunately, it was not possible to test the 
functional effect of the -86/-241 variants variant in this ASD subject, as CHRNA7 expression is too 
low in blood to be assessed by RT-PCR. 
Interestingly, the subject with the CHRNA7 duplication developed complex partial seizures with 
secondary generalization, at age of 13 years. However, while epilepsy has been strongly associated 
with microdeletions of CHRNA7 (Helbig et al., 2009), seizures are not reported as a common 
features of patients carrying the microduplication (Szafranski et al., 2010). However, it is not 
possible to exclude that some participants of pediatric cohorts may develop epilepsy at a later time. 
To better understand the complex genotype-phenotype correlations of the reciprocal microdeletions 
and microduplications, a detailed clinical characterization of the individuals carrying the CNV 
would be very useful, especially if followed up over time. The co-occurrence of ASD and epilepsy 
in the proband with the CHRNA7 duplication, may suggest that the microduplication involving 
CHRNA7 could have the same role of the deletion in ASD/epilepsy susceptibility although with 
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lower penetrance. In accordance with this hypothesis, CHRNA7 transcript levels were recently 
found reduced in neuronal cells (Meguro-Horike et al., 2011) or brain samples with maternal 15q 
duplication, in contrast to what is expected according to the gene copy number.  
The observation that deletions and duplications at the same locus may yield similar phenotypes is 
quite common and it could be explained by the sensitivity of certain cellular functions to dosage 
imbalance, as described for the 1q21.1 region (Harvard et al., 2011).  
The phenotypic variability at locus 15q13.3 may also be controlled by second-site CNVs, in line 
with the recently proposed “two-hit model” for severe developmental delay (Girirajan et al., 2010). 
Support to this model comes from a recent study where five out of 11 patients with small 
microduplications involving CHRNA7 and showing a variety of neuropsychiatric disorders, carried 
at least one additional different CNV of potential clinical relevance (Szafranski et al., 2010). 
In addition, two ASD individuals carrying a small CHRNA7 duplication and a de novo SHANK2 
deletion on distinct parental chromosomes, were recently observed, suggesting the presence of 
epistasis between these two loci (Leblond et al., 2012). Another report described a boy with severe 
ID, language impairment, and behavioral anomalies, carrying a de novo balanced translocation 
disrupting the SHANK2 gene as well as an inherited duplication of CHRNA7 (Chilian et al., 2013). 
In our study, no other clearly pathogenic CNV has been identified in proband 3474_3, and no 
CHRNA7 sequence variants have been detected, even if we cannot exclude the presence of a 
sequence variant elsewhere in the genome that could act within the same pathway to increase the 
risk of ASD. 
In conclusion, our results do not support the hypothesis that rare sequence variants in CHRNA7 
significantly contribute to ASD susceptibility in our ASD cohort, which is charactherzed by a low 
degree of medical comorbidities, e.g., the frequency of epilepsy in our sample is only 1.5%, while it 
is commonly reported to occur in 5% to 46% of individuals with ASD (Viscidi et al., 2013).  
Therefore, analysis of much larger cohorts of individuals is thus warranted to elucidate the role of 
rare CHRNA7 sequence variants in ASD risk and to discriminate if CHRNA7 might be mainly 
implicated in ASD cases associated to other clinical features that would be consistent with the 
significant enrichment of 15q13.3 CNVs observed in individuals with comorbid phenotypes.  
Moreover, it would be interesting to extend the analysis of the CHRNA7 promoter to the distal 
upstream regulatory region, which contains SNP rs3087454 (-1831bp), reported to be associated 
with schizophrenia (Stephens et al., 2009). 
We are also currently investigating the role of the chimeric CHRFAM7A gene product (dupα7) in 
the ASD phenotype. Recent data have suggested that dupα7 acts as a dominant negative regulator of 
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CHRNA7 function, as it assembles with α7 subunits and causes a decrease of acetylcholine-
stimulated current. Furthermore, the CHRFAM7AΔ2bp gene product (dupαΔ2), containing a 2bp 
deletion in exon 6, is a more potent inhibitor in comparison with the wild-type dupα7 (Araud et al., 
2011) and interestingly, this 2 bp deletion was significantly associated with schizophrenia (Sinkus 
et al., 2009). Therefore, we plan to assess the CHRFAM7A copy number and the presence of the 2 
bp deletion in order to evaluate CHRNA7 function in human diseases. 
 
9.4 Analysis of a rare microdeletion on chromosome 2q31.1 
The rare chromosome 2q31.1 microdeletion was identified in a subject with ASD and borderline 
cognitive impairments and it encompasses three genes:  the last exon of KLHL23, the entire SSB 
gene and the last two exons of METTL5. 
SSB (Sjogren syndrome antigen B) encodes La protein, that is involved in different aspects of RNA 
metabolism, including binding and protecting poly(U) termini of nascent RNA polymerase III 
transcripts from exonuclease digestion (Teplova et al., 2006). Autoantibodies reacting with this 
protein are found in the sera of patients with Sjogren syndrome and systemic lupus erythematosus. 
The METTL5 gene (methyltransferase like 5) encodes a protein of unknown function, probably 
belonging to the methyltransferase superfamily. The methyltransferases catalyze the transfer of a 
methyl group to diverse substrates, including nucleic acids (DNA and RNA), proteins and lipids, 
and they essentially influence multiple cellular regulatory mechanisms by modifying their targets. 
KLHL23 is a member of the kelch-like (KLHL) gene family, whose specific role has not yet been 
elucidated. The KLHL family is conserved throughout evolution and consists of proteins with a 
variety of functions, including actin binding, cytoskeletal organization and ubiquitination (Adams, 
Kelso, & Cooley, 2000). In general, KLHL proteins have similar structural motifs as they contain 
one BTB/POZ domain, one BACK domain, and five to six Kelch motifs. 
It is not straightforward to distinguish which of the genes in the deleted region, alone or in 
combination, contribute to the disorder. To this aim we searched the available databases for the 
presence of additional deletions overlapping this locus, which might help to restrict the region of 
interest. 
In the Simons Foundation Autism Research Initiative (SFARI) AutDB database (Basu et al., 2009), 
we identified an intragenic deletion in PHOSPHO2-KLHL23 (Prasad et al., 2012), while there are 
no CNVs affecting SSB and/or METTL5, thus suggesting a causative association between disruption 
of KLHL23 and ASD.  
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The identification of two rare damaging missense variants (p.Met65Val and p.Thr522Met) in two 
unrelated ASD probands, affecting two conserved domains (the BTB domain and the last Kelch-
repeat, respectively), provides another line of evidence for a role of KLHL23 in ASD susceptibility.  
In conclusion, we propose that KLHL23 might constitute a new ASD gene, even if confirmation in 
large ASD cohorts is needed to implicate it with certainty; further studies are also warrented to 
understand its biological function and its role in the developing brain. 
 
9.5 Analysis of CADPS2 in individuals with ASD and ID 
My role on this topic was to further investigate the hypothesis that CADPS2 might be subjected to 
imprinting. 
Previous results have demonstrated that CADPS2 is monoallelically expressed in blood. My first 
task was to investigate CADPS2 expression in different brain regions. This analysis revealed that 
the gene is monoallelically expressed in blood and amygdala, and the expressed allele is the 
maternal one. 
Subsequently, I carried out a quantitative epigenetic analysis of CADPS2 CpGs regions. This led to 
the identification of a cluster of differentially methylated CpGs sites in the first intron of the gene in 
bisulfate treated DNA from the blood and amygdala, while a differential methylation in this region 
was not observed in the cerebellum, in agreement with the biallelic expression of the gene in this 
brain area. 
The regulation of CADPS2 expression via monoallelic expression in the amygdala, which plays a 
key role in regulating social interactions, supports the importance of a fine modulation of CADPS2 
for human behavior. Although the function of CADPS2 in amygdala has not yet been elucidated, 
recent findings have shown that human CADPS2 expression in amygdala is lower in the prenatal 
period and starts to increase in late fetal stage until mid-childhood (H. J. Kang et al., 2011). 
Moreover, given that amygdala is known to be involved in attention, perception and in memory 
formation, it is not surprising that amygdala dysfunction has been reported in various psychiatric 
conditions such as schizophrenia, autism and anxiety (LeDoux, 2007). 
In order to detect whether the CpG sites identified in CADPS2 first intron show a 
parent‐of‐origin‐specific differential methylation, I analysed the methylation status of four control 
individuals heterozygous for a SNP near to these sites. The analysis did not reveal a reproducible 
parent-of-origin methylation profile for CADPS2, suggesting that other genomic regions in this 
gene or other regulatory mechanisms may be related to the presence of a monoallelic pattern of 
expression.  
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Therefore, further gene expression and methylation analyses of CADPS2 genomic region in diverse 
brain areas and in larger samples are warranted in order to elucidate the regulation pattern of this 
gene and to identify additional maternal variants, which may contribute to the ID/ASD phenotype. 
 
CONCLUSIONS 
Taken together these results confirm the striking complexity of pathophysiology of ASD and 
Intellectual Disability and the role of rare genetic variants, both CNVs and point mutations, in the 
etiology of these complex disorders.  
Specifically, our findings further support the observation that rare genetic variation contributes to 
disease risk in different ways: some rare mutations, such as those impacting the CTNNA3 gene, act 
in a recessive mode of inheritance, while other chromosomal rearrangements, such as those 
occurring in the 15q13.3 region, are recurrent CNVs, implicated in multiple developmental and/or 
neurological disorders, which could contribute to overall risk, possibly interacting with other 
susceptibility variants elsewhere in the genome. On the other hand, the discovery of a tissue-
specific monoallelic expression for the CADPS2 gene, implicates the involvement of epigenetic 
regulatory mechanisms as risk factors conferring susceptibility to ASD/ID. 
Considerable progresses in the genetics of ASD and ID have been made with the recent introduction 
of Next-Generation Sequencing (NGS) technologies, which have allowed to accelerate the 
identification of rare risk-conferring variation.  
Whole exome sequencing (WES) studies in large cohorts of ASD/ID patients, provided further 
evidence for a contribution of rare inherited and de novo variants to heritability of these complex 
traits. More recently, whole-genome sequencing (WGS) are becoming a powerful method to assess 
genetic variation, as they allow the detection of all classes and size of mutations. Although the 
largest WGS study performed to date in 170 ASD individuals (Yuen et al., 2015) had highlighted 
the genetic heterogeneity underlying ASD, both between and within the multiplex families 
analyzed, the data emerged from this analysis represent an important first step in a much large 
initiative to sequence the genome of about one thousand of other ASD families. 
Although many rare variants are predicted to disrupt the gene function, only few mutations are 
expected to be causative, as most of them have an unknown clinical significance and therefore it is 
essential to distinguish disease-causing variants from false-positive findings. Therefore the greatest 
challenge in the next few years will be to develop bioinformatic methods, analytical strategies and 
tools to interpret the significance of the huge amount of genomic data stemming from NGS studies. 
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Multidisciplinary approaches will also be crucial to enhance our knowledge on the biology of 
neurodevelopmental disorders, including deep phenotypic characterization of cases, the 
development of animal models, pluripotent stem cells (iPSCs) derived from patients and epigenetic 
studies. 
Additionally, since neurodevelopmental disorders, such as ASD and ID, share many risk factors and 
they often co-exist in the same individual, the analysis of large cohorts of individuals with different 
co-morbidities might be very useful to better understand the mechanisms by which specific 
molecular pathways result in common vs. different developmental outcomes. Understanding this is 
essential to identify targets for novel aetiology-based treatments. 
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